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Abstract 
There is a huge unmet clinical need for a new, safe and effective minimally invasive 
treatment for Acute Ascending Aortic Dissection (AAAD) (1).  In 2012 AAAD has a 
mortality rate of 1-2% per hour within the first 24 hours, and even with contemporary 
surgical techniques, advanced intensive and post operative care, the mortality from 
AAAD following surgery in most series remains in the unacceptable range of 10-30% at 
30 days (2;3).  28% of patients presenting with AAAD are denied life saving surgery often 
because of age or co-morbidity - medical therapy alone associated with an in hospital 
mortality rate in excess of 50% (2;4-6). 
Currently available endovascular stent grafts used in the descending thoracic and 
abdominal aorta are not adequately designed to be utilised within the ascending aorta.  
They have a large stowed diameter 22-25 French (F), with a rigid covering of either 
Dacron or ePTFE, and a stiff inflexible delivery system unlikely to traverse the aortic arch 
without complication. 
While the contemporary results of elective surgery for ascending thoracic aortic 
aneurysm (ATAA) are good, with an elective mortality of <5%, surgical results for AAAD 
have improved little over the last 20 years, with a 30 day mortality rate between 10-30% 
(3;7).  With the emerging role of endovascular stent grafts in the treatment of thoracic 
aneurysm and dissection, with shorter hospital stays and improved outcomes I believe 
now is the time for the development of a percutaneous solution for AAAD. 
Potential ascending thoracic aortic graft (ATAG) designs must take into account the very 
close proximity of intimal tear to both the coronary arteries and aortic valve, allowing a 
4 
 
good proximal graft seal without compromising coronary flow or aortic valve 
competence.  ATAG should have a low profile, with a thin non porous covering and a 
flexible delivery sheath with accurate and precise deployment characteristics. 
Following a literature review and novel anatomical data collection from computerised 
tomography (CT) and magnetic resonance imaging (MRI) scans of AAAD and ATAA 
patient cohorts, it seems that 3 embodiments of ATAG should be designed and 
developed, all sharing advanced core technologies including a laser-cut nitinol stent 
frame, thin polyurethane (PU) material covering and accurate and precise deployment 
mechanisms: 
1) The “supra-coronary tubular ATAG”, for treating AAAD with an intimal tear in the 
ascending aorta, no coronary or aortic valve involvement and adequate landing 
zones above the coronary arteries and before the right brachiocephalic trunk 
(RBCT).  It is likely that this graft will be capable of treating at least a third of all 
patients with AAAD (8). 
2) The “inverted t-shirt ATAG” to proactively protect coronary artery flow and achieve 
proximal seal within the sinuses in patients with an intimal tear in close 
association or involving the coronary arteries. 
3) The “valved ATAG” to treat patients who have significant aortic regurgitation (AR), 
to achieve a proximal seal at the annulus when anatomy suggests it would be 
difficult to achieve with embodiment 1) or 2), and in those patients who have a 
hugely dilated aortic root, so that the ATAG can seal proximally at a relatively 
normal annulus size, and seal distally at a normal ascending aorta diameter 
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proximal to the RBCT.  This could be the treatment option for the 25-35% of 
AAAD patients who currently require aortic valve repair or replacement (9). 
The most complex of the 3 devices above is embodiment 2), the “inverted t-shirt ATAG”, 
as it must ensure proximal aortic seal within an often dilated sinus, without compromise 
to aortic valve and proactively protect both coronary arteries with 2 coronary sleeves.  
Basic proof of concept (PoC) of this embodiment has been demonstrated in vitro within a 
normal sized aortic glass model, with some important study limitations, nevertheless it 
does demonstrate that tracking an ATAG branched graft with 2 coronary sleeves is 
possible over 3 guidewires and deploying accurately within the aortic root under both 
direct vision and fluoroscopy. 
Following successful PoC deployment I then specified and had manufactured a 2nd 
Generation ATAG (2G ATAG), with a laser-cut nitinol frame, longitudinal tie bars, and a 
novel thin PU graft covering material.  The 2G ATAG has been shown to have adequate 
radial strength when compared to competitor devices, and can be stowed to 28 F for 
deployment. 
During ATAG development 2 patents have been filed, and I wrote with Professor 
Rothman a successful NIHR I4I grant for £743,000 to take ATAG from the current 28 F 
2G device, towards the goal of an 18 F device with bench testing, in vitro flow rig and 
deployment analysis, and in collaboration with the Royal Veterinary College (RVC) into 
an animal model over the next 3 years (beyond the scope of this thesis).  I hope that 
within this next development cycle ATAG can be iterated into a device that might be 
ready to embark on a first in man (FIM) trial to offer the AAAD population an effective 
and less invasive treatment strategy. 
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An overview of my thesis 
Descending thoracic aortic dissection and aneurysm are now commonly treated using 
endovascular stent grafts, inserted through a small calibre (approximately 6-8 mm) 
access sheath placed into the iliac or femoral artery.  Stent grafts consist of an 
expandable stent scaffold, covered in a material which lines the inside of the dissection 
or aneurysm excluding flow into the false lumen, or preventing outward pressure on the 
aneurysmal segment.  Endovascular treatment of the descending thoracic aorta when 
compared to an open surgical approach results in reduced mortality and morbidity as well 
as reducing hospital stay (5;6;10).  Figure 1 below shows a schematic of a endovascular 
stent graft: 
Figure 1: Schematic of a thoracic stent graft within the descending aorta 
 
 
 
 
 
Covered descending thoracic endovascular stent graft, deployed percutaneously from a peripheral arterial sheath.  The 
stent graft has a proximal seal within a normal diameter descending aorta, the graft material then excludes the 
aneurysmal segment with a distal landing zone within normal sized aorta. 
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In 2012 no commercially available endovascular stent graft yet exists to treat Acute 
Ascending Aortic Dissection (AAAD) or Ascending Thoracic Aortic Aneurysm (ATAA).  
Contemporary treatment remains open surgical, involving sternotomy, cardio-pulmonary 
bypass (CPB), and reconstructing the aorta with a graft material.  To maintain coronary 
perfusion, coronary arteries are often re-implanted, and the aortic valve may be replaced 
or repaired to ensure aortic valve competence (9). 
In 2007 Professor Rothman’s concept of an Ascending Thoracic Aortic Graft (ATAG) was 
to design, develop and test a percutaneously deliverable stent graft with covering that 
would enable endovascular treatment of AAAD and potentially ATAA.  In addition to 
excluding an ascending thoracic dissection flap or aneurysm, ATAG should have design 
features allowing preservation of coronary flow and aortic valve integrity - a vital feature 
given the close proximity of the ascending aorta to the aortic valve and coronary artery 
ostia. 
There exists currently a huge unmet clinical need as 28% of patients presenting in the 
Western world with AAAD are turned down for conventional surgery, with an in hospital 
mortality rate of >50% (2).  Not only that but despite improvements in AAAD diagnosis, 
surgical techniques and intensive care provision there has been very little improvement 
in AAAD surgical outcomes over the last 3 decades, despite falling mortality and 
morbidity associated with elective ATAA surgery (2).  Newer, less invasive treatments 
must be sought for both AAAD and ATAA.  
The aim of this thesis is to understand why there is currently no device capable of 
percutaneously treating AAAD and ATAA, and to then take the reader on a journey from 
the conception of ATAG in 2007, and document its development up to a 2G device ready 
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for advanced in vitro and in vivo testing.  I hope this thesis will show the methodical, and 
meticulous iterative process necessary for a successful outcome as one must navigate 
through technical, scientific, clinical, commercial, financial, and regulatory challenges all 
of which must be overcome to achieve the ultimate aim of delivering a novel and effective 
minimally invasive solution to treat patients with ascending thoracic aortic disease - many 
of whom are currently turned down for conventional surgery with appalling clinical 
outcomes (2). 
After original ATAG concept discussions with Professor Rothman I felt that because of 
the close proximity of both aortic valve and coronary arteries to the diseased aortic 
segment, the aortic root anatomy must be very well understood.  The AAAD and ATAA 
disease processes must be well characterised and I wanted to understand the current 
gold standard surgical treatments available for these aortic syndromes, as any proposed 
endovascular solution must be capable of replicating the surgical end-result with regard 
to dissection exclusion, preservation of coronary flow, and retained integrity of aortic 
valve function.  
In my search for understanding of the normal and diseased aortic root anatomy I 
collaborated with Professor Ho, Cardiac Morphologist at the Royal Brompton Hospital 
who demonstrated the aortic root and coronary anatomy to me with her cadaveric 
samples.  She is well published in this area, but after discussions and literature searches 
in 2007 when this project began there appeared to be a paucity of anatomical data on the 
aortic root dimensions and coronary angulation in AAAD and ATAA; information that I felt 
was vital to allow me to proceed to design specification of the ATAG.  
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To acquire this novel aortic root and coronary anatomical data on AAAD and ATAA I 
collaborated with Professor Salah Qanadli, a Consultant interventional radiologist at the 
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland and Dr Raad 
Mohiaddin, Consultant Cardiologist in CMR at the Royal Brompton Hospital, London.  
Both are well published in the arena of aortic root measurement, and have appropriate 
cohorts of AAAD and ATAA patients from which I could perform my desired retrospective 
CT and MRI measurements (11). 
Having gained a thorough understanding of the disease processes (AAAD and ATAA), 
current surgical treatments and an in depth anatomical assessment of the aortic root and 
coronary anatomy, I proceeded to describe a design input specification for the ATAG.  
As an interventional cardiologist in training I was somewhat apprehensive about the 
transition from device design specification to the PoC prototype build, as I have limited 
understanding of materials science, and prototype manufacture.  Throughout this 
process I collaborated with medical engineers who built the stent graft prototypes.  
During the PoC build I was supported by Andrew Pacey an engineer working for Advotek 
Medical devices (AMD), Hitchin, UK, and Leena Jatinen a PhD student from Imperial 
College, working with AMD.  All subsequent medical engineering support (2G ATAG 
onwards) was provided by Qualimed GmbH, Hamburg, Germany. 
My thesis describes in detail the design specification formulation and testing of the PoC 
ATAG and the 2G ATAG.  This includes sections on the design and testing of the stent 
frame, the covering material (PU), and the delivery system.  Lessons learned from testing 
enabled me to formulate a potential design specification for a 3G ATAG device ready for 
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sophisticated pulsatile flow in vitro analysis and potential in vivo animal model 
implantation. 
At the time of my research fellow appointment Professor Rothman had already secured 
PoC funding and a small amount of follow on funding to proceed towards a 2G ATAG.  
During my research period I wrote as co-applicant, with Professor Rothman and was 
awarded a NIHR I4I grant for £743,000 (grant application detailed within Appendix) to 
develop a 3G ATAG with delivery system and test this within an in vitro flow rig, and 
within an in vivo animal model.  To prepare for this next stage of work (to be performed 
by my successor) I collaborated with Professor Steve Greenwald (Professor of 
cardiovascular mechanics, QMUL, London) to set up a basic flow rig for in vitro testing, 
and with Professor Dan Brockman (Professor of small animal surgery, RVC, London) to 
investigate an appropriate animal model. 
There are also short sections within this thesis on intellectual property (IP) and an 
overview of health economic data for the current costs of treating patients with AAAD. 
The journey of this thesis from idea conceptualisation, literature review, anatomical data 
acquisition, design specification, through graft and delivery system build and testing, to 
setting up in vitro and in vivo testing protocols has been fascinating and I now have a 
more complete understanding of the steps involved in translating a new medical device 
from initial concept towards clinical reality.  
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Chapter One: Introduction  
1.1 Medical device innovation – the process 
Many health care professionals will have in the course of their career what they believe 
to be a “novel” or “innovative” treatment solution, whether it be a simple change in design 
to an existing technology (an iterative design improvement), or a potentially “disruptive” 
technology which can completely change the treatment landscape for a particular clinical 
problem, for example balloon expandable stents in percutaneous coronary intervention 
(12).  For a variety of reasons only a tiny proportion of all ideas will manage to make it to 
clinical utility, manufacture and widespread use.  
Within the innovation department at Barts Health NHS Trust Professor Rothman set up 
an innovation development process which helps to “de-risk” and streamline the process 
from the outset and optimise the chances of an idea becoming a clinical reality.  For the 
purposes of explanation this process is outlined below.  While at first glance this may 
look like a linear progression from idea to manufacture, in the real world all factors are 
considered from the outset, as it would be pointless to design and develop a device that 
fulfilled all developmental criteria but could not then be mass produced cost effectively. 
1 – IDEATION / EVALUATION OF FACTS 
The first process after idea creation is a rigorous and critical evaluation of facts.  This will 
encompass a review of the literature for clinical need, potential market size and value, 
device competition and early intellectual property searches establishing the likelihood of 
freedom to operate (FTO). 
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2 - FEASIBILITY (PoC) 
Once an idea has been identified as fulfilling an important clinical need, and having an 
adequate market size, preliminary searches are undertaken to ensure that there is no 
obvious competitor device on the market and that there is freedom to operate.  The next 
important step is to prove feasibility or PoC.  This is often done relatively cheaply utilising 
off the shelf materials which are modified to fit the new purpose and prove the concept.  
PoC devices are then often used to raise early stage funding for the next development 
stage. 
Feasibility studies also allow the inventor to crudely estimate the possible build costs, 
and compare that to the cost of the current standard of care. 
3 - INTELLECTUAL PROPERTY (IP) 
For a medical device to be successful in the market place the unique novelty points must 
be intellectually protected, usually through a family of patents.  Throughout a 
development project like ATAG intellectual property is constantly collected and patents 
adjusted / drafted in collaboration with intellectual property lawyers from specialised 
medical device IP law firms.  Also important, but often not patentable is the development 
of manufacturing “know-how”.  
4 - REGULATORY ASSESSMENT 
It is important early on in the process to engage and collect data for the relevant 
regulatory bodies.  Many development companies have in-house regulatory personnel to 
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evaluate and collect the necessary device, material and processes information to 
minimise regulatory risk.  Regulatory approval is vital in both Europe (to obtain CE Mark 
Conformité Européenne, meaning "European Conformity") and the USA (to obtain Food 
and Drug Administration - FDA approval) to enable companies to sell their device for a 
specified indication within these countries. 
5 – RISK ANALYSIS  
Risk to the success of the project is continually assessed.  In general these are divided 
up into device specific failure modes, and more generic device and regulatory risks.  
Failure Mode Effect Analysis (FMEA) allows risk from the worst case scenario, to the 
more trivial ones to be fully appreciated and evaluated. 
6 – DESIGN INPUT SPECIFICATION  
With lessons learned from the PoC model and key user needs specification a “wish list” 
of design input characteristics are formulated.  
7 – DESIGN OUTPUT SPECIFICATION  
An assessment of what has been produced by the manufacturer and how it compares to 
what was specified in the design input specification. 
8 – BENCH TESTING REQUIREMENTS  
Bench testing is an essential element to ensure that the user need specifications are met 
in the design input and output specifications.  The chosen bench tests must accurately 
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assess whether the design meets the user needs requirements.  Throughout this process 
information about the design, manufacture and testing must be documented meticulously 
for the regulatory bodies so that the appropriate approval can be sought as expediently 
as possible. 
9 – PROTOTYPES 
Prototyping and bench testing is an iterative process gradually working towards a device 
that fulfils the user specification. 
10 – ANIMAL TESTING 
Most implantable devices will go through in vivo testing in an appropriate animal model.  
This phase of the development further validates the device and technique and there are 
inevitable new design inputs which are validated by the design outputs and results. 
Throughout all in vitro and in vivo testing there will be collection of data concerning 
material biocompatibility, toxicity, and thrombogenicity.  Materials that are already in 
clinical use within the vascular arena will already have a regulatory dossier and this can 
in some cases streamline the regulatory process. 
11 – CLINICAL TESTING & REGULATORY APPROVAL  
Although beyond the scope of this thesis a device like ATAG will only achieve clinical 
utility and market acceptance after clinical testing in the form of a clinical trial and the 
achievement of regulatory approval (CE mark in Europe, FDA approval in USA).  
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12–MANUFACTURING  
A manufacturer must be sourced which has the technical, regulatory and manufacturing 
skill and capacity to produce the device for market to the correct standards and quality, 
in adequate numbers in an appropriate time scale for an agreed cost.  One must also 
consider manufacturer location, materials supply chain, and consideration of second 
suppliers.  QualiMed GmbH, Hamburg, Germany - our partner for the 2G ATAG 
development has established a manufacturing skill set recognised by its ISO 13485:2003 
and ISO 9001:2008 standards. 
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1.2 Anatomy of the ascending aorta, and its relationship to 
coronary arteries, aortic valve and great vessels in health  
In 2007 I met with Professor Rothman to discuss an idea he had for a novel 
endovascular treatment modality for AAAD and potentially ATAA.  His sketches 
showed a stent graft (length and diameter undetermined) with 2 coronary arms 
broadly looking like an “inverted t shirt”.  
To enable me to design a PoC ATAG device I wanted to understand the anatomy 
and dimensions of the aortic root and ascending aorta in health, and elucidate how 
much information existed about this region in aortic disease.  Only with a high 
degree of anatomical understanding would I be able to commence on a design 
specification for the ATAG.  This first section details the available normal aortic 
anatomical information, much of which was published from 2009 onwards in part 
due to the increased interest and number of Trans-catheter Aortic Valve 
Implantation (TAVI) procedures performed worldwide. 
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1.2.1 The Normal Aorta 
The aorta is the main arterial route for carrying oxygenated blood from the heart to all of 
the body’s tissues.  For descriptive purposes it is divided into regions as documented in 
Figure 2 below: 
Figure 2 Anatomy of the aorta 
 
  
 
 
 
  
 
Blood is ejected from the left ventricular cavity out through the Left Ventricular Outflow Tract (LVOT) and aortic valve.  
There are then 3 sinuses of Valsalva - the right and left of which usually contain the ostia of the coronary arteries.  The 
sinotubular junction (STJ) is where the aortic root becomes the ascending aorta.  The ascending aorta becomes the arch 
at the right brachiocephalic trunk (RBCT) and then the descending aorta after the left subclavian artery (LSCA).  Once the 
aorta has moved through the diaphragm it becomes the abdominal aorta (AA). 
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In order for me to develop a novel endovascular stent graft for the ascending aorta I felt it 
was vital to focus attention to understanding the anatomy of the portion of aorta from the 
left ventricular outflow tract (LVOT) up to the RBCT.  This region includes the aortic valve 
whose integrity must be ensured, and the coronary arteries whose coronary flow must be 
preserved. 
1.2.1.1 The LVOT to RBCT 
It is universally accepted that for any patient undergoing endovascular intervention the 
specific vascular anatomy must be well understood.  Work up for endovascular 
intervention including TAVI usually includes a high resolution heart and vascular CT 
scan.  The information gathered allows the interventional team to plan the endovascular 
procedure, including device selection, accurate sizing, and access route planning.  
Normative thoracic aortic dimensions have previously been determined by CT 
angiography, however they were not electrocardiograph (ECG) gated and as such were 
subject to considerable axial and transverse motion during the cardiac cycle making the 
ascending aorta measurements less accurate and precise (13;14). 
Professor Salah Qanadli an interventional radiologist working at the CHUV hospital in 
Lausanne, Switzerland and his cardiothoracic surgical colleagues have recently 
published data documenting normative size values for the ascending aorta, providing 
reference measurements in order to understand the ascending aortic anatomy better for 
the future development of novel endovascular procedures (11).  Their results are 
interesting and provide “normal values” in patients without ascending aortic abnormality.  
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The CHUV group utilised a 64 slice ECG gated CT scanner and protocol giving high 
resolution (0.625 mm slice thickness).  Acquisitions were obtained after injection of 100-
120 ml of non-ionic contrast medium.  ECG assistance for aortic studies allows the 
synchronisation of data acquisition to the heart cycle in order to obtain CT data during 
the diastolic phase when heart and aortic movement is minimal thus reducing the motion 
artefact.  Dynamic data were also used for the pulsatility of the ascending aorta.  The 
dynamic diameter change, and the torsional forces placed upon the ascending thoracic 
aorta with each and every systole and diastole add complexity both to how a the ATAG 
device might be appropriately sized, and also exerts mechanical challenges to the stent 
graft body, stent graft covering material, and the stent graft  / vessel interface.  If these 
torsional factors can be better understood and the ATAG device designed to 
accommodate these physiological stresses it is likely to have increased longevity.  
Pulsatility was defined as the percentage difference of minimal and maximal antero-
posterior (AP) and latero-medial (LM) diameters of the mid ascending aorta.  Mean, 
median, maximum and minimum values were considered with standard deviations (SD).  
The 77 patients in the Qanadli study consisted of 59 men and 18 women with an age 
range from 22 to 83 years.  Mean age was 54.7 years (median 54).  
Qanadli et al. measured 4 main diameters (D1-D4) and 4 lengths (L1-L4) as described in 
Figure 3 below: 
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Figure 3 CT aorta measurements according to Qanadli protocol 
       
 
 
 
 
 
 
Figure adapted from Qanadli et al. (11).  Qanadli protocol for aortic dimensions and lengths.  Diameters measured 
included D1 - LVOT diameter, D2 coronary sinus diameter, D3 - STJ diameter,  D4 - Mid ascending aorta diameter.  
Lengths measured included L1 - Length from coronary ostia to RBCA, L2- Length from annulus - coronary ostia, L3 - 
Distance between coronary ostia, L4 - Minimal arc from LMCA to RBCA. 
The method by which Qanadli and colleagues manipulate the 3D CT dataset is also 
important.  During post processing the group formulate a “centre line” to reflect the best 
possible “true” measurement of aortic diameters and distances i.e. truly perpendicular to 
the vessel, as shown in Figure 4 below: 
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Figure 4 Measurement at the level of the STJ in a 54 year old woman.  
 
 
 
 
 
 
 
Reproduced with kind permission of Salah Qanadli (CHUV, CH) (11).  a) Shows a volume rendered 3D reconstruction of 
the ascending aorta and the aortic arch with centre line super-imposed, and a circumferential measurement of the aortic 
diameter at the STJ.   b) Lumen view of the ascending aorta, reconstructed from the centre line. 
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The Qanadli data of normative aortic measurements is summarised in Table 1 below: 
Table 1 Normative mean aortic measurements by CT: 
Measurement Mean diameter (mm +/- SD) 
D1  Outflow tract 20.3 +/- 3.4 
D2  Coronary sinus 34.2 +/- 4.1  
D3  STJ 29.7 +/- 3.4 
D4  Mid ascending aorta 32.7 +/- 3.8 
Measurement Mean distance (mm +/- SD) 
L1  Annulus to RBCT 92.6 +/- 11.8 
L2  Annulus to coronary artery 12.1 +/- 3.7 
L3  Distance between coronary ostia 7.2 +/- 3.1 
L4  Minimal arc of ascending aorta from LMCA to RBCT 52.9 +/- 9.5 
AP and transverse LM diameters of the mid ascending aorta during the cardiac cycle 
varied from a maximum of 34.2 mm to a minimum of 31.3 mm and from a maximum of 
33.6 mm to a minimum of 31.2 mm.  Computed cycle variations are therefore 8.4% and 
7.3% respectively.  This variation is lower than that described by Van Prehn et al. where 
using a similar CT protocol they described cycle diameter variation at 3 points as shown 
in Figure 5 below: 
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Figure 5 Points of aortic dimension variation with cardiac cycle  
 
 
 
 
 
 
Adapted from Van Prehn et al.(15)  Aortic dimension variation with cardiac cycle  A) 5 mm above the coronary arteries 
17.4%  B) 5 mm below the RBCT 13.9%  C) In the mid aorta 12.9%.  All 3 levels showed significant maximum diameter 
change.  Level A displayed significantly higher “pulsatility” compared to level B or C (p=0.02).  Level B and C did not differ 
significantly. 
One possible explanation for the higher pulsatility compared to Qanadli’s data could be 
related to the small cohort size (n=15) and that Van Prehn’s cohort was made up of  
patients with diseased aortas – all had an abdominal aortic aneurysm (AAA mean 
diameter 6.5 cm) and a higher average age of 72.2 years (15).  A recent study by De 
Heer et al. also support this dynamic aortic root sizing, with systolic diameters being 
significantly greater than those seen in diastole (16). 
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Conclusions relevant to ATAG: 
The normal aorta measures around 20 mm at outflow tract, 34 mm at the sinus of 
Valsalva, 30 mm at the STJ and 33 mm at the ascending aorta (11). 
The aortic annulus to the RBCT is less than 100 mm in length, the annulus to the RCA is 
12 mm, and on average in this normal cohort the LMCA is 7 mm above the RCA.  The 
inner curve from the LMCA to the point opposite the RBCT is approx 50 mm.  Depending 
on the patient size, sex, curvature of the aorta, and the proximal and distal sealing zones 
the proposed ATAG device is likely to be between 50 and 100 mm in length (11). 
In a normal cohort there is a systolic / diastolic pulsatility of 8%, which in diseased 
cohorts with AAA is described as up to 17% (11;15).  ATAG must have an appropriate 
sizing protocol to enable the endograft to have a sufficient proximal and distal seal, 
preventing endoleak.  The graft frame and the material must undergo rigorous fatigue 
testing as the aortic pressure and dynamic movement will place the graft materials under 
considerable mechanical stress. 
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1.2.1.2 Normal coronary artery anatomy and association with the aortic valve  
The ascending aorta has remained a “no-go area” for routine endovascular 
therapy for numerous reasons including proximity to the aortic valve, difficulty in 
navigating devices into position around aortic arch, inadequate landing zone, size 
variation and difficulty in achieving accurate and precise deployment.  
A further layer of complexity is then added when one considers the close 
proximity of the coronary arteries to the aortic valve.   
This next section describes the size, angulation, take off and relationships 
between the coronary arteries and the aortic valve. 
1.2.1.2.1 Coronary artery anatomy 
The majority of the human population have 2 main coronary arteries a right coronary 
artery (RCA) and a left main coronary artery (LMCA) which splits into the circumflex (Cx) 
and left anterior descending artery (LAD) (17).  
Approximately 1% of the population will have an anomalous coronary artery anatomy, 
which can be further sub-divided as follows: 
30% - LAD and Cx coronary ostia originate separately from the left sinus of Valsalva 
rather than a LMCA that bifurcates. 
28% have an anomalous origin of the Cx from the right sinus of Valsalva or RCA.   
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The RCA directly originating from the aorta in 11.2% of anomalous patients. 
8% have an RCA originating from left sinus of Valsalva (17;18). 
The location of the RCA as described by Qanadli et al. is 12 mm above the aortic 
annulus and more often than not within the sinus of Valsalva (11). 
Christensen et al. measured the length of the LMCA using dual source CT images in a 
patient group with normal coronary arteries.  The average LMCA length was 9.9 +/- 4.15 
mm (mean +/- SD) (range 2-21).  There was no significant difference in LMCA length 
between groups with right or left sided coronary dominance (19).  These findings are also 
in reasonable agreement with a contemporary cadaveric study by Reig et al. in 2004 
finding a mean LMCA length of 10.8 +/- 5.52 mm (mean +/- SD) (20). 
1.2.1.2.2 Coronary artery anatomy in relation to the aortic valve 
In 1997 Ho et al. published “the location of the coronary arterial orifices in the normal 
heart” in which they provided a very detailed analysis of relevant anatomy (21).  The 
group examined 23 normal hearts collected at necropsy from male and female subjects 
who died from non cardiovascular causes.  The age of death ranged from 29 to 79 years, 
with all hearts opened and dissected via an incision in the anterior longitudinal wall. 
In all specimens the aortic valve possessed 3 leaflets, which were nearly equally spaced 
around the aorta – in only one case was there perfect symmetry.  In each valve the mean 
height of the leaflets measured 13.4 +/- 1.43 mm (mean +/- SD) (range 10-15). 
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In all specimens the coronary arteries arose from the appropriate aortic sinuses.  In 69% 
of specimens the LMCA arose below the level of the STJ.  It arose at the level in 9%, and 
above the level in the remaining 22%.  The highest position was 2 mm above the STJ, 
the lowest 2 mm below.  The mean length of the LMCA was 10 +/- 2.3 mm (mean +/- 
SD). 
The RCA arose below the STJ in 78% of specimens, at the level in 9% and above in 
13%.  The highest position was 2.5 mm above the junction.  This is represented in Figure 
6 below adapted from the Ho et al. paper (21). 
Figure 6 Representation of location of coronary ostia 
 
 
 
 
 
Adapted from Muriago et al (21).  Figure shows the 3 aortic sinuses (anterio, right posterior and left posterior).  RCA and 
LMCA orifices (dots) are not located in the centre of each aortic sinus, but instead there is a tendency for all orifices to be 
towards the zone of apposition of adjacent leaflets at the STJ. 
These findings are consistent with McAlpine et al. who proposed that because the RCA 
is destined to pass around the tricuspid valve, it is appropriate for its orifice to be located 
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in the right half of the anterior aortic sinus therefore allowing the RCA to take a more 
direct path (22).  Table 2 below shows the relationship between coronary ostia and STJ: 
Table 2 Relationship between coronary ostia and STJ.  
 
 
 
Adapted from Muriago et al.  Right (R) and Left (L) coronary orifices above, below, or at the level of the STJ (21) 
These data are important, as with such close proximity of the ostia of both the LMCA and 
RCA to the zone of apposition of the aortic valve leaflets (as seen in Figure 7 below) any 
endovascular device design which has a proximal sealing in this area must ensure that 
coronary artery flow is protected, without disrupting aortic valve function and integrity. 
Figure 7 LMCA and RCA relative position to the STJ 
 
 
 
 
Conus branch, RCA and LMCA seen to originate within the sinuses of Valsalva below the STJ.  RC – right coronary 
artery, R – right cusp, P - posterior cusp, STJ – sinotubular junction, L – left cusp, LC – left coronary artery. 
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If the ATAG is to be designed as an “inverted t-shirt” with coronary sleeves it is important 
to understand the diameters and length of both the LMCA and RCA, as well as the 
angulation and “take off” from within the respective aortic sinuses. 
Dodge et al. in a cohort of 83 patients with normal coronary angiograms, report that the 
mean size of the LMCA was 4.5 +/- 0.5 mm (mean +/- SD), and the RCA varied between 
a mean of 3.9 +/- 0.6 mm (mean +/- SD) in right dominant circulations and 2.8 +/- 0.5 mm 
(mean +/- SD) in left dominant circulations.  Women on average had smaller epicardial 
coronary arteries by -9% (p<0.001) even after correction for body surface area (BSA) 
(23).  Dodge et al. in an earlier publication described the spatial location of the coronary 
arteries represented in Figure 8 and 9 below: 
Figure 8 Spatial location of coronary arteries 
 
 
 
 
 
Figure adapted from Dodge et al (24).  Spatial location of the coronary arteries in the Z-axis (antero-posterior), Y-axis 
(cephalad / caudal) and the X-axis lateral direction.  S1 – 1
st
 Septal, L2 – 2
nd
 part of LAD, D2 – 2
nd
 part of 1
st
 diagonal. 
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Figure 9 Diagrammatic representation of normal coronary orientation 
 
 
 
 
 
 
 
Adapted from Dodge et al.(24).  Looking down on the heart from above, the LMCA and RCA are shown on the left with 
their branches detailed and labelled.  The right hand figure shows a view of the aortic valve and coronary ostia from 
above, with the mean normal angle drawn between the LMCA and RCA.  The LMCA has a take-off that is angulated 7 
degrees cranial, and 83 degrees anti-clockwise from the AP plane (i.e. looking down on the aorta as a clockface 
originating at approximately the 9 o’clock position).  In contrast the mean angulation of take-off of the RCA is 22 degrees 
caudal and -71 degrees in the clockwise direction from the AP plane (just after 2 o’clock on a clock face).  CB – conus 
branch artery, AM – acute marginal artery, RCA – right coronary artery, T – tricuspid valve, PD – posterior descending 
artery, Circ – circumflex artery, M – mitral valve, OM – obtuse marginal artery, Inter – intermediate artery, A – aortic valve, 
LAD – left anterior descending artery, P – pulmonary valve, Diag – diagonal artery 
Therefore in this cohort of normal individuals the mean angle between the LMCA and the 
RCA is (83 + 71) = 154 degrees. 
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Conclusions - Coronary artery and aortic valve anatomical association  
The coronary arteries appear to have their origins about 12 mm above the aortic annulus, 
and the LMCA ostium is approximately 7 mm above the RCA ostium (11). 
99% of the population have 2 main coronary arteries with >70% located within the 
respective sinus of Valsalva (i.e. below the STJ).  Approximately 10% of coronary ostia 
originate at the level of the respective STJ, and approximately 15% originate above the 
STJ. 
The LMCA is on average 4.5 mm in diameter and approximately 10 mm long (17;18).  
The LMCA ostium projects at a 7 degree angle slightly cranial, and 83 degrees 
anticlockwise from the AP plane, while the RCA is on average 3.9 mm in diameter 
(dominant circulation), with a 22 degree cephalad take off, 71 degrees clockwise from the 
AP direction, making an average angle between the 2 coronary ostia of 154 degrees 
(24). 
Conclusions relevant to ATAG design specification: 
The 2 coronary arteries are close to the aortic annulus (within 12 mm in this normal 
cohort).  The ostia of the coronary arteries tend to sit within the respective sinus of the 
aortic valve - making the proximal fixation point / seal extremely important and potentially 
difficult to achieve without compromising the competence of the aortic valve.  Achieving 
sufficient proximal seal, without endoleak, and preserving coronary flow without 
interruption of the aortic valve competence is going to be a real challenge. 
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The coronary arteries come off at an angle of 154 degrees to one another.  To facilitate 
ATAG design specification it will be important to understand if this angle is maintained in 
AAAD and ATAA, as this will impact upon the degree of coronary sleeve angle variation 
required for the ATAG graft and what design features / materials / graft sizes and 
angulations will allow this to occur. 
 
1.2.1.3 Aortic arch and peripheral vessels 
For the ATAG to be delivered in a percutaneous fashion, from a distal access 
sheath, similar to that used with current TAVI devices, it is fundamental that the 
vascular tree diameters are well understood.  In keeping with TAVI patient 
standardised work up, patients with AAAD and ATAA will also require a full 
vascular CT angiography or MR angiography (MRA).  I will now review the available 
literature on normal artery diameter from aortic arch down to femoral artery. 
I have condensed the maximal diameters of vessels from the aortic arch down to the 
femoral arteries into Table 3 below: 
Table 3 Artery diameters from aortic arch to femoral artery 
Artery Mean maximal diameter (+/-SD) Author / Modality 
Aortic arch 27 +/- 3.6 mm  Dart et al. (25) / US 
Descending aorta 24.6 +/- 3 mm Wolak et al.(26) / CT 
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Table 3 cont. Mean maximal diameter (+/-SD) Author / Modality 
Mean maximal common Iliac 
artery diameter 
Male      13.3 +/- 2.0 mm 
Female  12.2 +/-1.3 mm 
Paivansalo et al. (27) / US 
Mean maximal common 
femoral artery diameter 
Male       11+/-1.5 mm 
Female   9.7 +/-1 mm 
Paivansalo et al. (27) / US 
Mean maximal artery diameter and modality of measurement in large populations without CVD. US – Ultrasound , CT 
Computerised tomography. 
While these are helpful data, the iliac and femoral diameters consist of a mean maximal 
diameter.  In the setting of percutaneous therapies it is often more important to have the 
minimal diameter and the extent and position of calcification / stenoses to guide the 
location of the percutaneous puncture and ensure that the calibre of the vessel is 
sufficient and the tortuosity acceptable for insertion of a suitable introducer sheath. 
In modern endovascular therapy work up all patients have a full vascular CT scan so that 
the access route and the type of sheath can be tailored to the patient.  In poor quality 
small diameter femoral and iliac vessels, particularly in the elderly it is frequently 
necessary to place the introducer sheath into a surgically attached Dacron conduit often 
attached directly to the iliac artery – this is a potential access option for the ATAG device. 
Over the last 5 years there have been considerable advances in the development of 
percutaneous TAVI technologies (28).  As the devices and delivery systems have 
become of a smaller diameter, new access routes of insertion have evolved - including 
sub-clavian, direct aortic and left ventricular trans-apical (29).  All access routes have 
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potential risks and benefits and access choice must be decided on a case by case basis, 
offering the patient the best possible outcome with the lowest possible risk. 
1.2.1.4 Endovascular aortic nomenclature 
Current aortic endovascular convention has divided the aorta into a number of “landing 
zones” allowing health care professionals to discuss aortic anatomies and interventions 
in a standardised manner.  Figure 10 below shows this landing zone nomenclature (i.e. 
standardised description where an endovascular stent graft is positioned): 
Figure 10 Endovascular aortic landing zone nomenclature 
 
 
 
 
 
Adapted from Ishimaru (30).  The positions of the proximal and distal ends of the endograft are indicated as zones (Z).  
The proximal end of the endograft should be indicated separately (i.e., as uncovered versus covered with graft material).  
As the nomenclature stands currently zone 0 encompasses the ascending aorta from the STJ up to and including the 
RBCT. Z1 – left common carotid, Z2 – LSCA, Z3 and Z4 which is sub-divided into T4-T12.  The border between zones 3 
and 4 is the end of the aortic arch curvature. The thoracic vertebral level (T4–T12) is aligned with the end of each 
vertebral body.  Once the aorta has crossed the diaphragm it becomes L1-L4. 
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I think it is likely that as devices for ascending aortic intervention and TAVI evolve a 
further descriptive convention will be required to further sub-divide zone 0, and the aortic 
root below it.  This would likely include the landing zone of the LVOT, the annulus, 
involvement and management of the coronary arteries as well as the sinus of Valsalva. 
Conclusion - Aortic Arch to Femoral artery diameters 
The aortic arch is on average 2.7 cm in diameter (although this is a diastolic 
measurement), leading down to a mean descending aortic diameter (at the level of the 
pulmonary bifurcation) of 24.6 mm.  An average common iliac artery measures 12.2 mm 
in women, and 13.3 mm in men, values being significantly higher in both hypertensive 
males and females when compared to their normotensive controls (25-27).  
The femoral artery diameter is on average 9.7 mm in women, and 11.0 mm in men, being 
significantly elevated in hypertensive females when compared to their normotensive 
controls (9.9 mm vs 9.6 mm in women p<0.001), but not significantly different in the male 
group 11.1 mm vs 10.9 mm p=0.058 (27). 
We must accept that these are all findings and conclusions in a relatively “normal” 
population and that these values cannot be extrapolated to the severely dilated and 
dissected ascending aorta populations.  In chapter 2, I will describe novel CT and CMR 
anatomical data collected from both a cohort of AAAD patients, and a group of patients 
with Marfan syndrome and ATAA. 
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1.3 The ascending aorta in diseased states  
Although the major unmet clinical need for an endovascular device is in the 
treatment of AAAD, there is significant overlap in the pathophysiology and 
surgical management with patients presenting with ATAA.  I wanted to understand 
the pathophysiology of ATAA, the current treatment modalities available and 
outcome data.  
1.3.1 Ascending thoracic aortic aneurysm (ATAA) 
ATAA is defined as a dilatation of the ascending aorta producing a cross sectional 
diameter of more than 1.5 times its normal value; values between 1.1 and 1.5 are 
considered dilated or ectatic ascending aorta (31).  Normative values have already been 
discussed (Section 1.2.1.1) and there is generally good agreement between different 
imaging modalities including Echo, CT and MRI.  Thoracic aortic aneurysms (TAA) 
involve the ascending aorta (ATAA) most commonly (50%), followed by descending 
(40%) and 10% affect the arch.  25% of patients with ATAA will have a concomitant 
abdominal aortic aneurysm (AAA) (32). 
Aneurysmal disease of the aorta is clinically important because as the diameter of the 
aorta expands, linear wall stress increases which directly increases the risk of aortic 
rupture – an event with an extremely grave prognosis.  Aneurysmal ascending aortas are 
also more likely to result in aortic dissection and other aortic syndromes often associated 
with a similarly poor outcome (33).  
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1.3.1.1 Incidence 
The true incidence of ATAA is difficult to determine as many go undiagnosed.  It has 
classically been quoted as being 2-5 cases per 100,000 / year, however in the Mayo 
Clinic sampling from 1980 – 1994 the incidence in Olmstead County, USA was of 10.4 
cases per 100,000 / year (34).  A possible explanation for this rising incidence is an aging 
population and increased utilisation of screening diagnostic imaging techniques (Echo, 
CT and MRI). 
There are several significant differences between thoracic and abdominal aortic 
aneurysms.  Age at onset for TAA is 10 years earlier (65 years versus 75 years); AAA 
are more predominant in men with a 6:1 male to female ratio, whereas TAAs occur only 
1.7 times more frequently in men compared to women (35). 
1.3.1.2 Pathogenesis 
The ascending aorta has a greater concentration of elastic fibres and is more compliant 
than the descending aorta.  The elastin to collagen ratio progressively decreases as the 
aorta traverses distally into the descending thoracic aorta.  Elastin fibres and fibrillar 
collagens are the main determinants of the mechanical properties of the aorta and loss of 
elastin is one of the most consistent histo-pathological findings in patients with ATAA 
(35). 
The pathophysiology of aneurysm formation is a complex and multi-factorial process 
involving interplay between genetic predisposition, haemodynamic stressors and 
concomitant aortic valve disease.  Despite a diversity of genetic defects aortic diseases 
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develop through a common pathway of inflammation, proteolysis and disturbed survival 
of smooth muscle cells.  A pronounced elevation in proteolytic matrix metalloproteinase 
enzymes and a notable decrease in inhibitory enzymes have been described in the wall 
of the aorta as mechanisms for the deleterious change in aneurysm disease (36).  The 
medial degeneration results in a weakening of the aortic wall, which in turn leads to 
progressive aortic dilatation and eventually aneurysm formation (37). 
1.3.1.3 Aetiology 
Most ascending aneurysms have an unknown aetiology and are classified as idiopathic.  
Atherosclerosis is associated with aneurysms of the aortic arch and descending aorta, 
but spares the ascending aorta in which the pathogenesis appears more related to a 
genetic predisposition, haemodynamic stressors (hypertension) and bicuspid aortic valve 
(BAV) (32;38). 
1.3.1.3.1 Degenerative aneurysms 
Degenerative aneurysms comprise the majority of those seen in the ascending aorta.  
Cystic medial degeneration is known to occur to some extent with aging, but this process 
is accelerated by hypertension, with degradation of the extracellular matrix, loss of elastic 
fibres, and smooth muscle cell necrosis.  As a consequence the aortic wall becomes stiff 
and progressively dilates (38). 
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1.3.1.3.2 Connective tissue disease 
When cystic medial degeneration occurs at a younger age it is classically associated with 
recognised connective tissue disorders such as Marfan syndrome or less commonly, 
Ehlers Danlos syndrome (32). 
In those with Marfan syndrome ATAA predominantly involves the aortic root in a pattern 
known as “annulo-aortic ectasia”.  Penetrance is variable, and in some with Marfan 
syndrome the aortic root is significantly aneurysmal by teenage years while others have 
much slower progression of disease or no aortic dilatation (38).  Marfan syndrome is an 
inherited connective tissue disorder which has an incidence of 1 in 5000, and about 25% 
of cases represent new mutations.  While the syndrome affects many systems, the most 
prominent manifestations are skeletal, ocular and cardiovascular.  60-80% of all adults 
with Marfan syndrome have a dilatation of the sinus of Valsalva (32). 
The Marfan gene mutation occurs in the portion of the genome encoding Fibrillin-1 on 
Chromosome 15q21 a key component of the elastic scaffold.  The Fibrillin-1 mutation 
results in fragmentation of the elastin network by matrix metalloproteinases, leading to 
inflammation, and cystic medial degeneration.  There is also some data suggesting that 
the abnormal Fibrillin-1 has a low affinity for transforming growth factor Beta 1 (TGF) 
leading to excessive production of TGF-1 (39). 
1.3.1.3.3 Bicuspid aortic valve 
Bicuspid aortic valve (BAV) is a common congenital cardiac anomaly with an incidence of 
1-2% of the general population (32).  There has been considerable controversy as to 
62 
 
whether the aortic wall changes and the predisposition to aortic aneurysm are due to the 
abnormal haemodynamic stresses brought about by the BAV, or are caused by an 
associated inherited aortic wall abnormality (40). 
Fedak et al. have shown that patients with BAV have an inherited defect in the genes 
that encode matrix elements resulting in Fibrillin-1 deficiency that might trigger matrix 
metalloproteinase production, which in a similar way to Marfan syndrome may accelerate 
cystic medial degeneration and increase aortic dilatation and aneurysm formation (41).  
More indirect evidence to support this hypothesis is the fact that once a stenotic BAV is 
replaced surgically it does not prevent progressive dilatation of the ascending aorta 
suggesting a more inherent structural defect (41). 
1.3.1.3.4 Familial predisposition 
Barbour et al. have demonstrated that development of aneurysmal disease can be linked 
to genetics in a non-syndromic way.  Of patients with an aortic aneurysm, 15% had first 
degree relatives who were shown to have an aneurysm as well.  This potential genetic 
pre-disposition suggests that screening of asymptomatic 1st degree relatives of patients 
with confirmed ATAA may be useful so that any early disease can be treated through 
surveillance, prophylactic optimal medical therapy (OMT) and early intervention if 
necessary (36). 
Figure 11 below summarises the potential mechanism and interactions thought to be 
involved in ATAA formation: 
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Figure 11 Mechanisms of ATAA formation.  
 
 
 
 
 
 
 
Mechanisms of ATAA adapted from Evangelista A.(32)  TAA formation and expansion is an interplay between genetic 
predisposition, cardiovascular risk factors, and their effect upon the induction and activation of proteolytic enzymes.  This 
can lead to extra cellular matrix (ECM) breakdown, bringing about an inflammatory response, aortic wall sheer stress and 
further aortic dilatation. 
1.3.1.4 Clinical diagnosis 
In the United Kingdom (UK) with increased screening (the use of cardiac 
echocardiography in heart failure) and the use of advanced imaging techniques (CT and 
MRI to investigate cardiac and lung abnormalities) many dilated or aneurysmal 
ascending aortas are an incidental finding. 
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1.3.1.4.1 Echocardiography 
Trans-thoracic echocardiography (TTE) is an excellent imaging modality for both the 
diagnosis and follow up of the aortic root dimensions in the first 3-5 cm of the ascending 
aorta.  Echo utilises ultrasound waves and is therefore safe, portable, rapid and relatively 
cheap.  It does not require intravenous access and can be easily performed in outpatient 
clinics or in the community.  In the majority of subjects it allows reproducible 
measurement of the aortic diameters and assessment of the degree of aortic valve 
involvement (either BAV, aortic stenosis or regurgitation). Figure 12 below shows a TTE 
image of a patient with an ascending aortic aneurysm: 
Figure 12 TTE image of the annulus to ascending aorta 
 
 
 
 
 
 
 
2D transthoracic echocardiogram, parasternal long axis view of the heart and aorta showing LV – left ventricle,  1) Sinus 
dimension (4.01 cm)  2) STJ dimension (4.26 cm)  3) Grossly dilated ascending aorta dimension (6.94 cm). 
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In patients with poor TTE windows then trans-oesophageal echocardiography (TOE) can 
be extremely useful giving similar information and visualising the ascending aorta with 
excellent resolution. 
1.3.1.4.2 Tomographic imaging modalities 
1.3.1.4.2.1 CT scanning 
While TTE is a great screening and surveillance tool, vascular CT with its sub-millimetre 
spatial resolution is an extremely rapid and accurate modality to image the entire aorta 
(32).  The only disadvantage is the need for intra-venous contrast agent which can cause 
contrast nephropathy, and that the technique utilises potentially harmful ionising 
radiation.  This technique is described in more detail within Chapter 2.1 “CT 
measurement of ascending aortic size in 9 patients with AAAD.” 
1.3.1.4.2.2 Magnetic Resonance Imaging (MRI) scanning  
MRI also offers excellent visualisation of the whole aortic anatomy. This technique is 
described in more detail in Chapter 2.2 “CMR assessment of the aortic root, coronary 
arteries and ascending aorta of 62 patients with Marfan syndrome”.  MRI does not utilise 
ionising radiation. 
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1.3.1.5 Natural history 
In general aortic aneurysms develop slowly over many years, silently growing at an 
average rate in the ascending aorta of around 1 mm / year (32;42). 
There is a very clearly defined “hinge point” in ascending aortic size after which 
complications are much more likely to occur.  Figure 13 below demonstrates the “hinge 
point” of aortic size below: 
Figure 13 Graph showing aneurysm size versus probability of complication  
 
 
 
 
 
 
There is a very clear hinge point at 6 cm in size, where the risk of probability of complication increases dramatically.  It is 
vital to recommend surgery before the ascending aortic dimension reaches this point.  The recent AHA 2010 guidelines 
however go further and in patients with high risk of rupture surgery can be mandated with a smaller diameter.  Adapted 
from Evangelista et al. (32).  
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The key with ATAA is firstly to make the diagnosis, and then surveillance and optimised 
medical therapy (OMT) until a point where the benefits of surgical management outweigh 
the risk of continued OMT. 
1.3.1.6 Optimal medical treatment 
OMT involves aggressive control of hypertension utilising most commonly beta-blockers 
and angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers 
(AIIRB) as first line agents (43).  It has been suggested that beta-blockers reduce aortic 
wall stress and are indicated for non-operative candidates with dilated aortas (>4 cm) in 
the absence of aortic regurgitation (AR), but like almost all of the AHA 2010 guidelines 
this recommendation is based on consensus opinion rather than clinical trials (44). 
In patients with Marfan syndrome, beta-blockers have been the mainstay of 
pharmacotherapy based on a theoretical decrease in aortic wall stress.  However, there 
are conflicting data regarding the effects of beta-blockers on elastic properties of the 
Marfan aorta. 
A recent meta-analysis of six studies (one of which was a prospective randomised 
controlled trial (RCT) with >800 participants) showed no clinical benefit of beta-blockers 
in Marfan syndrome (45).  In a study comparing the ACE inhibitor enalapril versus beta-
blockade (propanolol or atenolol), the ACE inhibitor treated group had a significantly 
lower aortic stiffness index and a significantly lower rate of aortic root growth (46).  The 
AIIRB Losartan has also been shown to reduce the rate of aortic dilatation in patients 
with Marfan syndrome (43).  There is no evidence as to whether beta-blockers or ACE 
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inhibitors, alone or in combination, are preferable in the treatment of BAV or other ATAA 
aetiologies. 
1.3.1.7  2010 AHA guidelines on the management of ATAA 
A summary of the 2010 AHA guidelines on the management of ATAA is presented below 
(44): 
The guidelines are divided into asymptomatic and symptomatic patients. 
1.3.1.7.1 Recommendations for Asymptomatic Patients With ATAA 
Class I 
1. Asymptomatic patients with degenerative thoracic aneurysm, chronic aortic dissection, 
intramural hematoma, penetrating atherosclerotic ulcer, mycotic aneurysm, or pseudo 
aneurysm, who are otherwise suitable candidates and for whom the ascending aorta or 
aortic sinus diameter is 5.5 cm or greater, should be evaluated for surgical repair. (Level 
of Evidence: C) 
2. Patients with Marfan syndrome or other genetically mediated disorders (vascular 
Ehlers-Danlos syndrome, Turner syndrome, BAV, or familial thoracic aortic aneurysm 
and dissection) should undergo elective operation at smaller diameters (4.0 to 5.0 cm 
depending on the condition) to avoid acute dissection or rupture. (Level of Evidence: C) 
3. Patients with a growth rate of more than 0.5 cm / year in an aorta that is less than 5.5 
cm in diameter should be considered for operation. (Level of Evidence: C) 
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4. Patients undergoing aortic valve repair or replacement and who have an ascending 
aorta or aortic root of greater than 4.5 cm should be considered for concomitant repair of 
the aortic root or replacement of the ascending aorta. (Level of Evidence: C) 
Class IIa 
1. Elective aortic replacement is reasonable for patients with Marfan syndrome, other 
genetic diseases, or BAV, when the ratio of maximal ascending or aortic root area (r2) in 
cm2 divided by the patient’s height in metres exceeds 10. (Level of Evidence: C) 
2. It is reasonable for patients with Loeys-Dietz syndrome or a confirmed TGFBR1 or 
TGFBR2 mutation to undergo aortic repair when the aortic diameter reaches 4.2 cm or 
greater by TOE (internal diameter) or 4.4 to 4.6 cm or greater by CT imaging and / or 
MRI imaging (external diameter). (Level of Evidence: C)  
This guidance assumes that the risk of operation is low (<5%), and that the risk of an 
adverse event (rupture, dissection, death) exceeds the risk of elective operation. 
1.3.1.7.2 Recommendation for Symptomatic Patients With ATAA 
Class I 
1. Patients with symptoms suggestive of expansion of ATAA should be evaluated for 
prompt surgical intervention unless life expectancy from co-morbid conditions is limited or 
quality of life is substantially impaired. (Level of Evidence: C) 
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1.3.1.8  ATAA conventional surgical treatments 
The type and timing of a curative surgical procedure is dependent on a number of 
genetic, anatomical, and physiological patient factors, as well as a number of surgeon 
and cardiothoracic centre factors.  
1.3.1.8.1 Ascending aortic aneurysm  
ATAA may cause dilatation of the STJ, which pulls the cusps apart preventing central co-
aptation resulting in central AR as demonstrated in Figure 14 below: 
Figure 14 Aortic dilatation preventing aortic valve co-aptation causing central AR 
 
 
 
 
 
The diagram on the left shows a normal sized aortic root and sinuses with aortic valve cusps that are seen to co-apt in the 
midline preventing aortic incompetence.  The diagram on the right side shows a dilated aortic root and ascending aorta 
which prevents leaflet co-aptation resulting in a degree of central AR (arrowed).  
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It is of paramount importance that the degree and mechanism of AR is carefully 
elucidated along with the dimensions of each component of the aortic root.  Only with this 
information can a surgical procedure be properly planned. 
Surgery for ATAA is performed using CPB.  If the aortic valve is competent, “simple” 
replacement of the ascending aorta with a tubular Dacron graft is all that is needed with 
an “interposed graft”.  Figure 15 shows this below: 
Figure 15 An interposed ascending aortic graft 
 
 
 
 
 
 
 
 
The interposed ascending aortic Dacron graft.  The aortic root is of a normal diameter, and the Dacron graft (white with 2 
blue strips) has an anastomosis just above the STJ, and just proximal to the RBCT.  The aortic valve and the coronary 
arteries are not disturbed as both are functioning normally. 
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If the aortic valve is incompetent but the aortic cusps are normal and the mechanism is 
dilatation of the STJ, then the surgeon must re-establish valve competence by reducing 
the diameter of the STJ, as shown in Figure 16 below: 
Figure 16 Valve competence is re-established by reducing the diameter of the STJ 
 
 
 
 
 
 
 
The aorta on the left hand side shows a dilated STJ resulting in poor aortic valve co-aptation and resultant significant AR.  
The diagram on the right shows a surgical technique that can be used to reduce STJ diameter and re-establish valve 
competence.  The ascending aorta is cut 5 mm above the STJ, all 3 commissures are then pulled upwards and towards 
each other until the cusps co-apt centrally.  At this smaller diameter a Dacron graft is then sutured to the ascending aorta 
at the level of the STJ, replacing the aneurysmal ascending aorta and at the same time re-establishing aortic valve 
competence. 
If the non-coronary aortic sinus is aneurysmal it should be replaced along with the 
ascending aorta.  This is accomplished by selecting a graft of an appropriate diameter 
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and then creating a neo-aortic sinus.  This is then sutured directly to the remnant of the 
arterial wall and aortic annulus as shown in Figure 17 below: 
Figure 17 Surgical neo-aortic sinus formation 
 
 
 
 
 
 
 
 
Non coronary neo-aortic sinus formation is accomplished surgically by selecting a Dacron graft (white material with 2 blue 
strips) of an appropriate diameter and then manually creating a neo-aortic sinus by cutting the Dacron in a bespoke 
manner.  This is then sutured directly to the remnant of the arterial wall and aortic annulus. 
Patients with ATAA and aortic valve disease not amenable to valve repair are treated by 
aortic valve replacement and supra-coronary replacement of the ascending aorta.  
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1.3.1.8.2 Aortic Root aneurysm 
Aortic root aneurysm usually begins with dilatation of the aortic sinuses.  Once this 
involves dilatation of the STJ and / or the aortic annulus, AR can become significant.  
The coronary artery orifices are often displaced cephalically.  It is important to ascertain 
usually by TOE the precise mechanism of the AR – is it just dilatation with normal cusps, 
or are the cusps abnormal giving rise to greater than expected insufficiency.  Larger 
aneurysms often give rise to overstretched aortic cusps which become thinned and 
develop large fenestrations in the commissural areas. 
Replacement of the aortic root with a valved conduit has been the standard treatment for 
patients with aortic root aneurysms – the most commonly used conduit being a Dacron 
graft containing a mechanical valve (The Bentall procedure first described and performed 
in 1965) (47).  Aortic valve homograft and bio-prosthetic valves can also be used, see 
Figure 18 below: 
Figure 18 Bentall grafts with incorporated aortic valve 
 
  
 
 
Image on the left shows the Dacron tubular graft with an integrated mechanical aortic valve.  The image on the right hand 
side shows a similar Dacron graft with an integrated bioprosthetic aortic valve. 
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Replacement of the ascending aorta alone or in combination with aortic valve 
replacement can be performed with low operative mortality – Sioris et al. in 2004 
reported elective operative mortality of less than 5% (7). 
An alternative surgical option in patients with aortic root aneurysm and normal aortic 
cusps is aortic valve-sparing operations.  These are more complex surgical procedures 
whereby the coronary arteries are detached from the root, and the aortic sinuses are 
excised and the aortic cusps are left attached to the aortic annulus and LVOT. 
In essence there are 2 types of valve-sparing operation: 
 i) Remodelling of the aortic root and  
ii) Re-implantation of the aortic valve. 
1.3.1.8.3  Aortic root remodelling 
In this operative procedure the aortic sinuses are excised and the coronary arteries 
detached as demonstrated in Figure 19 below: 
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Figure 19 Aortic root remodelling operation  
 
 
 
 
 
 
 
 
 
On CPB, the aortic sinuses are excised and the coronary arteries detached.  Following which an appropriate sized piece 
of Dacron graft with “neo-aortic” sinuses (white material with blue stripes) is tailored and sutured to the remnants of the 
aortic sinuses and aortic annulus.  The coronary arteries are the re-implanted into their respective neo-sinus. 
1.3.1.8.4 Re-implantation of the aortic valve  
This is an even more complicated procedure, see diagrammatic representation in Figure 
20 below: 
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Figure 20 Surgical re-implantation of the aortic valve 
 
 
 
 
 
 
 
 
The coronary arteries are detached and the aortic sinuses excised as in Figure 19, but the aortic root is freed from the 
surrounding tissues to a level below the nadir of the aortic annulus.  Following this a Dacron graft of appropriate size is 
sutured to the left ventricular outflow tract immediately below the aortic annulus.  The remnants of the aortic sinus and 
aortic annulus are sutured inside the graft recreating the normal scalloped shape of the aortic annulus.  The coronary 
arteries are then re-implanted. 
Although there are only a few long term follow up studies, the results of aortic valve 
sparing operations are promising.  In a recent review by David et al. of 103 Marfan 
patients prospectively followed for a mean of 7.3 years only 2 patients required re-
operation for AR and 1 for infective endocarditis.  Re-implantation of the aortic valve 
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appeared to show more stable valve function as compared to remodelling of the aortic 
root (48). 
1.3.1.8.5 Elective aortic aneurysm surgery - outcomes 
If dilatation of the aortic root is left untreated there is a high risk of death due to 
dissection or rupture of the aorta or heart failure resulting from severe AR (49).  Since the 
first Bentall procedure in 1965, aortic root replacement has dramatically improved the 
survival of these patients (50).  In 2012 there is still no agreement about the best method 
of dealing with malfunction of the aortic valve caused by dilatation of the Marfan aortic 
root. 
Bentall and De Ba introduced total aortic root replacement (TRR) using a composite 
mechanical valve conduit and this was long considered the “gold standard”, providing 
excellent early and late operative outcomes (47).  However a proportion of patients 
receiving mechanical valves in this fashion do experience complications related to long 
term anti-coagulation. 
Recently valve-sparing aortic root replacement (VSRR) operations have emerged as an 
alternative as already discussed.  This technique preserves native valves and avoids the 
disadvantages of mechanical valve and long term anti-coagulation.  However given the 
fact that Marfan patients carry a structural fibrillin-1 defect, controversy has risen about 
the durability of such a reconstruction (51).  No RCT has ever addressed this problem.  
In 2011 Benedetto et al. published a systemic review and meta-analysis on the surgical 
management of aortic root disease in Marfan syndrome (52).  
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A total of 530 studies were identified, but after numerous exclusions to optimise quality 
eleven publications were included in the final analysis.  Overall a total of 1385 patients 
were analysed (972 had TRR and 413 had VSRR).  Mean follow up time was 8.0 years 
for TRR and 4.7 years for VSRR (p=0.003).  The total number of patient years follow up 
was 935 and 344 respectively.  
VSRR was associated with a fourfold increased rate of re-intervention on the aortic valve 
when compared to TRR (1.3% / year vs 0.3% / year p=0.02).  When the VSRR was 
broken down further into re-implantation (0.7% / year re-intervention rate) and 
remodelling (2.4% / year re-intervention rate), re-implantation was superior to 
remodelling, but both were inferior as compared to TRR (p=0.02).  
TRR was associated with an increased rate of thrombo-embolic events (0.7% / year vs 
0.3% / year; p=0.01).  There were no significant differences in endocarditis rates (0.3% 
vs 0.2% p=0.32).  Overall the incidence of all valve related complications were 
comparable after TRR and VSRR (52). 
1.3.1.8.6 Conclusions about elective ATAA surgery 
In patients with ATAA, replacement of the ascending aorta alone or in combination with 
aortic valve replacement can be performed with low operative mortality – Sioris et al. in 
2004 reported elective operative mortality of less than 5% (7). 
VSRR has emerged over the last few years as an alternative to TRR in Marfan patients 
with little or no valve involvement.  While anti-coagulation is not mandated with this 
approach in an often young group of patients this risk is exchanged for a greater re-
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intervention rate, and concerns long term that the abnormal valve leaflets will not be 
durable.  This data will only become available with time, and already there are ongoing 
prospective international registries comparing VSRR with TRR. 
1.3.1.9 Alternatives to conventional aortic root surgery for ATAA 
I felt it important to look beyond conventional aortic root surgery and investigate 
whether there are any minimally invasive or novel treatment modalities for the 
treatment of ATAA.  External aortic root support (EARS) for Marfan Syndrome 
appears to be a novel and less invasive strategy to treat Marfan aortic dilatation 
and the technique with early data is described below: 
In 1994 Robicsek et al. described an alternative to replacement of the ascending aorta, 
by externally wrapping the aorta at various aortic sites.  This approach has however been 
largely abandoned because of several patterns of failure (53).  
In 2004 Golesworthy an engineer suffering from Marfan syndrome described in 
collaboration with cardiothoracic surgeons Pepper and Treasure the development of a 
bespoke external aortic root support (EARS).  The proposed EARS operation can be 
performed without CPB, without entering the circulation, and without interfering with the 
aortic valve in any way.  If this external support can hold and support the whole of this 
aortic segment at a size where the risk of dissection is low, it may obviate or greatly 
postpone the need for more radical and ablative surgery (54). 
The exact dimensions of the individual patient’s aorta are taken from MRI images and 
processed using computer aided design to produce a 3D reconstruction of the patient’s 
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aorta from the aorto-ventricular junction to beyond the RBCT (55).  The X, Y and Z co-
ordinates of the reconstructed aorta are then exported to a rapid prototyping machine 
and a model of the patient’s aorta made in thermoplastic.  This model then acts as a 
former upon which an external support is manufactured from medical grade polymer 
mesh.  The finished support is then sterilised, packaged and sent to the surgeon with a 
vertical seam that can be opened by the surgeon to place the support around the aorta. 
Figure 21 below shows the EARS support. 
Figure 21 Photograph of EARS 
 
 
 
 
 
Bespoke made polymer mesh is sterilised, and the graft is brought onto the operating table, the longitudinal seam is 
opened and the support placed around the aorta, and then sutured to enclose the aorta.(56) 
At operation through a median sternotomy the aorta is completely dissected from aorto-
ventricular junction to the origin of the RBCT.  The patient specific bespoke EARS graft is 
then brought onto the operating table, placed around the aorta, and then sutured to 
enclose the aorta preventing further aortic dilatation. 
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The first 20 patients (13 men and 7 women) underwent EARS from May 2004 to October 
2009.  There have been no operative deaths and the operation was completed exactly as 
planned in 19/20 patients while the 20th patient had partial release of the external 
support.  In no patient was there a need to convert to root replacement or any other form 
of surgery.  CPB was utilised for 20 minutes during the first patient only. 
Only patient 20 had a complication - post operatively suffering a VF arrest.  The 
circulation was restored after removing the anterior closing suture on the aortic root 
support.  The patient made a normal recovery and was discharged home day 8.  As a 
result the aorta in this patient is only partially supported and will be closely monitored.  
The 20 patients involved in the EARS cohort had a median age of 33 years and had a 
median aortic diameter of 47 mm (range 40-54).  The median operation time was 148 
minutes compared to 374 minutes for conventional Marfan aortic root surgery.  Patients 
had a shorter length of hospital stay when compared to their conventionally treated 
comparators (6 days vs 8 days in the conventional surgery cohort) (55).  Table 4 below 
shows EARS demographic and follow up data (55): 
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Table 4 EARS demographic and follow up data (n=20) 
Variable Median Inter-quartile range Range 
Age at operation (years) 33 26-39 16-58 
Aortic diameter (mm) 47 43-48 40-54 
Operation time (min) 148 136 – 163 125-415 
Length of stay (days) 6 5-7 3-16 
Follow up (months) 20 10-39 0-67 
Change in aortic diameter (mm) 
(n=16) 
-1 -2 - +1 -6 - +3 
Meticulous follow up of these 20 patients has occurred and the dimensions of the 
ascending aorta at the level of the aortic valve cusps is presented in Figure 22 below: 
Figure 22 Dimensions of the ascending aorta (mm) in the EARS cohort  
 
 
 
 
Dimensions of the ascending aorta (mm)  (A) at the level of closure of the aortic valve cusps before operation, (B) at the 
first postoperative scan and (C) most recent MRI scan.  There appears to be a tendency for EARS to reduce the diameter 
of the Marfan aorta which remains stable thereafter.  The longest follow-up scan is five years after surgery (55). 
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1.3.1.9.1 Conclusions about the EARS procedure 
The purpose of aortic root surgery in Marfan syndrome is to pre-empt the risk of dilatation 
thus saving the patient from AR and death due to aortic dissection.  Successful 
placement of the external aortic support was achieved in 19 of the 20 patients, with only 
partial success in the 20th patient. 
It would seem that the EARS procedure is safe, and that the magnitude of the surgery is 
greatly reduced when compared to conventional aortic root replacement.  The hazards 
associated with CPB, myocardial ischaemia, deep circulatory arrest and the neurological 
risks associated are obviated.  Operation times and hospitals stays are also shorter. 
The follow up so far of this small cohort of patients would appear to suggest that the 
EARS procedure provides a robust and dependable result in preventing further 
ascending aortic dilatation.  More patients will need to be treated in this manner, and 
their longer term outcomes published before EARS can be considered for RCT against 
conventional surgery, only then might it become an accepted treatment strategy for 
Marfan dilated aorta. 
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1.3.2 Ascending type A aortic dissection (AAAD) 
Before considering the design specification of an endovascular solution to treat 
the unmet clinical need of AAAD it is mandatory to understand the disease 
process and the current treatment strategies and outcomes.  Any endovascular 
solution must provide a similar technical result to that achieved by open surgery, 
including exclusion of the intimal tear, preservation of coronary artery flow, and 
maintenance of aortic valve competence. 
AAAD is a challenging clinical emergency first described by Morgagni more than 200 
years ago (57).  In 1958, Hirst et al reviewed 505 patients with the condition, highlighting 
the high mortality rate and the infrequency of ante-mortem diagnosis (58). 
One of the earliest and most famous documented deaths from AAAD was that of King 
George II: 
On 25 October 1760 George II, then 76, rose at his normal hour of 6 am, called as usual 
for his chocolate, and retired to the closet-stool.  The German valet de chambre heard a 
noise, memorably described as ‘louder than the royal wind’, and then a groan; he ran in 
and found the King lying on the floor, having cut his face in falling.  Mr Andrews, surgeon 
of the household was called and bled his Majesty but in vain, as no sign of life was 
observed from the time of his fall.  At necropsy the next day Dr Nicholls, physician to his 
late Majesty, found the pericardium distended with a pint of coagulated blood, probably 
from an orifice in the right ventricle, and a transverse fissure on the inner side of the 
ascending aorta 3.75 cm long, through which blood had recently passed in its external 
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coat to form a raised ecchymosis, this appearance being interpreted as an incipient 
aneurysm of the aorta” (59). 
The typical AAAD process is characterised by rapid development of an intimal tear with a 
flap separating a true and a false lumen, as shown in Figure 23 below:  
Figure 23 Aortic dissection showing intimal tear, true and false lumen 
 
 
 
 
 
 
Figure shows a schematic of an arterial wall with three layers – the Adventitia, Media, and Intima.  An Intimal tear is seen 
as a break within the Intima, allowing blood to track in both a true and false lumen.   
In the majority of cases intimal tears are identified as sites of communication between 
true and false lumens.  The dissection can spread from diseased segment of the aortic 
wall in either an antegrade or retrograde fashion, involving side branches and causing 
complications such as malperfusion syndrome by dynamic or static obstruction (from 
coronaries to femoral arteries), tamponade or AR (60). 
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1.3.2.1.1  Classification 
The simplest classification described is that of Stanford and distinguishes between Type 
A and Type B (61).  Type A means the dissection involves the ascending thoracic aorta; 
Type B dissection does not involve the ascending aorta.  Most current consensus 
treatment guidelines are based on the Stanford nomenclature.  Other classifications do 
exist including Debakey, and Penn and these are only briefly discussed within this thesis.  
Figure 24 below describes the Stanford aortic dissection classification: 
Figure 24 Stanford classification of aortic aneurysm 
 
 
 
 
 
   Type A   Type B 
Type A aortic dissection affects the ascending aorta.  The intimal tear is most commonly within the ascending aorta, but 
can be within the arch or descending with retrograde propagation of the false lumen.  Type A dissections commonly 
propagate into the arch and descending aorta where there may be a re-entry tear.  Type B dissections do not affect the 
ascending aorta. 
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1.3.2.1.2 Incidence 
The true incidence of AAAD is difficult to determine as many cases go undiagnosed, but 
its documented incidence is approximately 3 per 100,000 per year, with at least 7,000 
documented cases per year in the United States (62).  A population based study in 
Sweden between 1987 and 2002 revealed 4425 cases of aortic dissection within a 
population of 8.7 million, equating to 3.4 cases per 100,000 people per year (63).  During 
the 16 year study period the combined yearly incidence of aortic dissection and 
aneurysm increased by 50% in men and 30% in women.  The reasons for this increase 
are unknown but might relate to improved identification of cases with enhanced imaging, 
or increasing age of the population or both.  Overall about 20% of patients died before 
reaching hospital, 30% during hospital admission, and a further 20% over the next 10 
years (63).  AAAD continues to this day to be one of the most feared diagnoses with its 
early mortality rates remaining similar to that described by Hurst and Kime in their 
seminal article describing a mortality rate of 1-2% per hour for the first 24 hours after 
symptom onset from AAAD (58). 
The peak incidence of aortic dissection is in the sixth and seventh decades of life, with a 
mean age of 62 years among more than a thousand subjects in the International Registry 
of Aortic Dissection (IRAD).  Overall men are affected twice as often as women (68% vs 
32%) and are affected at a younger age with male patients having a mean age of 60 
years and women patients a mean age of 67 years (64). 
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1.3.2.1.3 Pathophysiology 
A healthy aorta with an intact medial layer rarely dissects.  Any disease process or 
condition that damages the elastic or muscular components of the media predisposes the 
aorta to dissection.  The commonest associated factors for aortic dissection are a history 
of hypertension, old age, atherosclerosis, and previous cardiac surgery.  Marfan 
syndrome is an important risk factor for aortic dissection especially in young patients 
(<40 years).  Table 5 details the incidence of risk factors for AAAD in IRAD (65): 
Table 5 Incidence of AAAD risk factor variables 
Variable Incidence in IRAD (n=617)  
Age (mean in years at presentation) 61 years 
Sex (male) 67% 
Hypertension 67% 
Atherosclerosis 28% 
Previous cardiac surgery 16% 
Known aortic aneurysm 7% 
Marfans syndrome 6% 
Bicuspid aortic valve 4% 
Previous aortic dissection 3% 
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Like ATAA there seems to be a significant genetic basis for AAAD that is not associated 
with a recognised connective tissue deficiency syndrome.  Up to 19% of patients who 
present with a thoracic aneurysm or dissection have a first degree relative with a similar 
history (66). 
The increasing use of high resolution imaging to assess the aorta has led to the 
identification of a range of intimal and intramural pathological changes that have been 
related to dissection – including intramural haematoma, and atherosclerotic ulcers.  
Commentators have suggested that aortic dissection is the end process of an array of 
different pathological processes, many of which promote weakening of or increased 
stress on the aortic wall, or both.  The sequence of events might begin with a tear in a 
damaged intima possibly evolved from an atherosclerotic ulcer.  Alternatively disruption 
of the vasa vasorum might result in an intramural haematoma which later ruptures into 
the aortic lumen (66).  Regardless of the sequence of events once a dissection path is 
started, blood can travel for a variable distance in an antegrade or retrograde manner, or 
both before commonly re-entering the arterial true lumen.  
1.3.2.1.4 Complications of aortic dissection 
In an established aortic dissection the principle complications are aortic rupture, AR, 
acute myocardial infarction (AMI), tamponade and end organ ischaemia (malperfusion 
syndrome) as shown in Figure 25 below: 
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Figure 25 Complications of aortic dissection 
 
 
 
 
 
 
 
 
Malperfusion syndromes can compromise flow to the coronary arteries resulting in AMI, or cerebral arteries causing 
cerebro-vascular accident (CVA).  The dissection can cause AR, and tamponade causing the patient to present with 
hypotension and shock.  Depending on the path of the dissection, patients can present with malperfusion of spinal cord, 
liver, bowel, kidneys and legs.  
Malperfusion to any organ can be static as a result of fixed obstructions at the arterial 
origin, or dynamically affected by pressure changes in the true and false lumens.  High 
pressure within the false lumen can compress the true lumen inducing ischaemia to any 
end organs fed by that artery. 
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1.3.2.1.5 Clinical presentation and diagnosis 
Most patients present with chest pain which is classically described as “tearing” or 
“ripping” through to the back.  Hypotension or shock is seen in about a quarter of AAAD 
patients at presentation (usually as a result of tamponade, AR, or heart failure), whereas 
hypertension is a more common finding in those with Type B dissection (2).  Table 6 
below summarises the commonest AAAD presentations seen in the IRAD registry (65): 
Table 6 Clinical characteristics of AAAD presentations 
Symptom and signs IRAD Type A database (n=617)  
Chest / back pain 85% 
Severe / worst pain ever 90% 
Hypotension / shock 27% 
Aortic regurgitation 44% 
Pulse deficit 33% 
Widened mediastinum on CXR 63% 
Myocardial ischaemia or infarction (on ECG) 24% 
 
Aortic dissection can be extremely difficult to diagnose as given the varying malperfusion 
syndromes it can mimic the de novo presentation of AMI, CVA, thrombo-embolic 
peripheral vascular disease, acute abdomen – the list is extensive.  CT angiography or 
echocardiography is usually needed in patients in whom clinically acute aortic dissection 
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is suspected on the basis of presentation (67).  A systemic review of the diagnostic 
accuracy of TOE, CT angiography, and MRI reported a mean sensitivity of more than 
95% for all 3 investigations (68).  MRI was slightly better than the other two at showing 
aortic dissection in a patient with high pre-test probability, whereas CT was better at 
correctly excluding an aortic dissection in a patient with a low pre-test probability. 
In the UK the most commonly utilised diagnostic modality available in most hospitals 24 
hours a day is the CT scan.  High resolution CT scanning enables 3D reconstruction to 
be made, which in turn can help to plan appropriate management.  Size of the true and 
false lumen can be measured, localisation of the intimal tear established, and 
involvement of aortic branches can be ascertained.  The presence or absence of other 
complications including peri-aortic haematoma, AR, mediastinal haematoma and 
pericardial effusion and tamponade can also rapidly be elucidated.  Current guidelines 
recommend the use of echocardiography or CT, or both in the initial imaging of patients 
with suspected AAAD.  Ionising radiation is a distinct disadvantage of CT, and therefore 
in the non urgent, chronic dissection follow up magnetic resonance angiography (MRA) is 
favoured (69). 
Figure 26 below shows CT, MRI, and TOE image diagnoses of AAAD: 
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Figure 26 Shows CT, MRI, TOE images obtained in the diagnosis of AAAD  
 
 
 
 
 
 
 
 
Images clockwise from top left show 1) CT imaging of AAAD, showing a almost central dissection line,2) and 3) MRI 
imaging of AAAD, showing smaller white “true lumen” and grey larger “false lumen”, and finally 4) a TOE diagnosis of 
AAAD showing an intimal flap (arrowed). 
1.3.2.1.6 Management and outcome 
AAAD is highly lethal, with mortality ranging between 1-2% per hour early after symptom 
onset (2).  AAAD is always a surgical emergency.  Medical management alone is 
associated with a mortality of nearly 20% by 24 hours, 30% by 48 hours, 40% by day 7, 
and 50% by one month.  Even with surgical repair, mortality rates are 10% by 24 hours, 
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13% by 7 days, and 20% at 30 days as recently documented in the largest registry of 
aortic dissection (2).  Figure 27 below shows a graph of mortality from Type A and Type 
B aortic dissection when treated medically compared surgical treatment. 
Figure 27 Graph of percentage cumulative mortality of Type A & B dissection 
 
 
 
 
 
 
 
Graph adapted from Mehta et al.  Mortality from both Type A and Type B versus time depending on medical or surgical 
management.(70)  30 day Mortality for AAAD is more than doubled if managed medically and not offered surgery (50% 
versus 20%). 
Aortic rupture, stroke, visceral ischaemia and cardiac tamponade or circulatory failure are 
the most common causes of death (70). 
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Mehta et al have also published a risk score for death in patients presenting with AAAD 
(70).  The most significant features at presentation are highlighted in the Table 7 below: 
Table 7 Presentation features seen in AAAD associated with death 
Variable Overall (%) Among 
Survivors  (%) 
Among 
deaths   (%) 
Score 
assigned 
 p-value Death odds 
ratio (OR) 
Age > 70 35.2 30 46.1 0.5 0.03 1.7 
Abrupt onset 
pain 
84.5 82.3 89 1.0 0.01 2.6 
Abnormal 
ECG 
69.6 65.2 79.5 0.6 0.03 1.77 
Pulse deficit 30.1 24.7 41.1 0.7 0.004 2.03 
Kidney 
failure 
5.6 2.9 11.9 1.6 0.002 4.77 
Shock / 
tamponade 
29 20.1 47.1 1.1 <0.0001 2.97 
 
A risk score of 1 results in a predicted and observed mortality of approximately 10%.  A 
combined risk score of 4.5, corresponds to a risk of death approximated to 80%.  These 
risk factors were statistically extracted from a retrospective analysis from the IRAD 
database, and then prospectively confirmed (70).  Figure 28 below shows a graph of 
observed and predicted mortality based on AAAD risk score: 
 
97 
 
Figure 28 Graph showing observed and predicted mortality for AAAD based on a risk 
score  
 
 
 
 
 
 
Adapted from Mehta et al. (70)  Observed mortality versus predicted mortality for patients presenting with AAAD based on 
a risk score retrospectively extracted and prospectively confirmed from IRAD database.  A risk score of 1 results in a 
predicted and observed mortality of approximately 10%.  A combined risk of score of 4.5 = risk of death is around 80%. 
1.3.2.2 Conventional AAAD surgical treatments 
Currently no RCT have been conducted to guide the management of AAAD.  Clinical 
pathways are therefore currently based upon registry data, consensus documents and 
local expertise. 
Surgical resection of the ascending aorta is the standard management of AAAD (71).  In 
case series of patients, only those with several co-morbidities and who were moribund or 
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refusing surgery are typically treated medically alone, with an in hospital mortality for 
these patients of 50% at 30 days (4). 
28% of patients with AAAD in IRAD were treated medically because of co-morbidities 
(33%), patient or family choice (25%), advanced age (21%), or the presence of 
intramural haematoma only on imaging (21%) (67). 
The principle aim of surgery for AAAD is to resect the ascending aorta and arch if 
affected by the intimal tear and replace it with a prosthetic graft (71).  Repair or 
replacement of the aortic valve is also needed if substantial pathological change of the 
aortic root or valves exists.  Depending on the state and anatomy of the coronary ostia, 
reconstruction of the coronary arteries may be required in some cases where aortic valve 
replacement is mandated.  
The exact surgical approach taken depends on a number of factors: 
Patient factors – preoperative condition, pre-existing pathological condition predisposing 
to dissection, extent of intimal tear and dissection, aortic root and aortic valve anatomy, 
coronary anatomy. 
Surgeon factors – Surgeon experience, training and preference (71). 
While AAAD patients share a common diagnosis every single patient will have a unique 
mix of anatomical and clinical parameters, and because patients present 24 hours a days 
they will often be met by a cardiothoracic surgeon who only performs a handful of type A 
repairs per year.  In a number of countries as with most interventional and surgical 
procedures there has been centralisation of services to optimise outcomes by allowing 
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teams to be on call for a particular service at a tertiary or quaternary centre.  As a result 
of the clinical and surgical variation many surgical approaches are used in large multi-
centre series. 
IRAD reported the results of surgical repair of AAAD in 682 patients treated at 18 tertiary 
centres in 6 countries (9).  Techniques used included: 
Supra-coronary aortic replacement in 399 patients (58.5%). 
Aortic valve sparing operations in 58 patients (8.5%). 
Aortic valve, root and ascending aorta replacement with coronary artery re-implantation 
performed in 101 patients (16.2%) by use of a composite aortic valve / aortic-valve 
conduit graft. 
Right hemi—arch replacement was utilised in 168 patients (27.3%), complete arch 
replacement in 72 patients (11.5%). 
An open procedure with hypothermic circulatory arrest was used in 597 patients (92%), 
with cerebral perfusion in 322 patients (51.4%).  Overall the aortic valve was replaced in 
152 patients (24.2%) and simultaneous coronary artery bypass grafting was performed in 
100 patients (14.6%). 
As has already been discussed in the previous section (1.3.1.8.5) there is considerable 
controversy in elective surgical repair of ATAA whether to repair or replace the aortic 
valve – this is also the case in AAAD surgery. 
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Suzuki et al. in their update on surgery for AAAD describe that there have been 
advances in operative methods, peri-operative management and that surgical outcomes 
are improving slowly, but that the in-hospital mortality is still unacceptable ranging from 
10% - 30% in most series (3). 
1.3.2.2.1 The techniques of aortic root repair in AAAD 
1.3.2.2.1.1 Use of “Bio-glues” 
Gelatin-resorcin-formaldehyde-glutaraldehyde (GRF) glue was created in 1966 and 
first utilised in aortic root reconstruction in 1977 by Guilmet et al (72).  Figure 29 below 
shows how bio-glues are utilised in the repair of AAAD: 
Figure 29 Use of bio-glues in AAAD surgery 
 
   
 
 
 
The bio-glue is applied between the intimal and media layers, to reinforce the aorta rendered fragile by the acute 
dissection, and also to strengthen the anastomosis. 
101 
 
In 1999 Bachet and colleagues reported 21% in-hospital mortality (39/204 patients) in 
operations using the GRF glue (73).  Subsequently GRF had been used widely in 
operations for AAAD.  There have however been reports of late toxic effects of the glue, 
and Kazui in 2001 reported re-dissection of the root in 4 of 57 patients (7%) who had 
undergone this technique (74;75).  Re-operation revealed dehiscence of the proximal 
suture line.  As a result of this GRF glue has fallen out of favour as it is felt that the toxic 
effects of formalin compromise an otherwise successful operation.  A relatively similar 
story was seen with BioGlueTM (Cryolife, GA, USA) composed of bovine serum albumin 
(BSA) with glutaraldehyde (76). 
In 1994 Seguin et al reported one non-valve related early death (6.7%), but no late 
mortality after aortic valve repair with fibrin glue for AAAD (77).  Suzuki  et al. report that 
they have utilised fibrin glue with Teflon strips on the inner and outer surfaces of the 
aorta for reinforcement since 2003, with an impressive in hospital mortality rate of 15.9% 
(3).  Nakajima and colleagues have adapted this technique by using a fabric neomedia 
and fibrin glue in patients undergoing supra-commissural aortic replacement.  Aortic re-
operation was not required in 98% of patients at 10 years (78).  Fabric neomedia and 
fibrin glue technique is shown in Figure 30 below: 
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Figure 30 Fabric neomedia and fibrin glue use 
  
 
 
 
 
 
Nakajima and colleagues use a fabric neomedia and fibrin glue in patients undergoing supra-commissural aortic 
replacement (78).  A bespoke cut piece of fabric neomedia is inserted between the intima and media, and then sealed in 
position with fibrin glue. 
1.3.2.2.1.2  Adventitial inversion technique 
Floten et al. described the adventitial inversion technique (AIT) to repair aortic dissection 
in 1995, and is described in Figure 31 below (79): 
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Figure 31 The AIT technique 
 
 
 
 
 
 
Adapted from Floten et al .(79)  During the resection of diseased ascending aorta and inner curve of the arch, the margin 
of the intima is trimmed back 1 cm distal to the adventitial resection line.  The redundant adventitia is then inverted into the 
aortic lumen and tacked to the luminal surface of the intima by horizontal 6-0 Prolene sutures.  This creates a tough yet 
soft aortic cuff. 
In 2005 Tanaka et al. reported using AIT in 18 patients with an overall in hospital 
mortality of 11.1% but no re-operation during the follow up period of 7-51 months.  They 
concluded that while it appears safe with good short term data more operations and 
longer term follow up is required to validate the technique (80). 
1.3.2.2.1.3  Composite Replacement 
This technique has already been covered in section 1.3.1.8.2 on treatment of ATAA.  The 
pros and cons versus more conservative but often more complex valve sparing 
techniques are exactly the same as in elective ATAA surgery.  Ergin et al. compared 19 
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patients having composite radical root replacement (Group 1) with 54 patients having 
valve-preserving root reconstruction (Group 2).  Despite Group 1 having higher risk 
features (more AR and coronary dissection involvement) the operative mortality of the 2 
groups was the same (15.7% vs 12.9% NS).  Group 1 also had better event free survival 
at  5 years (88 +/- 12%  vs 63 +/- 9%) and at 9 years (88 +/- 22% vs 63 +/- 19%), thus 
they recommended that composite root replacement be utilised more frequently (81).  
The only drawback with patients treated with mechanical valve conduits is the need for 
lifelong anticoagulation which in itself carries a risk of bleeding and a rate of thrombo-
embolic complications thought to be approximately 4 events per 1000 patient / years 
follow up (82). 
1.3.2.2.1.4  Aortic valve sparing techniques 
These techniques have already been described in detail within the ATAA section 
1.3.1.8.3.  In 2002 Leyh et al. reported that 30 patients with AAAD underwent valve 
sparing aortic root replacement (remodelling in 8 and re-implantation in 22).  The mean 
follow up was 22.6 +/- 15.4 months.  The overall 30 day mortality was 17% and late 
mortality 4%.  During the observation period 4 patients (13%) required re-operation (83).  
Long term durability of the valve sparing repairs is a surgical concern.  Not only that, but 
the results are very surgeon dependent and there appears to be a significant learning 
curve.  Most of the published series of valve sparing aortic repairs are in patients 
undergoing elective aortic aneurysm surgery.  In the 2002 series published by David 
approximately 12% of cases were in AAAD – it is therefore difficult to extrapolate elective 
outcomes and theoretical advantages into this very high risk AAAD cohort (84). 
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David (a pioneer of valve sparing aortic surgery) and Fazel from their paper in Current 
Opinions in Cardiology 2007 state: 
“patients with AAAD may also benefit from the aortic valve sparing operation, but as 
these are complex operations they should be performed only in centres with much 
experience.  Thus, the surgeon must be well trained in elective surgery to be confident 
using the technique when emergency surgery is performed for AAAD.  We need to 
investigate whether these benefits will outweigh the potential risk for re-operation” (85). 
1.3.2.2.1.5  Other controversy in AAAD surgery 
Extent of the distal resection remains a controversy in AAAD surgery.  The dissection 
frequently extends beyond the ascending aorta and arch, and thus theoretically the false 
lumen might remain patent after ascending aortic replacement.  With the substantial 
mortality and morbidity associated with resection of large parts of the aorta, there is 
increasing interest in combining open surgical repair of the ascending aorta with 
endovascular stent grafting (86).  These procedures might be combined or staged; 
however their exact role is unclear and are under investigation. 
1.3.2  Overall Conclusions from literature review of AAAD  
There are >7,000 documented cases of AAAD in the USA per year, and the incidence is 
increasing with better diagnostic identification and an aging population (62).  Currently 
AAAD is a surgical emergency with a mortality rate within the first 24 hours of 1-2% / 
hour.  Complications of AAAD include aortic rupture, AR, AMI, tamponade and 
malperfusion syndrome (2). 
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28% of AAAD patients are turned down for surgery, and medical management has a 
mortality rate of >50% at 30 days (2).  Even with surgical repair mortality rates are 
approximately 10-30% at 30 days (3).  The principle aim of surgery for AAAD is to resect 
the intimal tear and replace with a prosthetic graft (usually Dacron), ensuring coronary 
flow and aortic valve competence.  In IRAD nearly 60% of patients had a “simple” supra-
coronary replacement.  16% had aortic valve, aortic root and ascending aorta 
replacement, with coronary re-implantation.  8.5% had aortic valve sparing operations.  
27.3% had a right hemi-arch replacement, while complete arch replacement was 
performed in 11.5% of patients (9). 
A number of surgical techniques have been described, and operation choice is based 
upon patient, and surgeon factors.  Valve sparing aortic valve repair surgery appears to 
have a role, but must only be performed by surgeons experienced in this technique as 
there is a steep learning curve.  
1.3.2.3 Potential implications for ATAG design specification in setting of AAAD 
The important facts with regard to designing an ATAG endovascular stent graft to treat 
AAAD are as follows: 
AAAD is an emergency and must be treated quickly.  An endovascular graft, trained staff 
and a theatre with x-ray equipment must be rapidly available because untreated AAAD 
has a mortality of 1-2% per hour.  The manufacture of bespoke grafts will not be possible 
for this group of patients and we must have “off the shelf” grafts ready for this 
intervention. 
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An appropriately sized simple tubular graft starting at the STJ proximally and finishing 
distally before the RBCT might treat approximately 60% of AAAD (endovascular 
equivalent of a simple supra-coronary replacement).  Success will depend on having an 
adequate proximal and distal landing zone for the ATAG. 
Approximately 25%-35% of patients will require aortic valve intervention to render the 
aortic valve competent.  The ATAG will either need to have an integrated valved solution, 
or a commercially available TAVI will need to be implanted after the ATAG has been 
deployed. 
The ATAG will not be capable in itself of dealing with the 27% of patients that require 
right hemi-arch replacement, or the 11% requiring full arch replacement.  It is too early to 
suggest how these patients will be optimally managed, but dedicated endovascular arch 
solutions are being developed and tested, and there is much interest currently with 
“hybrid” endovascular and surgical techniques to deal with arch anatomy. 
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1.3.3 Aortic sizes in AAAD 
I now needed to understand the variation in aortic size in patients presenting with 
AAAD.  This would have profound effects on the size of stent grafts required, and 
the subsequent size to which they could be stowed.  For instance a 10 mm 
increase in deployed stent size could require a 2-4 F size increase in diameter of 
the delivery system.  This full literature review of aortic sizes in AAAD also enabled 
me to understand what parameters remained unpublished and poorly understood 
(e.g. coronary associations / angulations) and this helped inform my measurement 
protocol for the CT work that I performed with Professor Qanadli.   
In 2009 Parish et al. from Philadelphia published their data of 177 patients presenting 
with AAAD over a 10 year period (87).  The ascending aortic measurements were taken 
retrospectively from TOE images performed pre-operatively.  Measurements were taken 
at the anatomical landmarks shown in Figure 32 shown below: 
Figure 32 Parish AAAD measurement protocoll  
      
 
 
 
TOE aortic Measurements made 1 – Aortic annulus, 2 – Sinus of Valsalva, 3 – Sinotubular junction, 4 – Ascending aorta  
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Results were then compared to each patients predicted aortic dimension based on a 
large normative group corrected for age, sex and body surface area.  Patients with 
known inherited connective tissue disease (Marfan syndrome, Ehlers Danlos etc) were 
excluded from this analysis as were those individuals with BAV. 
The average maximal aortic diameter at any location was 53 +/- 10 mm (mean +/- SD).  
The maximum diameter occurred at the ascending aorta in 87.6% of patients, and 9.6% 
of patients in the sinus segment.  Table 8 below reveals the observed diameters versus 
the predicted aortic size from the Parish AAAD cohort (87): 
Table 8 Mean maximal aortic diameter at the time of dissection 
Location Observed diameter (mm) +/- SD Predicted diameter (mm) +/- SD 
Annulus 23 +/- 4 26 +/ - 4 
Sinus 40 +/- 7  34 +/- 2  
STJ 35 +/- 8  29 +/- 2  
Ascending aorta 53 +/- 10 30 +/- 4  
 
The graphical representation in Figure 33 below shows that 62% of this 177 non-marfan 
type AAAD cohort had a maximal aortic diameter of <5.5 cm (the current guideline for 
consideration of prophylactic aortic surgery).  Over 20% had a maximal diameter <4.5 
cm. 
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Figure 33 Maximum aortic diameter distribution 
 
 
 
 
 
 
 
Adapted from Parish (87).  The mean maximal aortic diameter in the Parish AAAD cohort was 5.3 cm.  62% (shaded bars) 
of the 177 non-Marfan AAAD cohort had a maximal aortic diameter of <5.5cm (the current guideline for consideration of 
prophylactic aortic surgery).  Over 20% had a maximal diameter <4.5cm.  
This study has important clinical implications, and its data is consistent with a similar 
analysis performed on the IRAD database (88).  More than 60% of patients presenting 
with AAAD had maximal aortic diameters <5.5 cm (the current guideline recommendation 
size for elective prophylactic ascending aortic replacement).  As a result the current 
surgical guidelines would fail to prevent the majority of aortic dissections seen in these 
large registry cohorts.  Even with the more aggressive guidelines adopted for the Marfan 
syndrome patients (surgery > 4.5 cm) 20% of men and 23% of women in the Philadelphia 
cohort would not have qualified for preventative aortic replacement (87). 
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The Parish et al. study described above measured the maximal aortic size after the 
dissection had occurred.  Although no data exist definitively demonstrating that aortic 
size immediately before aortic dissection is smaller than after dissection, it seems likely 
that this is the case. 
Neri et al. attempted to determine pre-dissection aortic size from surgical specimens 
removed from over 200 patients at the time of AAAD (89).  Perimeter of intimal layer was 
used as the measurement technique, as shown in Figure 34 below: 
Figure 34 Inner layer measurement technique 
 
 
 
 
 
Adapted from Neri et al (89).  Harvested cylinders of fresh aortic tissue were measured the inner layer of the true aortic 
lumen with a correction for the absence of perfusion pressure.  L - perimeter of intimal layer. 
The median ascending aortic diameter determined by this method was 4.1 cm (89). 
These data would all seem to suggest that currently accepted aortic size guidelines are 
not a sufficient index for the risk of AAAD.  To fully understand and predict those patients 
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at risk of AAAD we must study and understand the biomechanics of the ascending aorta.  
Dynamic mechanical factors such as aortic root motion, and the direction of twisting 
forces of the vessel may be important.  Improved vessel imaging modalities including 
magnetic resonance angiography (MRA) coupled with finite element analysis (FEA) may 
provide us with better risk stratification in the future. 
Further research is needed to develop effective algorhythms in the form of biomarker, 
genetic, or imaging strategies that can better identify patients with aortic sizes between 
4-5 cm who are at the greatest risk from AAAD. 
1.3.3.1  Conclusions about aortic size in AAAD important to ATAG design 
From the literature currently available, the majority of aortic diameters in AAAD are 
between 4.0–6.5 cm, with a mean diameter of 5.3 cm (87).  This covers approximately 
85% of the population with AAAD, with 5% having a diameter of <4.0 cm, and 10% 
having a diameter greater than 6.5 cm.  
This size variation and the need for the ATAG to be “on the shelf” will require ATAG to be 
developed in a number of different diameters (and lengths) to suit the aortic anatomy 
defined by pre-procedure tomographic imaging.  Different stent designs may be required 
for these sizes, and also it is highly likely that different diameter delivery systems will also 
be required, as the larger the diameter of the deployed stent generally the greater the 
stowed diameter within the delivery system.  During development we will determine the 
“maximal ATAG diameter” above which it is not technically feasible to make and stow a 
graft to a suitable diameter.  There may also be potential financial restrictions where 
manufacturing for instance a 8 cm graft is not financially viable because of the large 
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development costs and the very small numbers of patients who will have this degree of 
aortic dilatation. 
In the first instance ATAG design input will focus on developing a graft capable of 
treating patients with maximal aortic size of between 4-6.5 cm.  One must also remember 
that if we choose to treat patients with grafts oversized by 20% (as is common in other 
parts of the aorta) this means that stent frames have to cover the maximal diameter of 
48–78 mm.  To develop grafts to this size and also enable stowing is technically very 
challenging.  The largest commercially available graft for descending aortic treatment is 
the Medtronic CaptiviaTM which is 46 mm in diameter and stows to a minimum diameter 
of 25 F (90).  It must be remembered that descending thoracic aortic grafts are sized to 
the relatively “normal” aortic segment above and below the level of the dissection or 
aneurysm, a technique which if possible with landing zones we are likely to replicate. 
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1.4  “The endovascular revolution” - descending thoracic aortic 
disease, and aortic arch endovascular interventions - an 
overview of devices available and outcomes 
In the treatment of AAAD there is an unmet clinical need for both patients turned 
down for surgery, (patients have a 50% in hospital mortality), but also those 
operated on with contemporary surgical techniques have a 10-30% risk of in-
hospital mortality (2).  Traditional AAAD surgery is hugely invasive, involves the 
risks of CPB and deep hypothermic arrest. 
I wanted to understand what endovascular devices were available for treating 
other parts of the aorta, their design features, what had prevented them being 
utilised in the ascending aorta and what their mortality and morbidity outcome 
data was like compared to the previous gold standard treatments.  Also I wanted to 
evaluate whether treating other parts of the aorta in a percutaneous way was 
superior to the more invasive surgical techniques.   
1.4.1 Descending thoracic aorta endovascular stent grafting 
Optimal treatment strategies for pathology of the descending thoracic aorta are still 
controversial (69).  Open surgery is complex as thoracotomy, extensive surgical 
resection, left lung collapse, aortic cross clamping, and aortic replacement are all 
associated with considerable risks of visceral ischaemia and reperfusion, renal 
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ischaemia, hypothermia, and blood loss.  As a result significant morbidity and mortality 
following open thoracic aortic surgery is well known especially in the acute setting (91). 
Endovascular devices allow minimally invasive access to the thoracic aortic pathology.  
They can be inserted through a peripheral artery.  Deployment of an endovascular stent 
graft for thoraco-abdominal aneurysm was reported by Dake et al. as early as 1994 and 
eventually in 1999 in the setting of acute type B dissection (92;93). 
Thoracic endovascular aortic repair (TEVAR) has not been compared to surgery in RCT 
for patients presenting with descending thoracic aneurysm.  Moreover the current 
literature is very heterogeneous with most reports being case series or registry data.  
Nevertheless, both short and mid-term outcomes after TEVAR in patients with 
descending thoracic aortic aneurysm are encouraging with significantly lower morbidity 
and early mortality when compared with open surgery (5;10).  The rate of paraplegia and 
peri-procedural trauma are reduced as compared to open thoracic aortic replacement, 
although the incidence of stroke may be similar between the 2 approaches (6). 
Jonker et al in 2011 performed a retrospective comparison of TEVAR versus open 
surgery in the repair of ruptured descending thoracic aortic aneurysms.  The group found 
that the composite end point of death, stroke or permanent paraplegia was 36.2% in the 
open surgery group versus 21.7% in the TEVAR group (p=0.044) (94). 
While TEVAR is considered potentially life-saving in patients with acute type B aortic 
dissection complicated by contained rupture or organ malperfusion syndrome, results in 
stable type B dissection were less supportive (93).  The INSTEAD trial recruited 140 
patients with stable type B aortic dissection and randomised them to either receive OMT 
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(n=72) alone, or elective stent graft placement in addition to OMT (TEVAR + OMT n = 
68).  The primary end point was all-cause death at 2 years. 
There was no difference in all-cause death, with a cumulative 2 year survival rate of 95.6 
+/- 2.5% with OMT, versus 88.9 +/- 3.7% with TEVAR + OMT (p=0.15).  The trial 
however turned out to be underpowered.  Three neurological adverse events occurred in 
the TEVAR group compared to one in the OMT group.  The INSTEAD trial therefore 
supports the notion of a complication driven approach to TEVAR placement for patients 
that survive type B dissection (95). 
The consensus from expert endovascular surgeons is that TEVAR does have an 
emerging role in the treatment of descending thoracic aneurysm, ruptured aneurysms 
and complicated type B dissection, but that endograft design and manufacture has not 
kept pace with the rapidly growing clinical ambition (1;96).  Major challenges to be 
overcome include the rigidity of the endografts and delivery system.  Non conformity of 
grafts may lead to graft instability and procedural failure.  Current delivery systems are 
too large and inflexible to track through calcified tortuous vessels, and often require 
surgical exposure and iliac artery conduits to enable safe passage of the graft into the 
landing zone.  The challenges of providing conformability and fixation in the aortic arch 
and the thoracic aorta are considerable, given the spiralling movement of the thoracic 
aorta with each ventricular contraction. 
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1.4.2 Currently available thoracic aortic endovascular grafts 
I sought to understand the design features of currently commercially available 
descending thoracic aortic grafts - the materials utilised in the stents and the graft 
coverings, the stowage size and the delivery system attributes.  I also wanted to 
understand the current techniques to avoid endoleak, stent migration and the 
relative performance.  I wanted to see which mechanical and design features could 
potentially be incorporated into the ATAG, and at the same time identify those 
which had a low probability of success in the more challenging ascending aortic 
anatomy. 
There are currently no available endovascular graft for treatment of the ascending aorta.  
All commercially available thoracic aortic grafts are designed for treating the descending 
thoracic aorta, and some are in clinical trials for treating the aortic arch.  All currently 
available stent grafts have a self-expandable stent frame (generally z shaped nitinol stent 
frame), covered in a relatively non porous graft material (2). 
1.4.2.1 Graft covering materials 
Endovascular graft material must be durable and biocompatible, resist thrombosis and 
infection.  The graft must act as a barrier to blood (preventing blood flow into the false 
lumen in dissection, and preventing pressure on the thinned aortic wall in aortic 
aneurysm).  There are 2 commercially utilised stent graft coverings for descending 
thoracic and abdominal aortic endografts:  
i) Woven polyester (PET / DacronTM), and   
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ii) ePTFE.  
Both of these materials have been utilised in vascular applications for many decades.  
1.4.2.1.1 Dacron (Polyethylene terephthalate (PET)) 
Dacron is the most commonly utilised endograft material (used in the Medtronic, Jotec, 
Cook, and Bolton grafts) and has a long history of vascular and endovascular 
applications.  Figure 35 below shows 2 endografts with Dacron covering: 
Figure 35 Endografts with Dacron covering. 
 
 
 
 
 
   a) Medtronic Captivia graft     b) Cook Zenith graft 
Both stent grafts consist of z shaped nitinol stent frames with PET Dacron graft covering material, attached by sutures.  
PET can be manufactured with a very thin profile (typically around 100 m) (97).  
Drawbacks of the woven PET fabrics include an inability to stretch, a tendency to wrinkle 
easily and an inability to confirm to tubular shapes (98). 
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The biological response to PET vascular implants is characterised by a fibrous capsule 
on the outer surface of the graft with granulomatous tissue and abundant intracellular 
matrix infiltrating the fabric.  The luminal surface is composed of compacted fibrinous 
material with absent endothelial lining except in the vicinity of anastomosis.  A further 
drawback of PET is that when implanted in small vessels it induces an intense tissue 
reaction composed of concentric layers of eosinophils and lymphocytes, restricting the 
stent lumen, which can cause eventual thrombosis (99).  PET elicits increased 
thrombogenicity when compared to ePTFE, and this has been explained by enhanced 
stimulation of macrophage pro-coagulant activity (100). 
PET Dacron would seem to have a number of undesirable material properties that make 
it potentially sub-optimal for ATAG graft utilisation.  These include: 
i) An inability to stretch – which with the ATAG coronary projections is a highly 
desirable attribute given the potential variability in coronary ostia location.  
The material may also cope poorly being stowed to 18-24 F (6-8 mm) and 
then being expected to expand around the stent frame to a maximal diameter 
of 65 mm (i.e. 10 times expansion from stowed). 
ii) Tendency to wrinkle and poor conformation.  Studies have suggested that 
material wrinkle, and poor conformation to the aortic wall are positive 
predictors of endoleak risk.  Once again in the ascending aorta with high 
exposure to both twisting and shear forces a poorly conformed stent material 
is more likely to result in endoleak and subsequent procedural complications. 
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iii) In small vessels (i.e. studied predominantly in 6-8 mm peripheral vessels) PET 
induces an intense inflammatory tissue reaction resulting in lumen loss and a 
significantly increased risk of thrombus formation and vessel closure.  Given 
that potentially we will require the “arms” of the ATAG t-shirt to be stented into 
both the LMCA and the RCA ostium at a diameter of 3-4 mm, it is highly likely 
that PET Dacron would lead to coronary branch occlusion which is likely to 
result in a poor patient outcome. 
iv) Dacron when joined to form branched grafts tends to be “hand sewn”.  Sutures at 
haemodynamic stress points (like the attachment of the coronary branches) 
are likely to lead to increased risk of thrombus formation at the ostium of the 
coronary branches. 
In summary it seems unlikely that the material properties of Dacron are suitable for a 
branched aortic graft with small (<5 mm) branches into the coronary arteries.  It is 
important at this early stage that other materials are investigated and it is possible that 
the ATAG will require a novel material for the coronary sleeves with sufficient elasticity, 
and adequate prevention of cell migration / tissue ingression to prevent lumen stenosis 
and thrombosis. 
1.4.2.1.2 ePTFE (Expanded Polytetrafluoroethylene) 
ePTFE is chemically composed of carbon chains saturated with fluorine, this gives 
ePTFE conformational rigidity, stability and low surface energy, which results in low 
thrombogenicity and modest tissue reaction.  ePTFE is utilised in the LeMaitre and Gore 
grafts, and has high strength, but low surface friction which can make stent migration a 
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problem.  ePTFE grafts do not dilate over time and offer better resistance to infection 
when compared to the Dacron grafts, they are however more expensive to manufacture 
(101).  Figure 36 below shows 2 commercially available ePTFE covered grafts: 
Figure 36 Commercially available ePTFE covered grafts 
 
 
 
 
 
 
Commercially available ePTFE covered endografts.  On the left side the LeMaitre TAArget thoracic graft next to a 20 p 
piece, and on the right hand side the Gore TAG thoracic graft.  
ePTFE also exhibits some features which potentially make it unsuitable for use within the 
proposed ATAG graft.  It is relatively rigid which in keeping with PET will make 
conforming of the coronary sleeves to the variability of coronary take off more 
challenging.  Although better than PET with regard to thrombogenicity, 1 year patency 
rates in peripheral artery stenoses (femoral artery) are at best 80%, and this will not be 
acceptable in the coronary position.  Part of the reason for this is that ePTFE grafts 
exhibit a scant neo-intimal layer except at the adjacent vessel surface.  Endothelium has 
been found scattered through the lumen of the animal and human endovascular ePTFE 
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but it is never confluent or complete (102).  It would seem therefore that ePTFE is 
unlikely to be a perfect material for our ATAG graft with coronary sleeves. 
1.4.2.2 Design features of existing grafts dealing with branches 
1.4.2.2.1 Uncovered stent portions 
The proximal and distal ends of the stent grafts can either be covered with material as 
seen with the Gore and LeMaitre devices, or have some uncovered stent struts (like the 
Cook and Medtronic grafts in Figure 37 below).  This allows the proximal end of the graft 
to sit across for instance the left subclavian artery (LSCA) without compromising flow into 
the side branch.  
Figure 37 Uncovered proximal stent struts 
 
 
 
 
 
Having stent struts not covered with Dacron or ePTFE means that a seal can be achieved proximally (for instance lying 
across the LSCA), but that patency of the branch vessel can be maintained.  
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Alternatives to this include fenestrated grafts where holes in the fabric are aligned over 
the ostium of the side branch to enable uncompromised flow, and allowing access to 
stent the side-branch, optimising side branch flow and minimising endoleak risk.  An 
example of a fenestrated graft is shown in Figure 38 below: 
Figure 38 Fenestrated stent-graft 
 
 
 
 
 
Two circular fenestrations can be seen in the graft material above, which oppose branches of the aorta allowing 
uncompromised flow into the branch arteries. 
1.4.2.3 Anti-migration mechanisms  
To prevent migration of conventional thoracic stent grafts there are 3 main strategies: 
1) A proximal and distal flared portion to help anchor the graft in position, as shown 
in Figure 39 below: 
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Figure 39 proximal flared portion on Gore graft 
 
 
 
 
Proximal flared portion of a Gore endograft (arrowed). 
2) Anti-migration barbs that imbed into the aorta.  Figure 40 below shows the anti-
migration barbs featured on the Cook TX 2 aortic endograft. 
Figure 40 Anti migration barbs 
 
 
 
 
 
Anti-migration barbs are present on the Cook endografts (arrowed above). 
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3) Sufficient over-sizing to exert a constant outward radial force.  Most commercially 
available thoracic stent grafts are over-sized to the vessel in their instructions for use 
(IFU) by 10-20%. 
1.4.2.4. Stent sizing, availability and delivery systems 
The method of measuring the adequate size of the stent graft in aortic disease is the 
subject of debate and according to a recent literature review is in “desperate need of a 
consensus” (96).  This is especially the case in patients with aortic dissection.  Currently 
interventional radiologists and vascular surgeons use a variety of methods.  Some utilise 
the diameter of the proximal unaffected aorta and then oversize by anything between 10-
20%.  An alternative technique is to deliver a 10% larger graft than the average of the 
maximum and minimum diameters of the true lumen in acute dissection, or 20% in 
chronic dissection (103). 
Choosing too small a stent-graft diameter can cause endo-leak (leak around the graft – 
see classification in section 1.4.2.5.4), or migration.  Over-sizing may lead to infolding of 
the graft material, local trauma, retrograde propagation of the aortic dissection flap, and 
may lead to late erosion of the vessel wall.  
1.4.2.5 Problems, failure modes, and applicability of thoracic aortic stent grafts 
1.4.2.5.1 Mechanical failure of stent-graft 
Once implanted the endograft is subjected to external forces imposed by the geometry of 
the tortuous aorta and the impact of phasic blood pressure.  Mechanical failure of the 
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stent graft can occur in the form of metallic fracture, fabric tear, and suture breakage.  A 
recent large series identified 60 patients (9%) with mechanical failure of the stent graft of 
the 618 patients who underwent stent-graft implantation.  43 patients (6.9%) had metallic 
stent fracture, 14 suture disruptions (2.3%), and 3 graft wear (0.5%).  The average time 
to recognition of mechanical failure was only 19 months, with surgical conversion in 6 
cases (104).  At this time the clinical importance of any graft failure is not clear, and 
management of mechanical failure is on a case by case basis depending on clinical 
sequelae and risks versus benefits of re-intervention (either endovascular or open 
surgical). 
1.4.2.5.2 Access issues and stroke 
Although endovascular repair of the aorta avoids aortic cross clamping and is less 
traumatic than open surgery, the large calibre delivery systems often required can cause 
damage to access arteries.  For patients with small peripheral vessels a surgically placed 
funnel bypass conduit may be required to the common iliac artery. 
Cerebral ischaemic complication is reported to occur in 2.9-11% of stent graft procedures 
in descending thoracic aortic dissection, and is often associated with prolonged 
procedure time, manipulation of guide wire or device in the arch causing cerebral 
embolisation (105).  This compares to the risk of stroke in carotid stenting in the 
contemporary CREST trial of 4.1% at 30 days (106).  As graft technology becomes lower 
profile, delivery systems become more flexible, and cerebral protection devices become 
more advanced and established in practice we are likely to see a reduction in these 
complication rates. 
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1.4.2.5.3 Unintended side branch occlusion 
Management of the aortic arch branches ranks among the most significant unresolved 
and controversial issues (107).  Sufficient proximal anchoring and a landing zone of 2 cm 
is usually required to avoid type I endoleak, thus coverage of the LSCA or combined 
surgical extra-anatomical bypass of the aortic branches may be necessary. 
1.4.2.5.4 Endoleak 
Exclusion of the aneurysm sac is the main goal of endovascular stent graft treatment, 
and clinical success is defined by the "total exclusion" of the aneurysm.  However, failure 
of the stent graft to totally exclude blood flow to the aneurysm sac may occur, and this is 
termed “endoleak”.  Endoleak is a major cause of complications, causing continued 
pressurization of the aneurysm sac and may leave the patient at risk of an aortic rupture.  
Endoleaks are categorised into subtypes I – IV: 
Type I or attachment endoleak is the most frequent complication associated with stent 
graft treatment of aortic dissection or aneurysm and may result in clinical failure 
eventually (108).  The percentage of type I endoleak in the literature ranges from 1-44% 
(96).  A proximal neck <2 cm from the LSCA and existence of an entry tear at the lesser 
curve of the aortic arch predispose to endoleak and a “bird-beaking” appearance. 
The fate of type I endoleak is still a matter of debate.  Some experiences have shown 
spontaneous closure of the leak, while others have shown continuous expansion of 
endoleaks and failure requiring additional stent graft deployment for sealing, spot coiling 
or conversion to an open operation.  If endoleaks persist long term progressive 
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aneurysmal dilatation of the false lumen occurs requiring further ancillary procedures or 
conversion to a surgical approach.  
Type II endoleak is where blood continues to flow into the aneurysm sac from collateral 
vessels.  
Type III endoleak results from blood flow into the aneurysm sac due to inadequate or 
ineffective sealing of overlapping graft joints or rupture of the graft fabric.  This type of 
endoleak usually occurs early after treatment, due to technical problems, or later due to 
device breakdown. 
Type IV endoleak - blood flows into the aneurysm sac due to the graft fabric porosity. 
Figure 41 below shows the current endoleak classification I-IV: 
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Figure 41 Diagrammatic representation of the endoleak 
 
 
 
 
 
Type I or attachment endoleak is caused by a poor proximal or distal stent graft apposition allowing leak around the 
proximal or distal seal into the aneurysm sac.  Type II endoleak is where blood continues to flow into the aneurysm sac 
from collateral vessels.  Type III endoleak results from blood flow into the aneurysm sac due to inadequate or ineffective 
sealing of overlapping graft joints or rupture of the graft fabric.  Type IV endoleak - blood flows into the aneurysm sac due 
to the graft fabric porosity. 
1.4.2  Lessons learned from the review of currently available 
descending thoracic aortic endografts relevant to ATAG design 
specification: 
1) All currently available descending thoracic aortic stent grafts utilise a self expanding 
(usually nitinol) “Z” shaped stent frame. 
2) The majority are covered in a woven PET “Dacron” material, the rest covered in 
ePTFE.  Both materials bring about an inflammatory response and cell adhesion 
resulting in lumen loss, which in small diameter vessels is important and can lead to graft 
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thrombosis and occlusion.  Graft material choice will be very important for the ATAG if 
coronary projections are to successfully protect proactively the coronary flow.  Materials 
choice is covered in detail within the device specification. 
3) Thoracic and abdominal aortic grafts have a number of mechanisms to avoid branch 
occlusions.  These include open cell uncovered stent portions (i.e. commonly utilised to 
cover the LSCA without compromising flow), and fenestrations to allow flow through the 
graft and into the branch vessel.  It is unlikely that in the setting of ATAG open cell stents 
will be helpful, but certainly if protecting both coronary arteries with a stented “t-shirt” is 
too technically of physiologically challenging then one could use fenestrations over one 
or both coronary artery ostia. 
4) As with all aortic endografts it is vital that once correctly positioned there is minimal 
migration.  I think it is highly likely that the ATAG will integrate a flared portion at the 
proximal aortic valve end as this will allow it to optimise proximal seal to prevent 
endoleak.  Anti-migration barbs are likely to be overly aggressive in the landing zone of 
the aortic root and may well interfere in a detrimental fashion with the aortic valve 
leaflets.  In keeping with most thoracic endografts I think it is likely that the ATAG will be 
relatively “over-sized” - the exact amount assessed by further in vitro and in vivo 
experimentation. 
5) ATAG will be exposed to all of the physiological stresses that descending aortic 
endografts experience.  This will mean that the ATAG will be at risk of mechanical failure.  
During rigorous testing all component parts must be shown to be capable of withstanding 
these physiological stresses. 
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6) The commonest complications of TEVAR include vascular and stroke, and this 
represents the greatest risk to the potential ATAG patient.  To minimise this risk the 
crimping profile and delivery system must have the lowest possible profile and be 
flexible, and ATAG implantation may utilise cerebro-vascular protection devices like 
those used in carotid stenting and those emerging in TAVI.  
7) The ascending aortic anatomy poses many problems with regard to proximal and 
distal graft seal.  Design must be meticulous to minimise endoleak, a complication known 
to increase re-intervention rates. 
1.4.3 Innovations in arch endovascular stent grafts 
Devices for treatment of the descending thoracic aorta have been commercially 
available for a number of years and are now 2nd or 3rd generation devices.  With 
improving technology and tools interventional doctors are gradually moving more 
proximally into the aortic arch, where there are currently a number of devices in 
early clinical trials. 
I felt it was important to understand the current innovations in the aortic arch for 2 
reasons: 
i) To give me an insight into contemporary endovascular management of the 
head and neck vessels 
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ii) If ATAG is to provide a solution for the ascending aorta in AAAD, about 35% 
of cases will have concomitant arch involvement and as such it would 
be advantageous if there was a completely endovascular solution (9). 
Endovascular stent grafts have a role in the treatment of some patients with aortic 
dissection and aneurysmal disease in the descending thoracic and abdominal aorta.  The 
arch of the aorta with its three branches creates a number of technical issues which must 
be overcome before successful endovascular stenting can become commonplace.  I will 
now briefly outline some of the proposed solutions to treat by endovascular stent grafts 
the arch of the aorta.  None of them have reached the level of accepted clinical practice 
or “gold standard” status, but some are in large scale clinical trials. 
In 1999 Inoue proposed a branched aortic arch stent graft (109).  This was the first 
proposed endovascular solution branched graft, and shown in Figure 42 below: 
Figure 42 The Inoue branched aortic arch graft 
  
 
 
 
Photograph of the proposed Inoue branched aortic arch graft (109).  It shows a material arch graft with 3 great vessel 
branches. 
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Inoue reported a procedural success rate of 60% in a series of 15 patients.  There have 
been no large scale trials of this device since the FIM experience and many 
commentators cite that the procedure is very complex and not reproducible by the 
majority of interventional doctors (110). 
In 2003 Tim Chuter reported in vitro experiments using a modular branched system, 
some of the designs are represented in Figure 43 below: 
Figure 43 proposed drawings of the Chuter modular arch grafts 
 
 
 
 
 
 
A)               B) 
 
Adapted from Chuter et al.(110).  Out of 4 designs tested only the simplest (B above) was deployable without difficulty or 
delay.  B resembles essentially an upside-down version of a long-leg / short-leg bifurcated infra-renal stent-graft; even the 
delivery system had been used before to insert infra-renal stent-grafts.  
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WL Gore & Associates (Flagstaff, AZ, USA) are developing a branched graft with a limb 
into the LSCA, to avoid the need for LSCA occlusion or extra-anatomical bypass.  This 
device is currently in clinical trial and shown in Figure 44: 
Figure 44 WL Gore TAG branched device  
 
 
 
 
 
 
The WL Gore TAG endograft above can be seen to have a dedicated branch for preserved flow into the LSCA, avoiding 
the need for extra-anatomic bypass, or coverage of the LMSA (111). 
1.4.3.1 Hybrid aortic arch procedures 
Another potential solution, albeit more invasive is a hybrid procedure with extra-
anatomical bypass of a branch vessel, followed by endovascular stent-grafting covering 
grafted vessels.  Figure 45 below demonstrates the theory of extra-anatomical bypass for 
the arch vessels followed by endovascular stenting across the grafted branches. 
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Figure 45 Diagram representing a possible hybrid procedure for the arch vessels. 
 
 
 
 
 
 
Extra anatomical surgical bypass, with surgically attached grafts from the aorta onto the RBCT and the LCCA followed by 
endograft treatment, across the origins of the bypassed arch vessels.  Adapted from (31). 
There are many potential variations of this and beyond the realms of this thesis for full 
discussion. 
1.4.3 Endovascular solutions for the treatment of the aortic arch 
Conclusion 
In 2012 there is no accepted solution to treat the aortic arch in a satisfactory 
endovascular manner.  Treatment strategies vary according to local expertise, physician 
preference, patient anatomy, access to particular devices and regulatory issues.  
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Most physicians now accept that covering the LSCA without extra-anatomical bypass is 
associated with an increased risk of stroke and paraplegia.  Clinical trials are on-going to 
see if the LSCA and descending aorta can be treated with a branched graft (WL Gore 
and associates) (111). 
Treatment of the RBCT and left common carotid is more difficult and currently most 
endovascular solutions for these anatomical situations involve extra-anatomical bypass 
first.  As devices, materials, delivery catheters and techniques improve it may be possible 
that the arch may be treated in a totally endovascular manner, we await further device 
testing and clinical trials.  
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1.5 Percutaneous aortic valve therapies 
When the ATAG project commenced in 2007 TAVI was still in its relative infancy 
with early stage devices, large delivery systems, and no RCT data available to 
guide clinical indications.  
Because of the very close anatomical association between ascending aorta, aortic 
valve and coronary arteries and the potential in both AAAD and ATAA populations 
to require aortic valve replacement it is vital that the TAVI devices and data are 
well understood.  To treat the 25% of AAAD patients with incompetent aortic valve 
function, the ATAG would either need to have a “valved” version that could be 
implanted and perform aortic valve function, or the ATAG would have to be 
“compatible” with commercially available TAVI devices so that before or after 
ATAG implantation, the aortic valve competence could be restored with TAVI 
implantation (9). 
Below I present the 2 commercially available devices with safety and efficacy data 
available in 2012.  
The first percutaneous aortic valve implantation in man was performed in Rouen, France 
by Alain Cribier in 2002 (112).  Cribier delivered the valve via a 24 F sheath in the right 
femoral vein, the valve delivered in an ante-grade fashion through the inter-atrial septum 
to the aortic valve position without compromising the coronary arteries.  
The valve was manufactured by Percutaneous Valve Technologies (PVT Inc, Fort Lee, 
NJ, USA), was made of a slotted steel with 3 bovine pericardium leaflets, crimped onto a 
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commercially available NUMEDTM 23 mm diameter balloon, and shown in Figure 46 
below: 
Figure 46 shows the first pericardial PVT valve 
 
 
 
 
Photograph of the PVT valve (left), crimped down onto a 23mm NUMED balloon (right). Taken from the original 
description by Cribier (112). 
Edwards Lifesciences Corporation (Irvine, California, USA) purchased PVT in January 
2004, and since then the device has evolved dramatically.  The Edwards Sapien XT 
valve has CE mark in Europe and regulatory approval (FDA) in the US for inoperable 
patients.  It is currently in multi-centre, international RCTs (Placement of AoRTic 
TraNscathetER Valve Trial (PARTNER trials)).  The current device, the Edwards Sapien 
XT is available in 3 sizes (23 mm, 26 mm, and 29 mm) and has a delivery system 
diameter of 18 F.  The latest system Novoflex XT 18 F will pass through a specially 
designed eSheathTM which is actually 16 F and “expands” to accommodate the larger 
delivery system.  The Edwards valve can be delivered trans-femorally (Novaflex XT), and 
trans-apically (Ascendra 2 delivery system).  Figure 47 below shows the current Edwards 
Sapien XT valve: 
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Figure 47 Current Edwards Sapien XT valve 
 
 
 
 
 
The Edwards Sapien XT valve has a cobalt chromium balloon expandable stent frame.  Within the stented portion are 3 
bovine pericardium valve leaflets which are treated using a Thermafix
TM
 process to minimise subsequent calcification. 
The other currently available CE marked percutaneous aortic valve is the Medtronic 
CoreValveTM.  In contrast the CoreValve frame is made from self-expandable nitinol.  It is 
longer than the Sapien valve and has sections of differing diameters and radial strength 
to complement the differing portions of the ascending aorta and outflow tract.  It is 
delivered similarly in a retrograde manner using an 18 F delivery catheter.  Figure 48 
below shows the Medtronic CoreValve: 
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Figure 48 Medtronic CoreValve revalving system 
 
 
 
 
 
 
The CoreValve frame has three distinctive nitinol zones.  1) The inflow - radial force and frame elasticity are designed to 
maximise conformation and sealing to the native annulus.  2) Mid frame hoop strength designed to resist deformation and 
preserve geometry for leaflet co-aptation.  3) Outflow - Low radial force, which orients the valve to the aortic root to ensure 
optimal forward flow.  Within the frame is attached  a porcine pericardial aortic valve. 
To date in early 2012 there have been approximately 20,000 SapienTM and 20,000 
CorevalveTM implantations worldwide.  Both Edwards and Medtronic have ongoing large 
RCTs assessing the safety, efficacy and long term durability of their percutaneous 
valves.  
1.5.1 TAVI data so far 
The most robust RCT data so far published has been from the Edwards Lifesciences 
sponsored PARTNER trials utilising the Sapien balloon expandable valve.  
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1.5.1.1 PARTNER trial cohort B 
Leon et al published the first results of the PARTNER B cohort in the New England 
Journal of Medicine in October 2010.  358 patients with severe aortic stenosis (AS) 
having been turned down for surgical replacement were randomised to either receive 
OMT including balloon valvuloplasty, or TAVI via the trans-femoral route.  The primary 
end point was rate of death from any cause at one year (113). 
At 1 year of follow up, the rate of death from any cause was 30.7% with TAVI, compared 
to 50.7% with OMT (hazard ratio with TAVI, 0.55 p<0.001).  The rate of the composite 
end point of death from any cause or repeat hospitalization was 42.5% with TAVI 
compared to 71.6% with OMT (hazard ratio, 0.46; p<0.001).  Among survivors at 1 year, 
the rate of cardiac symptoms (New York Heart Association (NYHA) class III or IV) was 
lower among patients who had undergone TAVI than among those who had received 
OMT (25.2% vs. 58.0%, p<0.001). 
At 30 days TAVI, as compared with OMT, was associated with a higher incidence of 
major strokes (5.0% vs. 1.1%, p = 0.06) and major vascular complications (16.2% vs. 
1.1%, p<0.001).  In the year after TAVI, there was no deterioration in the functioning of 
the bioprosthetic valve, as assessed by echocardiogram. 
1.5.1.1.1 PARTNER B Conclusion 
In patients with severe AS who were not suitable candidates for surgery, TAVI, as 
compared with OMT, significantly reduced the rates of death from any cause, the 
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composite end point of death from any cause or repeat hospitalization, and cardiac 
symptoms, despite a higher incidence of major strokes and major vascular events. 
1.5.1.2 PARTNER trial cohort A 
Smith et al reported on the PARTNER trial cohort A in June 2011.  699 high-risk patients 
with severe AS were randomly assigned to undergo either TAVI with the Edwards Sapien 
Valve (either a transfemoral or a transapical approach) or surgical replacement.  High 
risk was defined as patients having a Society for Thoracic Surgeons (STS) score of 
>10%, which correlates to predicted 10% risk of death with 30-days from the cardiac 
surgery (28). 
The rates of death from any cause were 3.4% in the TAVI group and 6.5% in the surgical 
group at 30 days (p = 0.07) and 24.2% and 26.8%, respectively, at 1 year (p = 0.44), a 
reduction of 2.6 percentage points in the transcatheter group (p = 0.001 for non-
inferiority).  
The rates of major stroke were 3.8% in the TAVI group and 2.1% in the surgical group at 
30 days (p = 0.20) and 5.1% and 2.4%, respectively, at 1 year (p = 0.07).  At 30 days, 
major vascular complications were significantly more frequent with transcatheter 
replacement (11.0% vs. 3.2%, p < 0.001); adverse events that were more frequent after 
surgical replacement included major bleeding (9.3% vs. 19.5%, p<0.001) and new-onset 
atrial fibrillation (AF) (8.6% vs. 16.0%, p = 0.006).  More patients undergoing TAVI 
replacement had an improvement in symptoms at 30 days, but by 1 year, there was not a 
significant difference between the groups. 
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1.5.1.1.2 PARTNER cohort A Conclusions 
In high-risk patients (STS score >10%) with severe AS, transcatheter and surgical 
procedures for aortic-valve replacement were associated with similar rates of survival at 
1 year, although there were important differences in peri-procedural risks, with major 
bleeding and AF being more common in the surgical approach and stroke and vascular 
complications being more common in the TAVI group. 
1.5.2 TAVI discussion with relevance to the ATAG development  
Within a decade of FIM, TAVI is now a recognised and proven treatment option in 
patients deemed high risk for conventional corrective surgery.  Over the next 5 years 
ongoing studies will tell us more about the durability of these valves, and also whether 
they may have clinical benefit in lower risk patient groups and not just those at high risk 
for surgical valve replacement. 
A thorough understanding of TAVI technology is vital as it is likely that the ATAG 
procedure will share many of the most frequent complications (vascular and stroke) and 
it will be interesting over the next few years to see how new devices are developed to 
minimise the procedural complications of the TAVI procedure (smaller sheaths, embolic 
filters) – some of these devices may also be suitable for the ATAG procedure.  
The development of a covered ATAG may well be able to deal with and adequately treat 
the ascending aorta dissection flap, but the resultant AR from the dissection may need 
either an integrated valve within the ATAG graft (valved ATAG), or a hybrid approach 
using an established TAVI system following ATAG implantation. 
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1.6 Case reports of the ascending aorta being treated with an 
endovascular approach 
In 2011 Sobocinski published “Endovascular approaches to acute aortic type A 
dissection: A CT-based feasibility study”.  The purpose of this paper was to 
determine what percentage of patients presenting with AAAD that could potentially 
be treated with a simple tubular endograft.  Of a total of 102 patients analysed they 
deemed that an endovascular repair with a tubular endograft was feasible in 37 
patients (36% of cohort).  An additional 8 patients were also candidates for tubular 
endograft repair but would have required additional carotid-carotid bypass (8). 
I will now review the case reports of AAAD in the literature treated by endovascular 
grafts concentrating on the type of graft, the sizes and the access routes utilised.  
A literature review found tens of peer review journal published cases where a 
endovascular stent graft, designed for use in descending thoracic aortic aneurysms and 
type B aortic dissections, was used “off-label” to treat AAAD and aortic aneurysms / 
pseudo aneurysms.  All were compassionate cases where the patient had no other 
treatment options and had been turned down for conventional surgical treatment. 
There are currently at least 7 manufacturers in Europe of descending thoracic aortic 
stents with CE mark licensed for the endovascular treatment of the descending thoracic 
aorta.  “Off-label”, non licensed use of these devices poses a number of technical and 
anatomical challenges for both the device and its delivery by the interventional team. 
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1.6.1 Device challenges 
The devices available are designed for deployment in the descending thoracic aorta, a 
site that is approximately 50 cm from the femoral artery sheath insertion point, often with 
a fairly straight run from femoral artery, through the iliac artery and retrograde up into the 
descending aorta.  Having to manipulate the stent graft around the aortic arch and down 
into the ascending aorta is a large technical challenge for both the device (crimped stents 
can be very stiff and not want to track around the aortic arch), and for the delivery 
system.  Not only that, but once the device and delivery system are in the “landing zone” 
of the ascending aorta there is the matter of accurate and precise device placement 
against a significant cardiac output.  The landing zone is also in close proximity to the 
aortic valve and coronary arteries that must be avoided, and the RBCT that must be 
avoided distally.  
1.6.2 Delivery system challenges 
Over the last 5 years, with the rapid development of TAVI there has been significant 
innovation in both stent design, and also the manufacture of low profile, flexible, 
trackable delivery systems with transmitted torque for accurate positioning.  There are a 
number of design features which have enabled better manipulation around the aortic 
arch and improved accuracy of deployment of TAVI at the delivery zone. 
The Edwards Sapien XTTM 18 F percutaneous aortic valve and delivery system have a 
novel “RetroflexTM” feature, shown in Figure 49 below: 
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Figure 49 The Edwards Retroflex
TM
 delivery system 
 
 
 
 
 
Turning a handle on the delivery system enables the catheter tip to bend and track more smoothly around the arch 
allowing a less traumatic passage of the device and delivery system to the landing zone of the aortic valve.  
In contrast to the specially developed TAVI delivery systems, the thoracic stent graft 
delivery catheters are generally relatively short, and stiff.  There are however case 
reports featuring most of the top graft manufacturers delivering grafts to the ascending 
aorta, and they share common anatomical features.  All of the case reports published 
have a single intimal entry dissection flap, or aneurysmal portion of aorta in the straight 
part of the ascending aorta distant from both the coronary arteries, aortic valve and 
RBCT.  An endovascular prosthesis is then delivered to the site with both proximal and 
distal portions apposing “relatively normal aorta”. 
In one of the cases a MedtronicTM endovascular stent graft TC4646B 46 mm x 100 mm, 
was placed between the coronary arteries and the RBCT, to treat an aortic dissection in 
a 65 year old male with an intimal flap above the RCA.  The patient was deemed 
unsuitable for open surgery however the implantation of this stent allowed the patient to 
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be discharged on the fifth day after the procedure and there were no subsequent 
complications (114). 
While most cases published are technically successful at the time of procedure, there is 
still a considerable post procedure complication rate, morbidity and mortality.  Another 
case utilised a Gianturco Z-stent (Cook Inc.) in a 46 year old Marfan syndrome female 
with AAAD with intimal flap above the RCA.  However this led to severe cardiovascular 
complications 21 months after implantation with significant AR and impaired left 
ventricular function.  The stent had to be removed and the heart valve replaced in a 
conventional manner (115). 
In general the other published cases describe the use of stent grafts on average 40-46 
mm in diameter and 55–100 mm in length (with the aim of not occluding the RBCT). 
Case reports included: 
 40 mm x 10 mm Excluder stent graft (W. L. Gore & Associates, Inc)(116)  
 55 mm x 22 mm Zenith (Cook Inc.)(117)  
 44 mm x 70 mm EndoFit (LeMaitre Vascular, Inc)(118)  
One case report describes the use of a bespoke made stent: 
 46 mm x 85 mm custom stent (Jotec, Hechingen, Germany)(119)  
The implantation route is generally via femoral or iliac artery access.  Some cases 
describe more novel delivery access including trans-carotid and trans-apical 
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implantation, with the advantage of a shorter and straighter delivery route to the 
ascending aortic landing zone (29;118;120). 
It is difficult to assess the true number of compassionate cases performed in the 
ascending aorta as well as relative success rates as there is likely to be publisher bias in 
that successful cases are more likely to be published hence skewing the published data.  
It is fair to say that as the devices become of a lower profile with more sophisticated 
delivery systems and with novel routes of access it is likely that we will see more “off-
label” uses of thoracic aortic stents in the ascending aorta.  Not only that but in the last 5 
years the rapid development of TAVI has allowed us to understand the aortic valve, 
ascending aorta and coronary artery anatomy as well as the physiological tolerances and 
techniques for accurate deployment within this high risk area.  
The cases described are of the most “straight forward” aortic anatomy.  Routine 
endovascular treatment of ascending aortic syndromes will require the design of more 
sophisticated devices capable of conforming to a number of different anatomies and 
having special design features to maintain aortic valve competence, coronary artery flow, 
having a good proximal and distal seal, and being sized and deployed so as not to 
impinge on the great vessels.   
1.6 Conclusion 
In both AAAD and ATAA, where open surgery is not an option, and the ascending aortic 
anatomy is suitable; curative endovascular treatment is feasible using endografts 
designed for the descending thoracic aorta.  Complications do however occur and in this 
short series appeared to be related to interruption of aortic valve function and stroke.  At 
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present the long-term outcome is unclear, but endovascular stent treatment for AAAD is 
a promising option, at least for patients with multiple co-morbidities who are not 
candidates for conventional surgical repair. 
In the future dedicated grafts like ATAG need to be developed to take into consideration 
the proximity of the aortic valve, coronary arteries and great head and neck vessels.  
Specially designed delivery systems are required to enable safe passage and accurate 
deployment of the graft in the ascending aorta.  Embolic protection systems may be 
developed and deployed to minimize embolic stroke related to the device delivery. 
 
1.7  Innovation in endovascular repair of the ascending aorta 
In 2007 Tim Chuter a vascular surgeon and endovascular pioneer based in the 
United States published “Endovascular repair in the ascending aorta: Stretching 
the limits of current technology” (1).  In his commentary in the Journal of 
Endovascular Therapeutics he describes the case reported in the same edition by 
Lin et al of stenting the ascending aorta to treat pseudo-aneurysm (29).  He 
explains the theoretical advantages of the endovascular approach, but at the same 
time demonstrates the current limitations in the stent grafts to treat this 
challenging ascending aorta anatomy.  
Currently available TEVAR grafts are too long, while abdominal grafts are too short and 
narrow.  The delivery systems for these devices are also way behind in their 
development when compared to both the CE marked TAVI devices (Edwards Sapien 
NovaflexTM, and the Medtronic CoreValveTM).  To circumvent the short comings with the 
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graft technology (poorly flexible grafts and rudimentary delivery systems) Lin and 
colleagues accessed the ascending aorta via a trans-carotid route.  They shortened the 
nose cone (to prevent aortic valve disruption by the delivery system), and instead of 
delivering a bespoke or correctly sized stent grafts, instead delivered 3 x Zenith 
endovascular cuffs (short 32 mm stent grafts).  This was only feasible in this patient 
because of the combination of large right carotid artery and normal size ascending aortic 
portion (32 mm).  The stents were delivered by a 20 F delivery catheter inserted through 
a 22 F introducer sheath in the right common carotid artery.  The problem here therefore 
is that if a 36 mm stent was required for example because of the more bulky size it would 
have required a 26 F introducer.  Anything bigger in diameter would almost certainly not 
be feasible via the carotid route, and these sheaths (>8 mm diameter) need 
consideration of conduits to either the innominate artery or the iliac artery (29). 
Chuter describes the ascending aorta as “the new endovascular frontier, in which many 
cases of type A aortic dissection are potentially amenable to endovascular repair.  
However this tempting fruit will remain just beyond our reach until we have low profile 
stent grafts packaged within long, flexible delivery systems”(1). 
Chuter himself in collaboration with Cook Inc (Bloomington, IN, USA) is trying to develop 
and test a graft for ascending aorta treatment and it has a sleeve for each coronary 
artery.  At the Royal Society of Medicine (RSM) “Aortic disease symposium” in October 
2009 one of his collaborators presented a photograph of the Chuter ascending aortic 
prototype device, shown in Figure 50 below: 
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Figure 50 The Chuter ascending aorta prototype device. 
 
 
 
 
 
 
The Chuter ascending aortic stent-graft (unpublished photograph from RSM symposium) appears to have a zig-zag nitinol 
frame, covered in Dacron, with a proximal flare and 2 coronary Dacron sleeves. 
This work is as yet unpublished, and the group do not appear to have any robust patent 
protection for what appears to be a “t-shirt” like stent graft with coronary projections.  The 
stent appears to be self expanding, covered with a woven Dacron material (attached by 
sutures), with a significantly bulky material sewn into the coronary sleeves.  As an 
interventional cardiologist I feel that this bulky device with a poor profile, would interfere 
with the aortic valve functioning (the proximal skirt appears too long), and the coronary 
sleeves would be extremely bulky to deliver to the coronaries and the material (a woven 
Dacron) is unlikely to be compatible with long term patency in the coronary sleeves 
(which would be a very significant failure mode).  Chuter’s team described that during in 
vivo animal testing of the device in the porcine model there were no successful 
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implantations and cited a combination of device failures and that technically there were 
difficulties with the porcine model. 
All of the above reinforces the facts that for successful treatment of the ascending aorta 
using an endovascular approach the following must be overcome: 
i) The self expanding stent must be low profile, especially given the fact that the 
size needed to treat many aortic dissections may well be up to 65 mm in 
diameter (+ any over-sizing).  The larger the stent graft the more bulky and 
greater the profile.  There must be a great deal of investment in designing an 
aortic stent frame that has adequate radial strength characteristics, but that 
can be stowed within a flexible and deliverable sheath (likely to be <24 F as 
any size greater than this means that many patients may not have adequate 
sized vessels to allow stent delivery). 
ii) The stent graft delivery system must be flexible and in an ideal word navigate 
around the aortic arch with a minimal amount of trauma.  It must have 
predictable torque and allow precise and accurate delivery with reliable 
movement characteristics. 
iii) The graft covering material must be biocompatible, impermeable to prevent 
endoleak, and to seal the dissection flap blood flow.  It must be low profile, 
manufactured from a material which will not kink / crease, and that can be 
stowed to an efficient diameter when compared to the current industry 
standards which are Dacron and ePTFE. 
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iv)  The delivery system and stent should not interfere with aortic valve function.  If 
function is compromised the valve will either need to be rapidly replaced with 
a commercially available TAVI. The alternative is to develop a “valved ATAG” 
capable of treating the dissection / aneurysm, but at the same time replacing 
the aortic valve function. 
v) The coronary sleeves must protect the coronary blood flow rapidly and have a 
low risk of in stent graft thrombosis.  Again it is likely that given the coronary 
arteries are at their ostium in the range of 3-5 mm a thin and potentially novel 
material covering may be required that is not thrombogenic / platelet 
activating to retain long term patency and prevent coronary artery occlusion.   
 
1.8 What might the future ATAG look like? 
With the anatomical review completed and the pathophysiology and treatment 
modalities of AAAD and ATAA understood I now wanted to detail potential ATAG 
design features prior to formulating a 1st design specification. 
1.8.1 Anatomical considerations 
In keeping with all of the other endovascular treatments for vascular disease, a novel 
endovascular solution for ascending aortic disease should treat the disease process in a 
manner non-inferior to the currently accepted gold standard treatment (conventional 
surgery for AAAD i.e. match the 10-30% mortality at 30 days) as well as offering clinical 
advantages (less invasive, and shorter hospital stays).  It is also conceivable that a less 
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invasive, percutaneous solution that avoids the need for sternotomy, CPB, deep 
hypothermic circulatory arrest could provide a therapeutic strategy to the 28% of all 
patients who present with AAAD and are denied life saving surgery because of advanced 
age or co-morbidities (with a 50% in hospital mortality) (67). 
A broad variety of specific operative techniques will be required to combat the myriad of 
morphological possibilities for AAAD, driven by the original site of intimal tear(s), 
extension of and direction of false lumen proliferation and probably most importantly 
malperfusion syndromes.  Proximal extension to the aortic valve or ostia of the coronary 
arteries requires replacement of the aortic valve or coronary artery bypass; these surgical 
techniques were reported in 24% and 15% of IRAD type A dissections, respectively (9).   
Distal extension of the dissection beyond the replaced ascending aorta may require a 
hybrid endovascular procedure to seal the distal intimal tear; the optimal timing of this 
approach remains controversial and some experts prefer a staged approach (86;121). 
1.8.2 The stent graft body design considerations 
In its simplest embodiment the ATAG would consist of an appropriately sized self 
expanding or balloon expandable covered stent graft tube, which would be able to be 
deployed over the intimal tear with accuracy within the ascending aorta.  It must have a 
landing zone proximally, opposing the aortic wall achieving an adequate seal and 
preventing endoleak, but at the same time not interfering with aortic valve function (if it is 
preserved) or coronary artery blood flow.  It must also fall short of the first great head and 
neck vessel the RBCT.   
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In 2011 Sobocinski et al. suggested that based on CT angiography of the aorta, 
approximately 36% of patients presenting with AAAD could potentially be treated by a 
simple tubular endovascular stent graft (8).  A schematic of “tubular ATAG” is 
represented in Figure 51 below: 
Figure 51 Tubular ATAG 
     RBCT 
 
Endograft 
 
 Coronary arteries 
 
 
Schematic representation of a simple tubular graft from above the STJ to just before the RBCT.  The tubular ATAG 
consists of an appropriately sized graft frame, covered in material, with a proximal seal above the coronary arteries and 
aortic valve, excluding the intimal tear, and a distal seal before the RBCT. 
This tubular design however offers no proactive coronary flow protection, and its proximal 
portion is a straight edge, which if positioned slightly too low would run a reasonable risk 
of jeopardising coronary flow and potentially aortic valve competence.  It would however 
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be the easiest to deploy and may suit an intimal tear within a few cm of the aortic valve 
with no coronary or valvular involvement – this is in essence what all of the endovascular 
treated AAAD case reports have demonstrated.  This is likely to be the simplest 
embodiment of the ATAG. 
1.8.3 Coronary artery protection considerations 
The next consideration would be a graft capable of proactively protecting coronary artery 
blood flow.  This could be done unilaterally; with a “sleeve” or arm into either one or 
alternatively an “inverted t-shirt” design with arms into both coronary arteries.  While 
proactively ensuring coronary artery flow is a desirable device feature – it must not be 
forgotten that this will be technically challenging for both the device design, and 
deployment.  Figure 52 below describes the 3 main possible coronary artery treatment 
solutions: 
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Figure 52 ATAG coronary artery design considerations 
 
 
 
 
 
 
 
Potential ATAG coronary design considerations a) fenestrations over both coronary ostia allowing flow.  b) fenestration 
over one ostia and a protective sleeve in the other.  c) “Inverted t-shirt” graft ATAG with proactive sleeve deployment into 
both coronary ostia. 
In the vast majority of patients the LMCA is the most important vessel, giving rise to both 
the LAD artery and the Cx artery, while the majority of intimal entry tears occur within 2 
cm of the RCA ostium, as shown in Figure 53 below (122): 
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Figure 53 Site of intimal tear in Type A aortic dissection 
 
 
 
 
 
 
 
 
 
Site of intimal tear as described in the IRAD database(122).  It can clearly be seen that the majority (60%) originate within 
the ascending aorta, 23% in the arch, 6% in the descending, and 8% have multiple tears.  
One could therefore consider proactively protecting the coronary flow to the RCA (close 
to the site of many of the intimal tears), and have a fenestration within the graft over the 
ostium of the LMCA.  This may allow the ATAG to protect coronary artery blood flow 
where the risk is greatest, but simplify the deployment process and risk to coronary artery 
flow disruption. 
159 
 
As has already been outlined much of the ATAG design specification concern is with 
regard to the very close proximity of the coronary arteries to the aortic valve.  Figure 54 
below from the Muriago paper on location of coronary orifices shows very clearly that the 
vast majority of coronary ostia arise within the sinus (i.e. below the STJ) (21). 
Figure 54 Representation of location of coronary ostia 
 
 
 
 
 
Adapted from Muriago et al (21).  Figure shows the 3 aortic sinuses (anterio, right posterior and left posterior).  RCA and 
LMCA orifices (dots) are not located in the centre of each aortic sinus, but instead there is a tendency for all orifices to be 
towards the zone of apposition of adjacent leaflets at the STJ. 
If the ATAG is to proactively protect flow to the coronary arteries with a coronary sleeve 
or “inverted t-shirt” then this branch must come off of the main stent graft low down, and 
special design considerations may be required to mirror and fit the sinus anatomy so as 
to minimise the chance of aortic valve dysfunction.  One potential consideration is the 
formation of a tri-lobed proximal portion in an attempt to mirror the natural sinus of 
Valsalva anatomy.  This potential ATAG design is shown in Figure 55 below: 
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Figure 55 Potential ATAG design 
 
 
 
 
 
 
The proximal end of the ATAG device could have a tri-lobed appearance to mirror the anatomy of the sinuses of Valsalva 
enabling the proximal seal to conform and provide less risk of endoleak and potentially minimise aortic valve dysfunction.  
Proximal end fixation is also an important consideration to enable a good proximal seal to 
prevent both endoleak and stent graft migration when exposed to physiological systemic 
pressures.  Specific design features are likely to be required to enable a satisfactory 
proximal end “seal”, whether that is in the form a “flare” or expandable ring portion - 
accepting that achieving a seal in this area with such proximity to the coronary arteries 
and aortic valve is not straight forward both from a design and procedural perspective. 
If the ATAG is to proactively protect the coronary ostia with a sleeved “inverted t-shirt” 
then the material pushed with the stents into the coronary arteries must be as thin as 
possible (conventional woven Dacron material may be too thick, and its poor patency in 
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small vessels may be prohibitive).  Any new material for this purpose must be strong, 
durable, biocompatible and be low profile for packing into the delivery system.  It will also 
need to be potentially less rigid than Dacron displaying some flexibility with regard to 
coronary ostia position, and in small lumen diameters have less of a tissue ingression 
and inflammatory reaction to maximise medium to long term vessel patency.  
1.8.4 Aortic valve considerations 
All of the above design suggestions have been driven by the perceived need to avoid 
interfering with aortic valve integrity.  However we know that nearly a quarter of all AAAD 
will have significant AR, which if the patients are treated surgically will require aortic 
valve replacement or repair to regain integrity (9).  With TAVI rapidly gaining acceptance 
as a treatment strategy we have considered that after dealing with the intimal tear in the 
ascending aorta using the ATAG graft, one could then proceed on to deploy a 
commercially available TAVI to treat the AR which was either already present, or that 
was caused by the ATAG graft insertion.  Bonhoffer et al. in their large series of 
percutaneous pulmonary valve replacements utilise a bare stent in the pulmonary outflow 
tract into which the Medtronic Melody percutaneous valve is implanted (123).  The 
Seigburg group in Germany have already reported a case of iatrogenic AAAD during 
balloon valvuloplasty which was successfully treated by a CoreValve TAVI implantation 
without the need for surgery (124). 
The next design and intellectual property approach is to consider integrating a functional 
aortic valve into the ATAG graft so that the proximal end of the valved ATAG device 
could be positioned either into or just above the LVOT, gaining a good proximal seal 
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potentially at the site of the aortic annulus (a relatively uniform size), extending through 
the aortic valve portion, where a new integrated aortic valve would provide valvular 
function, into a coronary area - giving coronary protection and then finally leading into an 
ascending aorta section providing intimal tear exclusion before the distal seal falling short 
of the RBCT. 
The CoreValveTM percutaneous re-valving programme has taught us important lesions 
that the lower we implant devices into the LVOT the greater the potential disruption of 
conduction in the bundle of His and the greater need for permanent pacemaker (PPM) 
insertion post TAVI.  In the UK CoreValve registry the PPM implantation rate was 33% at 
30 days post CoreValve TAVI (125).  This is thought to have improved with the latest 
generation device and a slightly “higher” optimal CoreValve implantation position.  
This aortic valve design feature was captured within our second patent filing as illustrated 
below in Figure 56 with an integrated valve within the ATAG device, termed the “valved 
ATAG”.  The site of proximal seal would most likely be at the level of the aortic annulus, 
and as the aortic valve function is being replaced there is potentially no need for the 3 
feelers to fit into the natural sinus anatomy. 
 
 
 
 
163 
 
Figure 56 The Valved ATAG 
 
 
 
 
 
 
 
The “valved ATAG”.  A proximal skirt will sit at the level of the aortic annulus forming a proximal seal.  In the proximal 
section of the valved ATAG is a fully functional aortic valve.  This leads into the coronary sleeve portions, and then into the 
ascending  aorta endograft body. 
1.8.5 Other anatomical considerations 
As an interventional cardiologist I do not under-estimate the procedural challenges 
involved to successfully deploy an endovascular solution for acute ascending aortic 
syndromes.  A super-imposed challenge is going to be the design of family of devices in 
different “off the shelf sizes”, or rapidly available to a cardiothoracic centre to enable 
treatment to the widest possible spectrum of anatomical variations. 
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Another possibility is that if the device becomes indicated for use in a more chronic and 
stable patient cohort then bespoke grafts could be manufactured on a patient by patient 
basis manufactured from 3D reconstruction information gathered from either the CT or 
MRI scans.  This is currently the case in the descending thoracic aorta with endografts 
manufactured and dispatched within 6 days of order by the German based endovascular 
company Jotec (Hechingen, Germany). 
1.8.6 Procedural considerations 
It has always been the aim of the ATAG device from its very inception to be implanted 
using percutaneous techniques already established within the interventional 
cardiologist’s repertoire – the aim of this to help support early adoption of the technique.  
One only has to look at the rapid rise in TAVI implantation rates to see that when 
interventional cardiologists can use existing skills, with a new device, and a significant 
patient benefit, adoption of the technique is extremely rapid. 
 ATAG can learn much from the incredible development of TAVI devices.  Like TAVI the 
ATAG device if delivered truly percutaneously from the femoral artery must traverse the 
aortic arch and the delivery system must be low profile, trackable and the delivery must 
be precise and controllable.  As the TAVI devices have evolved and become of lower 
profile the associated cerebro-vascular and vascular complications rates have also 
decreased.  Both of the currently available TAVI devices utilise an 18 F delivery system 
and this is the profile that we are aiming for when we take ATAG into the FIM clinical 
trials.  Achieving this goal will rely upon state of the art nitinol frame design, thin low 
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profile covering material, and an efficient and reliable stowing and deployment 
mechanism. 
The device will be located into the landing zone using conventional “over the wire” 
techniques that all cardiologists are very comfortable with.  Again we do not 
underestimate the potential challenges of delivering a graft device potentially with 2 
coronary arms, and therefore up to 3 guidewires in total.  The guide wires are likely to 
have specific design requirements to enable stability; the device, and the procedure will 
require meticulous guide wire care so as to avoid “wire wrap” and tangling as delivery will 
be impossible if this were to occur. 
We anticipate that during the early FIM trials patients are likely to be under a general 
anaesthetic (GA), although again in a situation similar to that of TAVI after experience 
has been gained it may be a procedure that can be performed under conscious sedation 
avoiding all of the haemodynamic and respiratory risks of GA in this very sick patient 
cohort.  Other shared features with TAVI programmes are that the ATAG will be best 
implanted by a “Heart team”, with interventional cardiologist, cardio-thoracic surgeon, 
imaging cardiologist, cardiac anaesthetist, endovascular specialist within a hybrid 
catheter laboratory under fluoroscopy with the aid of either intra-cardiac echo (ICE) or 
TOE. 
Even if the procedure is successful at the time of implantation there will be many clinical 
and regulatory questions that must be answered and this information must be constantly 
collected during the development programme.  What is the long term durability of the 
graft material?  What is the durability of any integrated aortic valve?  What is the 
percentage endoleak rate?  Will the graft be prone to thrombosis?  What is the coronary 
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sleeve patency long term?  What is the optimal anti-platelet / anti-coagulation protocol for 
the ATAG device?  How will we follow these patients up?   
While currently we are not in a position to answer any of these questions we must be 
continuously collecting scientific data so that when the in vivo and FIM trials do arrive we 
are in a position to give our opinions and evidence based answers. 
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Chapter Two: Novel CT and MRI data 
2.0  Novel CT and MRI anatomical data in AAAD and ATAA 
In the previous chapter I have set the landscape in which ATAG is being 
developed.  The endovascular field is one that is fast moving, and much of the 
practice seems consensus and registry data driven.  I hope I have outlined the 
clinical problem of ascending aortic pathology, the current treatment modalities 
and their deficiencies. 
Since 2007 TAVI has become more widespread and as interest has grown there 
has been an exponential growth in the anatomical literature relating to the aortic 
valve, coronary arteries and ascending aorta.  Most data however focuses 
understandably on the TAVI patient cohort, and while this is interesting, very little 
still exists on either the AAAD or ATAA populations with similar details 
concerning aortic valve size, competence, coronary take off and angulation, and 
ascending aortic size.  
In 2008 to enable design of our ATAG graft within our target population required 
the collection of novel anatomical data.  To access sufficient numbers of these 
patients and the expertise to analyse CT and MRI images required collaboration 
with other institutions. 
I collaborated with Professor Salah Qanadli an interventional radiologist at CHUV 
Hospital, Lausanne, Switzerland to measure anatomical variables in a 9 patient AAAD 
cohort that he had collected over 4 years.  Accepting the limitation of small sample size I 
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felt that at the time in the absence of robust published data on the subject this would give 
me a tangible understanding of anatomical sizing and coronary angulation in this patient 
group. 
I also collaborated with Dr Raad Mohiaddin CMR consultant at the Royal Brompton 
Hospital who has a large cohort of patients with Marfan syndrome ATAA which he follows 
up.  There is a paucity of data on ATAA aortic size, aortic valve AV competence, 
coronary size and take off angulation, and if ATAG is going to be a potential treatment 
modality for ATAA in Marfan syndrome then devices need to be able to conform and treat 
the corresponding anatomy. 
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2.1 Aortic dimensions and coronary angulations measured in a 
9 patient cohort presenting with AAAD 
2.1.1 Study purpose 
A retrospective pilot study to measure aortic dimensions by CT angiography evaluated 
on true lumen 2D centre line based reconstructions, 3D and multi-planar reconstructions 
(MPR) at multiple levels in the aorta as described by O’Neill et al. to help understand 
aortic and coronary anatomy in a patient population presenting to hospital with a 
diagnosis of AAAD (126). 
2.1.2  Methods 
2.1.2.1 Study Cohort 
A total of 9 consecutive patients presenting to CHUV hospital in Lausanne, Switzerland 
between January 2007 and December 2010 with signs and symptoms of AAAD 
confirmed on CT scanning made up the study group.  
2.1.2.2 CT cardiovascular imaging 
All subjects were imaged using GE CT scanners within the CHUV radiology department.  
CHUV has a number of CT scanners and during the study period these were updated.  
As a result the temporal resolution and the speed of the scan generally improved with 
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time, the early scans being performed on a 16 slice CT, and the latest scans on a 64 
slice GE CT scanner.  None of the CT scans were ECG gated. 
CT scans where collected from the archive and anonymised.  Scans were reformatted 
using a GE Medical System Advantage Windows Workstation with version 4.3 software. 
3.1.2.3 Measurements  
The following patient characteristics in Table 9 below were collected: 
Table 9 Patient characteristics  
Age 
Gender 
Hypertension 
Diabetes 
Hyperlipidaemia 
Smoking 
Confirmed connective tissue disease / family history of connective tissue disease 
 
Aortic measurements of aortic diameter and lengths are shown in Figure 57, and Table 
10 below: 
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Aortic measurements (TK  / SP supervised by SDQ) 
Figure 57 Showing ascending aortic diameters and lengths measured 
 
 
 
 
 
 
 
 
 
For all diameters a maximal and minimal measurement were made. D1 – annulus diameter, D2 – Sinus diameter, D3 – 
STJ diameter, D4 – Mid ascending aorta diameter, D5 – Diameter just proximal to RBCT, D6 – Mid aortic arch diameter. 
L1 – Length from annulus to RCA, L2 - Length from annulus to LMCA, L3 – Length from RCA to RBCT, L4 – Length from 
LMCA to point opposite RBCT, 
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Table 10 Aortic diameters and lengths measured 
Number of aortic cusps 
D1a Maximal annulus diameter (mm)  
D1b Minimum annulus diameter (mm) 
D2a Maximal sinus of valsalva measurement (cusp to cusp mm),  
D2b Minimum sinus of valsalva measurement (cusp to cusp mm)  
D3a Maximal sinotubular junction diameter (mm),  
D3b Minimum sinotubular junction diameter (mm),  
D4a Maximal mid ascending aortic diameter,  
D4a Minimum mid ascending aortic diameter, 
D5a Maximal diameter of aorta at RBCA, 
D5b Minimum diameter of aorta at RBCA,  
D6a Maximal mid aortic arch diameter (mm),  
D6b Minimum mid aortic arch diameter (mm),  
D7a Maximal descending aortic diameter (mm), 
D7a Minimum descending aortic diameter (mm),  
D8a Left Iliac artery maximal diameter (mm)   
D8b Left Iliac artery minimum diameter (mm)   
D8c Right Iliac artery maximal diameter (mm)   
D8d Right Iliac artery minimum diameter (mm)   
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Table 10 Aortic diameters and lengths measured cont. 
 
D9a Left femoral artery maximal diameter (mm)   
D9b Left femoral artery minimum diameter (mm)   
D9c Right femoral artery maximal diameter (mm)   
D9d Right femoral artery minimum diameter (mm)   
D10 Distance from annulus to site of intimal dissection tear (mm) 
S1  Site of end of dissection flap 
L1 Annulus to right coronary ostium (RCA mm),  
L2 Annulus to left main stem coronary artery (LMCA mm),  
L3 Length RCA to RBCA (mm),  
L4 Length LMCA to RBCA (mm),  
 
Coronary artery angulation measurements recorded are demonstrated in Figure 58 
below: 
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Figure 58 Coronary artery ostia angle from aorta   
   
   A1    A2 
 
 
 
 
 
 
Coronary angle measurement with AP direction at 0 degrees.  A1 Angle of origin of the LMCA from aorta (degrees from 
AP), A2 Angle of origin of RCA from aorta (degrees from AP), A3 Delta angle between RCA and LMCA  
2.1.3 Results 
2.1.3.1 CT scanning information 
One patient was scanned with a 5 mm thickness slice (least accurate), 2 patients with a 
2.5 mm slice, 5 with a slice thickness of 1.2 mm, and one patient 0.6 mm.  All scans were 
of adequate resolution and quality to make the desired measurements. 
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2.1.3.2 Patient demographics 
The 9 patient cohort comprised 5 males and 4 females.  The mean age was 64.8 +/- 12.8 
years, (range 44-85).  3 patients were active smokers (33%), 1 patient (11%) was an ex-
smoker, and 5 (55%) were non smokers.  8 of the 9 patients were hypertensive (89%), 
none suffered with diabetes, and 2 (22%) were known to be hyperlipidaemic prior to 
presentation.  None had a known inherited connective tissue disorder.  
2.1.3.2 Aortic Valve 
All patients had 3 aortic valve cusps – there were no patients with a BAV. 
Table 11 below shows the aortic dimensions: 
Table 11 Dimensions in the 9 patient AAAD cohort 
Parameter  Mean (mm) Range (mm) SD (mm) 
D1a Max annulus diameter  27.4 24.4 - 31.3 2.1 
D1b Min annulus diameter 22.7 19.0 - 26.2 2.8 
D2a Max sinus diameter 33.3 29.5 - 41.1 4.2 
D2b Min sinus diameter 24.9 20.2 – 28.7 3.6 
D3a Max STJ diameter 43.1 31.4 – 56.6 7.7 
D3b Min STJ diameter 40.2 26.9 – 54.4 8.4 
D4a Max mid AA diameter 45.4 27.8 – 57.8 10.9 
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Table 11 Dimensions cont. Mean (mm) Range (mm) SD (mm) 
D4b Min mid AA diameter 41.6 24.9 – 51 8.9 
D5a Max diameter Ao RBCA 45.6 33.8 – 63.3 9.7 
D5b Min diameter Ao RBCA 40.9 28.4 – 58.2 9.8 
D6a Max mid A Arch diameter 36.4 27.8 – 59.9 9.6 
D6b Min mid A Arch diameter 30.9 25.8 – 34.5 2.8 
D7a Max desc Ao diameter 32.9 25.3 – 40.1 5.1 
D7b Min desc Ao diameter 31.5 24.7 – 39.9 5.0 
D8a Max L iliac diameter  15.5 11.7 – 23.4 3.5 
D8b Min L iliac diameter 14.9 9.9 – 16.3 6.6 
D8c Max R iliac diameter 14.5 9.4 – 26.9 5.8 
D8d Min R iliac diameter 12.8 8.4 – 15.6 4.2 
D9a Max L femoral diameter 9.5 6.4 – 13.2 2.1 
D9b Min L femoral diameter 8.6 5.9 – 11.7 1.9 
D9c Max R femoral diameter 10.3 7.5 – 13.5 2.1 
D9d Min R femoral diameter 8.5 6.2 – 11.2 1.9 
D10 Distance from annulus to site of 
intimal tear 
28.0 12 – 49.9 18.2 
L1 Annulus to RCA  23.0 16.9 – 40.4 7.1 
L2 Annulus to LMCA 23.8 20.1 – 30.2 2.9 
L3 Length RCA to RBCA  64.6 23.6 – 100.6 19.8 
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Table 11 Dimensions cont. Mean (mm) Range (mm) SD (mm) 
L4 Length LMCA to RBCA  33.1 18.2 – 59.1 12.5 
A1 Angle of origin of the RCA from 
aorta 
-51.0 -84.1  to  -26.5 18.8 
A2 Angle of LMCA from aorta 111.5 78.5  to  137.4  22.3 
A3 Angle between RCA and LMCA 162.5 131.6  to  201.8 27.5 
S1  Site of end of dissection false lumen  
Femoral artery                     3 / 9 (33%) 
Iliac artery    2 / 9 (22%) 
Aortic arch    2 / 9 (22%) 
RBCT     1 / 9 (11%) 
Distal descending aorta                    1 / 9 (11%) 
2.1.4.  Conclusions 
Any conclusions that are drawn from this CT analysis must be tentative as the sample 
size is small (n=9).  The difficulty with AAAD is that it is relatively rare and as such 
finding scans of adequate quality to assess can be difficult.  I do think that this data does 
give us some understanding of the aortic sizes and in particular looking at the coronary 
orientation and the peripheral access vessels. 
The mean age of this cohort (64.8 years) is similar to that reported in the IRAD database 
of 62 years.  In this small group we had a slight predominance of males (55%) compared 
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to IRAD of 68%.  8 of the 9 (89%) patients had a known history of hypertension 
compared to the IRAD literature which suggests figure of 67%. (64;88;127;128) 
The mean aortic annulus measurement is essentially normal at 25 mm (normal = 24.5 
mm), as is the mean diameter at the level of the sinuses 29.1 mm (normal = 32 
mm).(129).  The STJ dilates to 41.65 mm  (normal = 29.7 mm), with corresponding 
mean mid ascending aortic diameter dilated at 43.5 mm (normal = 32.7 mm) (11).  This 
is in very close agreement with the data from Neri et al. which in a much larger 
dissection cohort had a mean ascending aortic size of 41 mm (89).  Parish et al using 
TOE measurements calculated a mean aortic diameter of 53 mm (87). 
The aorta remains significantly dilated at the level of the RBCT at 43.5 mm, the level of 
the mid-point of the aortic arch at 33.6 mm, and at the descending aorta at 32.2 mm. 
In this AAAD cohort the mean distance from the annulus to the RCA was 23 mm 
(normal = 19.3 mm), and to the LMCA was elongated at 23.8 mm (normal = 12.1mm) 
(11).  The angle between the origin of the RCA and the LMCA from the aorta was 162.5 
degrees (normal 154 degrees)(24).  The angle between the orientation of the RCA and 
the LMCA had a standard deviation of 27.5, with 2 real outlying values.  The lowest 
angle was 110 degrees and the largest was 202.   
An important feature if we are to treat AAAD by percutaneous means is to ascertain the 
diameter of the access vessels i.e. the femoral and iliac arteries.  Although calcification 
and tortuosity were not assessed in this study the diameter assessment showed a mean 
left common iliac artery diameter of 15.2 mm, common right iliac artery 13.6 mm, 
common left femoral artery diameter 9.1 mm and common right femoral artery calibre of 
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9.4 mm.  All patients had a femoral artery diameter of >7.5 mm, which will comfortably 
accommodate an 18 F arterial access sheath. 
Worthy of note is that in 3 patients the false lumen extended down to the femoral artery, 
and a further two down to the level of the iliac artery.  It will be vitally important at the 
time of sheath implantation for ATAG delivery that the true lumen is selectively 
cannulated.  
Discussion with regard to ATAG design specification for AAAD 
This small pilot study has allowed me to measure accurately the aortic diameters, and 
discern the relationship between aorta, coronary arteries and aortic valve, in order to 
further develop the ATAG design specification.  It must always be borne in mind that this 
is a small cohort with the inherent errors associated. 
That said, the aortic diameter data is very much in agreement with the literature available 
from larger series, and the aortic diameter and peripheral vessels suggest a diameter 
that in the most part will accommodate a large sheath for ATAG device delivery.  
Looking at specific mean aortic diameters, Figure 59 shows the mean aortic diameters 
from the AAAD cohort: 
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Figure 59 Mean AAAD aortic diameters at specific landmarks 
 
   RBCT 43.5mm 
 
        AA  43.5mm 
 
  STJ 41.6mm     Sinuses 29.1mm 
Annulus 25mm  
 
 
The AAAD cohort seems to have maintenance of normal aortic diameter at the level of the aortic annulus and sinuses.  
The STJ, ascending aorta and aorta at the level of the RBCT are all dilated at a mean diameter of 41.6 mm, 43.5 mm and 
43.5 mm respectively.   
This has important implications for ATAG design.  If we are just to implant a simple 
tubular endograft as postulated by Sobocinski to treat at least one third of all patients 
then the endograft will be a uniform tube of around 40mm plus approximately 20% over-
sizing (8). 
Annulus  = 
25mm 
Sinus  = 
29.1mm 
AA  = 43.5mm 
Ao at RBCT  = 
43.5mm 41.6mm 
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If we are to design our ATAG as a t-shirt with one or more coronary branches then the 
proximal end will need to “cone down” to approximately 30 mm within the sinuses plus 
over-sizing.  If the proximal landing zone is to be the aortic annulus as with the proposed 
“valved ATAG”, then the proximal portion will measure 25 mm +/- over-sizing.  If the 
valved ATAG would to be implanted at this site there is a clear consensus as to annulus 
measurements and sizing from TAVI experience and this is device specific.  Our valved 
ATAG device is likely therefore to have a similar sizing protocol to the nitinol framed self-
expanding CoreValveTM revalving system (Medtronic, Santa Rosa, CA, USA).  
The coronary angle data is novel and suggests a mean angle between RCA and LMCA 
of 162.5 degrees relatively similar to that seen in normal human aortas (154 degrees).  
As well as requiring ATAG main body grafts in different sizes we may also consider the 
need for proximal portions with different coronary angulations.  As with any device it is 
important we are able to treat the majority of patient anatomies with this disease process, 
but there will always be patients particularly with the first device iteration that have 
anatomy beyond the realms of a device – the important thing is to understand the 
anatomical needs of the patient and treat as wider range of patients as is possible with 
the smallest possible range of off the shelf products.  It is clear that to cover and treat 
both coronary ostia with a true “t-shirt” graft, the coronary sleeves must have some 
flexibility to treat a variety of angulations, and bench testing will elucidate the degree of 
angulation that the ATAG can comfortably treat.  
The degree of AR was not assessed in this study, and this is something that I will seek to 
analyse from both TTE and TOE performed at the time as it has important implications as 
to the type of curative surgical or percutaneous procedure required (i.e. TAVI, or valved 
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ATAG).  It is also likely that we will extend our pilot to more patients within the CHUV, so 
that we might get more of a wealth of reliable data to publish these findings – at the 
moment from this pilot the numbers are simply too small. 
2.1.5 Recent data published on AAAD aortic size 
The CHUV AAAD anatomical data were accumulated in 2010 while I was an 
interventional fellow on exchange in Switzerland.  In 2011 Sobocinski published 
subsequent data in a larger group of patients outlining some very interesting anatomical 
measurements from a group of 102 patients presenting with AAAD (8).  This paper 
represents the most current and detailed assessment of aortic anatomy in AAAD and is 
highly relevant to the design of ATAG, and as such I will now proceed to summarise 
Sobocinski’s findings. 
102 patients were enrolled across 5 centres in France with a clinical and CT diagnosis of 
AAAD between 2006 and 2009.  Pre-operative CT scans were analysed and aortic 
measurements performed by 2 experience endovascular surgeons.  Echocardiography 
was also performed on all patients to assess the degree of AR. 
Mean age of patients enrolled was 64 years (36-85 years).  70% of patients were male, 
71 % having a history of hypertension.  Of the 102 patients enrolled in the study, 77% 
had a Debakey type I, 18% type II, and 5% retrograde type III.  The Debakey 
classification is briefly described in Figure 60 below: 
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Figure 60 Debakey classification of aortic dissection 
 
 
 
 
 
 
Type I – Originates in ascending aorta, propagates at least to the aortic arch and often beyond it distally. It is most often 
seen in patients less than 65 years of age and is the most lethal form of the disease.  Type II – Originates in and is 
confined to the ascending aorta. Type III – Originates in descending aorta, rarely extends proximally but will extend 
distally. 
Aortic regurgitation 
44% of patients on echocardiography had no AR, 23% had grade I AR, 20% grade II, 8% 
grade III and 5% grade IV.  
 Operation performed 
An ascending aorta replacement, a Bentall procedure and a Tirone-David procedure 
were performed in 70%, 29% and 1% of patients respectively.  An aortic valve repair or 
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replacement was performed in 35% of patients.  The mortality at 30 days was 24%.  
Table 12 below shows the aortic anatomical data (8).   
Table 12 Sobocinski AAAD cohort anatomical data 
 Mean diameter (mm) Range (mm) 
Aorta 15 mm above coronary (=STJ) True 38 22-78 
Aorta 15 mm above coronary (=STJ) Total 46 28-93 
Aorta diameter at RBCT True 35 19-67 
Aorta diameter at RBCT Total 42 27-61 
Distance from distal coronary to RBCT 85 40-130 
Distance from distal coronary to Entry tear (ET) 28 0-128 
Distance from ET to RBCT 59 0-118 
Dissection extension length 373 20-699 
 
The intended focus of the Sobocinski paper was to act as a CT based feasibility study to 
determine theoretically the proportion of patients presenting with AAAD in whom it might 
be possible to implant a tubular endograft between the coronary arteries and the RBCT 
to occlude flow into an ascending aortic entry tear.  The goal of such an intervention in 
AAAD is to cover the entry tear redirecting the entire flow into the true lumen and 
therefore enabling the false lumen to collapse or even thrombose.  Even if there are 
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multiple tears, simply covering the most proximal one is often sufficient to initiate 
remodelling and reverse malperfusion conditions.  
This feasibility analysis suggests that 36% of patients presenting with AAAD may be able 
to be treated with a simple tubular endograft.  A further 8% may be able to be treated the 
same way so long as they have an extra-anatomical bypass in case the endograft 
compromises the RBCT because of close proximity.  These figures probably represent a 
conservative estimate given that criteria for feasibility included having a landing zone 20 
mm from both the coronary arteries and the RBCT.  The maximum true lumen size 
considered for endograft placement was 38 mm, given that currently the largest 
commercially available stent graft is currently 46 mm (i.e. taking into consideration a 20% 
over-sizing).  
35% of patients required aortic valve repair or replacement because of 
echocardiographic Grade II – Grade IV AR.  These data are in agreement with the larger 
IRAD database and suggest that to treat these patients adequately will require either 
TAVI following endograft treatment, or a valved ascending aortic endograft as proposed 
by the “valved ATAG”. 
This paper also provides the most robust, in-depth analysis of entry tear location and the 
associated diameters of the aorta and great vessels in patients presenting with AAAD, 
and will help us in combination with our own and other published data to make the ATAG 
design specification. 
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Conclusions relevant to the formulation of ATAG design specification: 
i) A simple tubular endograft covering the entry tear, with a 20 mm landing zone 
between both the coronary arteries and the RBCT will be suitable to treat 
36% of patients presenting with AAAD (8). 
ii) Up to 35% of patients presenting with AAAD are likely to require valve repair or 
replacement, so an endovascular solution for these patients will require either 
a commercial TAVI implantation following endograft insertion, or a valved 
ATAG endograft. 
iii) The mean true lumen sizes in this cohort were 38 mm at the STJ, and 35 mm at 
the origin of the RBCT.  Current commercially available endografts for the 
descending aorta have a maximal size of 46 mm, and as such if we are to 
treat the majority of AAAD with an endograft (taking into account the standard 
20% over-sizing) we may well need to design and develop larger grafts which 
may pose technical challenges with crimping as well as delivery system size. 
iv) The mean distance from the distal coronary artery to the RBCT is 85 mm (range 
40-130).  We will clearly need a variety of “off the shelf” endograft diameters 
and lengths.  It is also possible that in keeping with practice in the descending 
aorta “extension cuffs” could be used at the distal end to ensure adequate 
coverage, but overlap and fall short of the RBCT. 
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2.2  A CMR investigation of the aortic anatomy of 62 patients 
with Marfan’s syndrome and ATAA 
There is little published data concerning ATAA coronary and aortic valve 
orientation and function.  To understand this area better I collaborated with the 
largest Marfan syndrome patient group in the UK, based in London at the Royal 
Brompton Hospital and St Georges Hospital. 
Dr Raad Mohiaddin is a Consultant MRI Cardiologist at the Royal Brompton Hospital, 
and he runs the MRI follow up service of the population with Marfan syndrome within this 
quaternary service.  He has approximately 150 patients in annual CMR follow up, 62 of 
which have a dilated ascending aorta / ATAA.  
Dr Anne Child is a clinical geneticist with an interest in Marfan Syndrome and forms part 
of the multi-disciplinary team managing all patients in Marfan syndrome follow up.  She is 
based at St George’s Hospital. 
Professor Ho is a cardiac morphologist based at the Royal Brompton hospital. 
I wrote the measurement protocol, but I received advice and support from all the 
collaborators listed above. 
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2.2.1 Study background 
Aortic root size has important prognostic implications in patients with Marfan syndrome 
(130).  Accurate measurements and follow up of the aortic diameters of patients with 
Marfan syndrome are required for informed decision making on the timing and nature of 
surgical treatment to the aortic valve and root.  
Cardiovascular magnetic resonance (CMR) is becoming increasingly available, and has 
the clear advantages over CT scanning of clear visualisation with freedom from ionising 
radiation.  It has become the gold standard for monitoring of aortic root dilatation 
providing guidance as to the prospective timing of prophylactic aortic root intervention. 
CMR has many advantages, allowing cine image acquisition of the aorta and re-
construction and measurements in any plane.  
2.2.2 Study purpose 
The purpose of this study was to measure aortic dimensions by CMR using planes 
transecting, as well as aligned with the axis of the aortic root to help understand aortic 
and coronary anatomy in a Marfan syndrome population with dilated aortic roots. 
190 
 
2.2.3 Methods 
2.2.3.1 Study Cohort 
Sixty-two patients with confirmed Marfan syndrome and dilated or aneurysmal aortas 
made up the study cohort, all patients were being actively followed up at the Royal 
Brompton Hospital, London. 
2.2.3.2 Cardiovascular Magnetic Resonance 
All subjects were imaged using a 1.5 Tesla system (Siemens Sonata, Erlangen, 
Germany).  Images were acquired using Royal Brompton standardised aortic follow up 
protocol.  The cardiac and standard aortic measurements were performed by AP and 
RM, all coronary and aortic valve measurements were performed by a single observer 
(TK, supervised by AP and RM), using CMRtools (Cardiovascular Imaging Solutions, 
London, United, Kingdom).   
2.2.3.3 Measurements 
Table 13 below shows the patient and cardiac characteristics measured: 
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Table 13 Patient and cardiac characteristics 
Patient features (AP / RM) 
Age, gender, Body surface area (BSA m
2
) 
Cardiac features (AP / RM) 
Left ventricular diastolic volumes (LVDV ml)  
Left ventricular systolic volume (LVSV ml),  
Left ventricular ejection fraction (LVEF %),  
Number of aortic cusps,  
Degree of aortic regurgitation (AR grade 0-4),  
Presence of mitral valve prolapse (MVP),  
Degree of mitral regurgitation (MR grade 0-4) 
 
Aortic measurements (TK supervised by AP / RM) shown in Figure 61, and tabulated in 
Table 14 below: 
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Figure 61 Aortic measurements from the 62 patient Marfan cohort 
 
 
 
 
 
 
 
 
 
D1 – annulus diameter, D2 – Sinus diameter, D3 – STJ diameter, D4 – Mid ascending aorta diameter, D5 – Diameter just 
proximal to RBCT, D6 – Mid aortic arch diameter. L1 – Length from annulus to RCA, L2 - Length from annulus to LMCA, 
L3 – Length from RCA to RBCT, L4 – Length from LMCA to point opposite RBCT, 
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Table 14 shows aorta measurements performed 
D1a Systolic annulus diameter in the 3 chamber view (mm)  
D1b Systolic annulus diameter in the cross sectional plane (mm)  
D2a Systolic sinus of valsalva measurement (cusp to cusp mm) 
D2b Systolic sinus of valsalva measurement (cusp to commissure mm)  
D3 Systolic sinotubular junction diameter (mm)  
D4 Maximal systolic ascending aortic diameter (mm)  
D5 Diameter of aorta at RBCA (mm)  
D6 Mid aortic arch diameter (mm)  
D7 Descending aortic diameter (mm)  
D8 Aortic diameter at diaphragm (mm)  
L1 Annulus to right coronary ostium (RCA)(mm)  
L2 Annulus to left main stem coronary artery (LMCA) (mm),  
L3 Length RCA to RBCA (mm), 
L4 Length LMCA to RBCA (mm)  
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Coronary artery ostia angle from aorta 
Figure 62 below shows the measurement of relative coronary ostia angulation from the 
aortic root in the AP plane: 
Figure 62 Measurement of relative coronary ostia angle in the AP plane. 
     
   A1     A2 
 
 
 
 
 
 
Coronary angle measurement with AP direction at 0 degrees.  A1 Angle of origin of the LMCA from aorta (degrees from 
AP),  A2 Angle of origin of RCA from aorta (degrees from AP)  
Figures 63 – 66 below show the various planes in which aortic and coronary 
measurements were made: 
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Figure 63 Shows a still frame from an oblique sagittal MRI systolic frame 
 
 
 
 
 
Oblique sagittal MRI systolic frame showing the levels of annulus, sinus, and STJ measurements (white arrow, black line, 
and black arrow, respectively). 
Figure 64 shows oblique coronal LVOT still image 
 
 
  
 
 
Oblique coronal LVOT cine showing the equivalent levels of measurement - annulus, sinus, and STJ measurements (white 
arrow, black line, and black arrow, respectively). 
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Figure 65 A systolic sinus plane MRI image, systolic frame 
 
 
 
 
 
A systolic sinus plane image, systolic frame, showing 3 cusp-commissure and 3 cusp-cusp lines of measurement 
(continuous and dashed black lines, respectively) 
Figure 66 Measurement plane for measuring the distance from annulus to coronaries 
 
 
 
 
 
Measurement plane for measuring the distance from annulus to RCA and LMCA 
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2.2.4 Results 
The patient cohort comprised 44 males and 18 females, with a mean age of 32 +/- 14 
years, (range 18 - 64).  Mean body surface area 2.1 +/- 0.23 m2.  Mean diastolic LV 
volume was 205 ml, with a mean systolic LV volume of 82 ml, giving a mean LV ejection 
fraction of 62 +/- 3.2%, (range 31 – 75). 
3 patients were found to have a BAV (5% of the cohort), the remaining 59 patients having 
tricuspid valves.  33 patients (53%) had no AR.  21 patients (34%) had mild AR, 2 
patients (3%) had mild-moderate AR, 1 patient (1.5%) had moderate AR, 1 patient 
(1.5%) had important AR, and 4 patients (7%) had severe AR.  The 4 patients with 
severe AR all had grossly dilated aortic sinus measurements of 60 mm, 79.5 mm, 71 mm 
and 80 mm respectively. 
22 patients (35%) had an associated mitral valve prolapse, giving rise to 10 patients 
(16%) having mild mitral regurgitation (MR), 2 patients (3%) with moderate MR, and 2 
patients (3%) with severe MR. 
2.2.4.1 Aorta and coronary measurements 
Table 15 below documents the results of the aortic and coronary measurements in the 62 
patient Marfan syndrome cohort: 
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Table 15 Marfan syndrome aortic and coronary measurements 
Parameter Mean Range SD 
D1a Systolic annulus diameter 3 C 
(mm)  
28.5  21-39 3.9 
D1b Systolic annulus diameter in the X 
plane (mm)  
29.4  24-39 4.3 
Mean annulus diameter (mm) ((D1a + 
D1b) / 2) 
28.9  22-39 3.9 
D2a Systolic sinus of valsalva (cusp to 
cusp)( mm) 
48.7  34-80 9  
D2b Systolic sinus of valsalva (cusp to 
commissure)( mm) 
46.9  34-80 9.7 
Mean sinus diameter (mm) 48  34-80 9.2 
D3 Systolic STJ diameter (mm) 37.7 23-85 11.5 
D4 Maximal systolic ascending aortic 
diameter (mm) 
34.1 21-115 15.1 
D5 Diameter of aorta at RBCA (mm)  26.1 18-35  4.4  
D6 Mid aortic arch diameter (mm) 22.9 16-37  4.8  
D7 Descending aortic diameter (mm) 22.5 15-32  3.7  
D8 Aortic diameter at diaphragm (mm)   19.8 13-27  3.6  
L1 Annulus to RCA (mm) 20 14-36  4.7  
L2 Annulus to LMCA (mm) 16.3  11-32  4.1  
L3 Length RCA to RBCA (mm) 101.5 63 – 160 19.9  
L4 Length LMCA to RBCA (mm) 59.6  40-85 10.2  
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Table 15 cont. Mean Range SD 
A1 Angle of origin of the LMCA from 
aorta (degrees from AP)  
+124  +80  to +160 14.8  
A2 Angle of origin of RCA from aorta 
(degrees from AP) 
-18 -40 to -80  18  
Angle between LMCA and RCA (degree 
total) 
142  120-175  12.6 
 
2.2.4.2 Discussion 
Many patients with Marfan syndrome who have a dilated aorta are young.  This is 
reflected by the mean age of this cohort being 32 years.  Certainly the group appears to 
have a relatively large end diastolic volume, but with a mainly preserved ejection fraction 
(mean EF = 62%). 
7% of the cohort had significantly dilated aortas giving rise to severe AR.  A further 2 
patients (3%) had either moderate or important AR with the mechanism of aortic 
dilatation.  This is likely to represent patients who have presented later on in their 
disease process, rather than patients with an early diagnosis and serially followed.  
Screening would normally not allow diameters to exceed 4.5 cm before offering a 
surgical correction in an attempt to avoid the exponential risk of aortic aneurysm rupture 
and the associated aortic regurgitation.  
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4% of patients had moderate (2 patients) or severe MR (2 patients) secondary to mitral 
valve prolapse (MVP).  MVP is associated with Marfan syndrome, and therefore it is no 
surprise to find this number in our cohort.  
For the purposes of comparison Table 16 shows the Marfan syndrome aortic diameters 
compared to normal values: 
Table 16 Marfan syndrome aortic diameters compared to normal values 
Measurement Marfan syndrome Normal values 
Aortic annulus (mm) 28.9 24.5 
Sinus (mm) 48 32 
STJ (mm) 37.7 29.7 
Ascending aorta (mm) 34.1 32.7 
All normal values are derived from the Qanadli data (11). 
The mean aortic annulus measurement is a dilated at 28.9 mm, dilating further to a 
maximal diameter of 48 mm within the sinuses.  The mean STJ measurement remains 
dilated at 37.7 mm, and by the ascending aorta the diameter is only mildly dilated at 34.1 
mm.  
In this Marfan syndrome cohort the mean distance from the annulus to the RCA was 20 
mm (normal = 19.3 mm), and to the LMCA was 16.3 mm (normal = 12.1 mm) (11).  The 
distance from the LMCA to the RBCT was a mean of 59.6 mm (normal = 52.9 mm), and 
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from the RCA to the RBCT was 101.6 mm (11).  The angle between the origin of the 
RCA and the LMCA from the aorta was 142 degrees (normal 154 degrees) (24). 
2.2.4.3 Conclusion 
The pattern of dilatation of the Marfan aorta is well described, but this novel data has 
allowed documentation of the exact annular and sinus diameters, focusing also on the 
take off, distance and angulation of the coronary arteries.  It would appear from these 
data that the Marfan syndrome aortic root dilates in a relatively uniform way maintaining 
relatively normal angulation between the LMCA and the RCA.  Most of the dilatation seen 
is at the level of the sinus, and STJ, and that by the mid portion of the ascending aorta, 
diameters are virtually back to normal values. 
I think we should not be too concerned by the very large diameter of 4 of the cohort and 
their associated severe AR.  With aggressive screening protocols these diameters and 
the concomitant AR will not been seen as surgery / treatment options will be offered 
before this degree of dilatation has occurred.  We must also be realistic that in the first 
instance the ATAG device is not primarily for ATAA patients, but the unmet clinical need 
of AAAD.  Not only that, but the ATAG device will not be capable of treating all 
anatomies, and rather like TAVI there will always be patients that fall beyond the 
treatment realms of any new percutaneous device. 
Conclusion on ATAA data and relevance to potential ATAG design 
Although the ATAG is being designed in the first instance as a device to treat the unmet 
clinical need of patients presenting with AAAD, there is no doubt that as endovascular 
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therapies evolve, devices and delivery systems improve ATAA could become a cohort 
capable of being treated by ATAG, avoiding the need for invasive cardiothoracic surgery.  
That said this novel ATAA data provides us with a number of patient and anatomical 
challenges: 
i) The Marfan syndrome cohort are generally young with little co-morbidity.  The 
mean age of this study group was 32 years.  As has already been outlined 
because these patients are in regular follow up they are generally stable and 
surgery is elective with a relatively low risk.  Any percutaneous solution for 
ATAA would need to have a similarly low procedural risk but also display long 
term durability which may prove challenging. 
ii) The pattern of the aortic dilatation is different to that of AAAD.  Marfans display 
“annulo-aortic ectasia”, where the annulus dimension is dilated (mean 28.9 
mm) leading into a dilated sinus (mean 48 mm), dilated STJ (mean 37.7 mm) 
into a relatively normal sized mid ascending aorta (mean 34.1 mm).  This 
anatomy poses a number of device design challenges:  
 Achieving an effective proximal endograft seal will be difficult in the 
dilated sinuses.  
 The proximal end of the graft will be relatively large for endovascular 
stents. The mean sinus dimension in this cohort was 48 mm, meaning 
that even the average aorta will potentially require a 58 mm endograft 
with 20% over-sizing. This poses device, crimping and stowing as well 
as delivery challenges. 
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 The graft will also need to have a cone-shape, given that at the 
proximal end it will be around 58 mm and by the mid ascending aorta 
the diameter will be closer to 40 mm (with 20% over-sizing). 
 The “valved ATAG” may suit the ATAA where the proximal seal is at 
the mildly dilated aortic annulus, and then the distal seal is at a 
relatively normal part of the aorta prior to the RBCT (in a similar 
fashion to descending and abdominal aortic endovascular exclusion).  
So long as the coronary perfusion is maintained and the new valved 
portion competent the ATAG would not necessarily need to be in 
contact with the most dilated portion of the aorta in the sinuses.  The 
valved ATAG would also enable satisfactory treatment of the 5% of 
patients with BAV, and the 10% of this cohort who had at least 
moderate AR, which would normally require treatment. 
 Despite the annulo-aortic dilatation the angle of the coronary arteries 
to one another is relatively preserved at 142 degrees (normal 154 
degrees, range 120-175).  
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Chapter Three  
ATAG device specification  
PoC ATAG graft and delivery manufacture and 
testing 
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Chapter 3: ATAG device specification and PoC build 
3.1 ATAG “inverted t-shirt” device specification 
Now that the pathophysiology, anatomical data and current treatment modalities 
and deficiencies have been established for AAAD and ATAA, I will now utilise this 
data to develop an general ATAG device specification.   
3.1.1 General device specification 
The ATAG is a proposed endovascular stent graft designed to treat AAAD, where there 
is a large unmet clinical need (the 28% of patients presenting who are turned down or 
who refuse a surgical approach) (67).  It is also possible as our experience grows that 
like in the rest of the vascular tree the ATAG device could become a treatment modality 
for ATAA, although the currently well established surgical treatments have a low 
operative morbidity and mortality (7). 
The key feature of ATAG is the insertion of a covered aortic endograft near the aortic 
valve.  Chapter 1.8 discussed generically the design possibilities with regard to 
maintenance of aortic valve function, protection of coronary artery flow, and exclusion of 
the intimal tear.  As has already been discussed, a simple tubular endograft will only be 
feasible to treat approximately 36% of AAAD patients, as the remainder have diseased 
segments too close to the aortic valve, coronary arteries, or RBCT (8). 
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It was decided early on in this project that one embodiment of ATAG should try to 
proactively protect flow into both coronary ostia with the delivery of an “inverted t-shirt” 
ATAG graft with 2 covered coronary sleeves attached to the main graft body.  If during 
testing the device and or the procedure is too technically or physiologically challenging 
then we can always retreat to a position where only one or none of the ostia are 
proactively protected.  Professor Rothman is always keen to focus on the “device end 
game”, and if this is found to be over-zealous or not technically feasible during testing a 
more simple solution can be sought.  
As a coronary interventional doctor commonly occluding flow during LMCA and RCA 
coronary intervention I am comfortable that I have the time available to deploy stents into 
both LMCA and RCA – the question is while the body commonly tolerates temporary 
LMCA or RCA occlusion, will it be able to cope with relative no flow simultaneously and 
potentially for a more prolonged time with no ischaemic pre-conditioning?   
The Muriago paper on normal coronary ostia position emphasises proximity of the 
coronary ostia in essence at or within the aortic sinuses, as a result if we are to 
successfully deploy coronary branches, the ATAG main graft stent will have a very short 
proximal section with attachment of coronary stents to minimize interference with the 
aortic valve apparatus in the sinuses of Valsalva.  The front section will be relatively 
short, sitting within the sinuses, minimising aortic valve interaction and maximising the 
chance of maintaining valve competence (21). 
The graft will be delivered in one percutaneous intervention. 
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3.1.2 Intended use 
The intended use is for a percutaneously delivered stent graft to treat acute aortic 
syndromes of the ascending aorta – namely AAAD.  It will need to adequately cover the 
intimal tear in the ascending aorta at the same time proactively protecting coronary 
artery flow and preventing interference with aortic valve function.  If the aortic valve is 
already significantly incompetent, or becomes so during the ATAG implantation, 
subsequent delivery of a commercially available TAVI is possible.  We have also 
captured within our intellectual property and we will seek to simultaneously develop a 
“valved ATAG” where the proximal fixation point will be at the aortic annulus and that the 
ATAG will have a fully functioning percutaneous aortic valve within its proximal end. 
3.1.3 Indication 
The ATAG is intended to be used in patients with AAAD.  Patient anatomy (particularly 
aortic dilatation) is likely to necessitate a number of “off the shelf” sizes (diameters and 
lengths, and possibly coronary angulations).  In the acute setting bespoke stent graft 
design based on CT / MRI data will not be possible because of the acute nature of 
treating AAAD and the 1-2% mortality per hour after diagnosis associated with this 
pathology (58). 
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3.1.4 ATAG device attributes 
ATAG device attributes are summarised in Table 17 below: 
Table 17 ATAG device attributes 
A self-expanding Nitinol aortic stent graft with an “inverted t-shirt” configuration integrating 2 coronary sleeves, covered in 
a biocompatible material 
The covering of the graft shall have two side branches attached.  These coronary side branches with integral balloon 
expandable stents (covered side arm stents) shall protect the coronaries and shall ensure coronary perfusion. 
The coronary side branches are of different diameters (LMCA 4.5 mm, RCA 3.5 mm).  Colour coding for left and right is 
required to minimize confusion and avoid incorrect placement.  There will be a single radio-opaque marker on the left 
coronary balloon, and a double marker on the right coronary balloon.  
Fluoroscopic markers will be vital in anterior / posterior and left / right orientation process. 
The device will prevent blood flow into the false lumen through the intimal tear, and protect the aortic wall from the 
pressure of the blood and as such a good proximal and distal seal will be needed to prevent endoleak and the graft covering 
material must be biocompatible but also relatively impermeable to blood. 
The ATAG graft will be inserted over a central 0.038” superstiff guide wire (positioned in the left ventricular cavity), and the 
coronary sleeve stents will run over 2 x 0.014”coronary guide wires (perhaps specially designed and configured) already 
placed into the LMCA and RCA 
The graft shall be delivered via percutaneous vascular access most likely the femoral artery, if the delivery sheath is 18 F or 
less, but other routes may be viable including iliac or femoral conduit, and direct aortic implantation especially during the 
development phase when the delivery system may be larger than 18 F. 
It is our aim that the diameter of the stowed graft should be 18 F by the time we reach our FIM cases.  
The graft should minimize any compromise of the aortic valve or it would require re-valving (utilizing a commercially 
available TAVI device).  If AR is present at commencement of case it is possible a “valved ATAG” may be able to treat the 
intimal tear and the concomitant AR. 
The graft will need to be visible during fluoroscopy and ultrasound examination ICE / TOE 
The graft shall have flexible coronary region to allow some variation in patient’s coronary angle anatomy. 
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Table 17 ATAG device attributes cont. 
The coronary stents should be attached as close to the leading front end of the lobes as possible to minimize the amount of 
lobe sitting in the sinuses with potential to disrupt the aortic valve.  The coronary stents will be attached with an angle of 
approximately 150 degrees between them so as to match the standard coronary angulation.  The attachment mechanism 
must allow for some coronary angle variability. 
The first device will be 65 mm in total length so when in position it will comfortably end before the RBCT to avoid 
compromise of blood flow to this vessel.  
3.1.5 Method of operation 
The following describes the theoretical steps of implantation of the ATAG device in the 
treatment of AAAD with an intimal tear in the ascending aorta: 
 ATAG device will be stowed to 18 F (stowage is likely to be performed in a sterile 
ice bucket to aid nitinol contraction).  All of procedure under taken using aseptic 
sterile techniques, with patient under GA. 
 Insertion of right femoral arterial 18 F sheath, pre-closed with suture based 
closure device (Prostar TM Abbott Vascular, USA).  Insertion of right radial artery 
(RRA) 6 F sheath for pigtail catheter to allow injection.  Left femoral vein insertion 
of 6 F sheath with insertion of a temporary pacing wire (TPW) in to the right 
ventricle for rapid ventricular pacing to allow reduced cardiac output during 
deployment and therefore greater deployment accuracy and precision. 
 Systemic anticoagulation and anti-platelet loading. (Regimens to be elucidated) 
 2 x 260 cm 0.014” coronary guide wires, one positioned into each coronary artery 
using standard guide catheters (wire into distal LAD and RCA).  A 260 cm x 
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0.038” Amplatzer Superstiff type guidewire with a pre-formed curve inserted into 
the left ventricle (LV).  Guidewires may be modified to provide additional stiffness 
where the device will enter the coronary ostium, and an anchoring technique to 
keep the wire fixed within the vessel during the positioning of ATAG. 
 Sterilised stowed ATAG device in delivery catheter placed into sterile operating 
field.  Central guide wire fed into the central delivery catheter lumen, both 
coronary guide wires fed into coronary sleeves.  Care taken to correctly align the 
guide wires and avoid twists or wire-wrap.  
 The ATAG is likely to take up the “diving man” position with coronary arms facing 
forwards, as shown in Figure 67 below:  
Figure 67 ATAG taking up the “diving man” position 
. 
 
 
 
 
Stowed ATAG with central wire and 2 coronary guidewires running though the coronary sleeves, within OTW push rods, 
taking up the “diving man” position with coronary arms pushed forward like a man preparing to dive. 
211 
 
 ATAG device within delivery catheter passed through sheath into femoral artery, 
into aorta, around arch and pushed towards ascending aortic landing zone.  
Ensure wires are unwrapped and that the coronary projections are aligned to 
respective coronary ostia. 
 Decision to implant at correct landing zone. 
 Rapid RV pacing allowing relative low cardiac output state. 
 Distal part of sheath retracted to allow proximal (aortic valve end) of the device to 
flare to free the coronary arms to reach the coronary arteries. 
 Coronary sleeves pushed into both coronary arteries and stents within each 
dilated into coronary ostia allowing graft fixation.  The LMCA stent will be 
delivered and stented in position first, before implantation of the RCA arm.  
 Rest of ATAG body graft delivered.  
 RV pacing stopped. 
 ATAG delivery catheter withdrawn 
 Check shot using pigtail catheter from RRA to globally look at coronary flow and 
degree of AR (can be confirmed with TOE or ICE) 
 Selective coronary angiography to check sleeve stent patency using left and right 
coronary guide catheters.  Post-dilatation can occur if flow sub-optimal or stents 
under-deployed.  Intra-vascular ultrasound (IVUS) of the LMCA / RCA may be 
helpful to ensure stent deployment. 
212 
 
 Aortic valve integrity must be critically assessed by aortic pressure trace / 
fluoroscopy and TOE.  Assess need for implantation of a commercially available 
TAVI.  
 Remove all guide wires, and sheaths and manage the puncture sites in the 
routine manner. 
 If the aortic valve is affected or re-valved the TPW may be left in for 48 hours 
post procedure depending on the pre-procedure ECG and perceived risk of 
bradyarrythmia / heart block. 
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3.2 Proof of concept (PoC) device specification  
3.1 has already detailed a general ATAG device specification.  To prove the ATAG 
concept (that a graft with 2 coronary sleeves can be deployed), it was decided to 
design an “inverted t-shirt” ATAG that could be deployed within a normal sized 
glass aortic model. 
The PoC model has a number of functions: 
i) To prove that the concept is feasible and identify future technical challenges for 
development. 
ii) To prove to potential investors that this is a technological reality and to seek 
further development funding. 
iii) To reduce to practice to allow for intellectual property (IP) filing i.e. IP is not just 
an idea but can be realised in the real world. 
iv) To generate new ideas and solutions from problems encountered strengthening 
IP position.  
It is vital that if at this first hurdle design specification simplifications are accepted, they 
must be acknowledged and plans for the “real life complexities” considered later in the 
specification process. 
This design specification intended to prove the “inverted t-shirt” ATAG concept and 
percutaneous delivery from femoral artery within a “normal sized” human adult glass 
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aorta model (Farlow Scientific Glass, CA, USA), under first direct vision and then under 
fluoroscopy.  Figure 68 below shows a photograph of the glass aortic model: 
Figure 68 shows a photograph of the glass aorta 
 
 
 
 
 
 
 
 
 
Photograph of the glass normal sized aortic model (Farlow Scientific Glass, USA).  For the purposes of PoC demonstration 
I mounted it upon a piece of hardboard for stability. 
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Figure 69 below shows a diagram of the glass model with dimensions: 
Figure 69 Diagrammatic representation of aorta glass model dimensions (mm) 
 
 
 
 
 
 
 
 
Despite the glass model being purchased as have “normal aortic anatomy”, actually it has a constant ascending and arch 
aortic size of 25mm, and a descending aortic diameter of 24mm.  The coronary arteries in this model come off at 180 
degrees to one another.  Simplifications in the design specification had to reflect this simplified aortic model anatomy.  
The PoC device design specification is split into 2 main parts: 
i) The ATAG endograft (inverted t-shirt graft with body for aorta and 2 coronary 
sleeves) 
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ii) The ATAG delivery system for delivery to the proximal aortic landing zone, around 
the arch of a glass aortic model from “a femoral access sheath”. 
3.2.1 ATAG graft body 
It can be clearly seen in Figure 69 that the “normal” glass vascular tree has simplified 
dimensions when compared to the normal human aorta.  With an ascending aortic 
diameter of 25mm, taking into account the current TEVAR graft over-sizing by 
approximately 20%, the PoC ATAG graft would have an expanded diameter of 30mm to 
provide continuous external radial force to maintain the graft in position once deployed 
(in keeping with current clinical practice).  
The ATAG graft itself is further subdivided into 3 sub-components:  
i) Self expanding nitinol body frame 
ii) LMCA and RCA stent projections (inverted t-shirt configuration) 
iii) ATAG graft covering material 
Table 18 below outlines the ATAG PoC graft design specification: 
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Table 18 ATAG  PoC graft specification 
ATAG diameter stowed in sleeve 6 mm (18 F) 
Diameter of main body when deployed  30 mm 
Diameter of proximal aortic lip 30 mm 
Diameter of RCA sleeve / stent 3.5 mm 
Diameter of LMCA sleeve / stent 4 mm 
Length of coronary sleeves 8 mm 
Angle between coronary branches 180 degrees 
Vertical Offset between coronary sleeves 0 mm 
Length of ATAG main body  55 mm 
 
To reflect the glass aortic model into which PoC ATAG is to be implanted, the device 
specification has a number of anatomical simplifications, when compared to the potential 
AAAD treatment population.  The glass model has a relatively constant diameter 
throughout aortic root and ascending aorta of 25 mm.  It also has a simplified aortic root 
with LMCA and RCA coming off at an angle of 180 degrees to one another, which we 
know is not found in the AAAD cohort (Section 2.1.3). 
The LMCA had a stented diameter of 4mm (rather than the literature which supports 
4.5mm) as this is the diameter of expired stents available.  For ease of manufacture I 
placed the LMCA and the RCA  sleeves at the same level with no “offset” (11).  The graft 
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will be a straight tube and not have any inherent aortic curve, and finally in a theoretical 
attempt to minimise aortic valve interference the coronary sleeves will be attached as 
close to the proximal end of the ATAG body as is technically feasible. 
3.2.2 Coronary Stents / sleeves 
The stented portions within this PoC model comprised a 4 mm x 8 mm bare metal stent 
into the LMCA and a 3.5 mm x 8 mm bare metal stent into the RCA.  For simplicity I 
elected to manually sew the covering material to the stents and then attach them with 
fine 6.0 sutures to the graft body.  I acknowledge that having a suture line at the ostium 
of both the LMCA and RCA is far from ideal and that this is unlikely to feature in the final 
product, given the potential risk of thrombus formation and the mechanical forces at this 
critical point.  
3.2.3 ATAG graft covering material 
Currently available thoracic stent grafts are either covered with a woven polyester (PET 
Dacron), or ePTFE.  We could have utilised Dacron as it is readily available, cheap and 
easy to use, but at the time of device build I was working with Andrew Pacey a medical 
engineer working for Advotek Medical Devices, Herts, UK.  Advotek had developed a 
silicone-coated polyester for another application.  It appeared to have greater elasticity, 
and be less stiff when compared to Dacron and I felt that this might offer some flexibility 
advantage compared to Dacron with regard to coronary angle variability in this first 
model. 
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3.2.4 ATAG delivery system 
3.2.4.1 Product description 
The following describes the proposed delivery system for the ATAG PoC graft.  
3.2.4.2 Delivery Catheter 
The delivery catheter has 3 main components: 
1) Central Shaft - The shaft that the graft is stowed around.  It tracks over the 0.038” 
stiff guide wire (which has been placed into the LV cavity). 
2) Push Rods - Incorporates balloon shafts and stents.  Used to deploy each of the 
coronary sleeves with stents.  Left and right push rods (graduated hypo-tube) 
identified with marker bands and 2 different coloured hubs.  Each of the push 
rods to be fitted within a 0.075 mm PTFE liner to ease guide wire movement 
through lumen.  The balloons are Over the Wire (OTW) construction, with 
variable shaft stiffness to aid tracking.  Hydrophilic coated inner diameter to 
aid the deployment.  These might have a monorail configuration eventually, if 
adequate “pushability” of the coronary sleeves can be achieved. 
3) Outer retractable sleeve.  A PTFE outer sleeve over the complete length of the 
device was used to act as the pod into which to stow the graft.  Deployment of 
the graft would be realised by relative retraction of the outer sheath and 
pushing of the inner central shaft / graft allowing graduated expansion of the 
ATAG graft. 
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Figure 70 below shows a schematic diagram of the proposed ATAG with delivery 
system prior to crimping: 
Figure 70 Schematic diagram of the ATAG graft with delivery system prior to crimping  
 
 
 
 
 
Figure above shows ATAG graft body prior to crimping, with 2 coronary sleeves.  Within the coronary sleeves are 2 OTW 
push rod balloons, for deployment of the coronary “arms”.  The delivery catheter tracks over 3 wires, 1x 0.38” central wire 
within the LV cavity and a 0.014” coronary wire in each coronary artery. 
 
3.3 ATAG Proof of concept  device build 
Now that both the device specification and the design had been specified for the 
PoC ATAG, it was time to build the PoC device.  The endograft was made with 
support from 2 medical engineers at Advotek Medical Devices, while I designed 
and built the delivery system. 
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3.3.1 ATAG “t-shirt” graft with coronary sleeves 
As already discussed, currently available thoracic aortic stent grafts consist of a nitinol 
self expandable frame and either Dacron or ePTFE graft material.  For the purposes of 
PoC we could have quite easily and legitimately “adapted” a commercially available stent 
graft, changing it to the desired size and length, and then adding the coronary sleeves.  
Instead however with Leena Jaatinen, a PhD student with Advotek medical devices it 
was decided to build our ATAG PoC graft with some bespoke made parts and the rest 
from “off the shelf” expired materials in a “make and do manner”. 
3.3.1.1 Nitinol frame 
All current commercially available aortic stent grafts utilise nitinol in a “zig-zag” formation. 
To achieve this pattern, firstly nitinol wire (Euroflex SE508; http://www.nitinoleurope.com) 
of an appropriate thickness must be formed into a zig-zag shape using a brass former.  
Figure 71 below shows nitinol wire being bent around the brass former.  The nitinol and 
former is then heated to 500oC in an oven for 15 minutes before being rapidly cooled in 
water. 
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Figure 71 Nitinol wire on brass former 
 
  
 
Nitinol wire of an appropriate thickness is bent around the brass former in a zig-zag pattern. 
The first 2 devices built as shown in Figure 72 had inadequate radial strength, firstly 
because the nitinol wire used was too thin (0.15 mm), and then with appropriate wire 
thickness (0.4 mm), the zig-zag pattern was too sinusoidal and rounded at the apex (12 
cycle pattern), with reduced resultant radial strength. 
Figure 72 The first 2 PoC ATAG builds 
 
 
 
a)            b) 
 
a) First ATAG graft lacked radial strength as you can see the nitinol frame cannot even hold open the graft material  b) was 
better but still inadequate. 
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The third graft that was made had the correct dimensions and adequate radial strength 
for the purposes of PoC demonstration.  No formal radial strength testing was performed 
at this early PoC stage.  The PoC ATAG consisted of 5 zig-zag nitinol bands, 4 of which 
were made from 0.4 mm diameter wire, and 1 frame was made of 0.23 mm wire - this 
was the centre band.  Figure 73 below shows the bend radius of the zig-zag brass 
former: 
Figure 73 Bend radius of the zig-zag pattern of nitinol brass former 
 
 
 
 
Figure shows the bend radius of the zig-zag pattern of nitinol on the brass former. 
3.3.1.2 Graft material 
Advotek had recently produced a polyester fabric material impregnated with silicone 
rubber.  For the purposes of the PoC ATAG only this material was ideal.  It was cheap, 
readily available, could be sewn easily to nitinol frame, and as compared to Dacron had 
some elasticity in its form allowing potentially some flexibility for the coronary arms. 
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It is unlikely that this material would be used in later generations as it does not have a 
vascular regulatory dossier (for CE Mark and FDA approval process), and currently lacks 
the thickness profile required for low profile crimping and stowing. 
The fabric is formed into a tube by wrapping and sewing the seam to form a tube using 
cotton thread.  The wire bands were then sewn into the outside of the graft material to 
create a 30 mm diameter tube. 
3.3.1.3 Coronary sleeves 
The coronary sleeves consist of tubes made of the graft fabric, formed into a tube and 
sewn at the seam.  A 4 mm hole was made at the LMCA and a 3.5 mm hole at the RCA 
ostium of the main body graft, inside the bend of the bottom frame.  The sleeves were 
sewn around each hole.  A 4 mm x 8 mm expired stent, and a 3.5 mm x 8 mm expired 
stent were then sewn around the sleeve to make the “inverted t-shirt”.  More complex 
discussion about potential coronary sleeve designs is covered in 4.5.2. 
3.3.1.4 Design output specification 
The first PoC ATAG endograft had the following properties in Table 19 below:  
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Table 19 ATAG PoC design output specification 
ATAG graft diameter 30 mm 
ATAG graft length 55 mm 
LMCA sleeve 4 * 8 mm stent 
RCA sleeve 3.5 * 8 mm stent 
Angle between stents 180 degrees 
Distance coronary sleeve from proximal frame 3 mm 
Figure 74 below is a diagrammatic representation of the PoC ATAG device, and Figure 
75 shows the first PoC device build: 
Figure 74 Diagrammatic representation of the PoC ATAG device 
 
 
 
 
 
The PoC ATAG consists of a stent body which is covered in graft material.  Attached to this body are the 2 coronary 
stented sleeves at and angle of 180 degrees to one another.  They are attached low down on the main body graft. 
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Figure 75 First PoC with “adequate” radial strength and coronary side-arms attached 
 
 
 
 
 
 
Photographs of the PoC ATAG with adequate radial strength utilising 5 zig-zag bands of formed nitinol, hand sewn to 
polyester silicone graft material.  Low down on the ATAG graft, 2 coronary sleeves with integrated coronary stents are 
attached to protect coronary artery flow. 
3.3.1 Conclusion 
The manufactured PoC ATAG endograft fulfilled our design specification for the purposes 
of proof of concept.  There are a number of deficiencies and simplifications that we 
accept in this first model including: 
i) Simplified graft dimensions for the purpose of demonstration in the glass model. 
ii) Untested radial strength just to allow demonstration that the technique is feasible. 
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iii) The use of an untested material covering that has no regulatory dossier and that 
is too thick for further testing. 
iv) The attachment of coronary stents using material and fine sutures, at a point 
where there is huge mechanical stress and blood flow turbulence, which in 
vivo is likely to lead to mechanical failure and high risk of thrombus formation. 
v) The coronary branches attached at an angle of 180 degrees to one another to 
match the glass model, rather than attached at 155 degrees which we know 
from anatomical review to be the normal coronary angulation. 
All these simplifications are accepted in this first iteration, but must be factored in for 
later device prototypes.  
3.3.2 Simple delivery system and stowage 
From the very outset I did not underestimate the complexity of accurate and precise 
delivery of the ATAG to the landing zone just above the aortic valve, avoiding aortic valve 
incompetence, while proactively securing both LMCA and RCA flow with the sleeves and 
stents of the ATAG “inverted t-shirt”.  
Before being able to design and specify a delivery system capable of deploying ATAG in 
the correct landing zone I felt that I had to make a simplified aortic model and break the 
delivery system down into the necessary constituent parts.  Within the Appendix are the 
details of the preliminary fact finding delivery system testing, enabling me to define the 
length of system components, procedure sequence and potential complications. 
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This enabled me to develop the following PoC delivery system, as shown in Figures 76 – 
81, breaking the system down into its constituent parts (described as a) – c): 
Figure 76 Photograph of delivery catheter parts 
      
     a)    
b)    c) 
          
        b) 
 
Delivery catheter constituent parts a) Retractable silicone sleeve, b) 2 x OTW balloon push rods and c) central core 
delivery catheter, with housing for the central 0.038” guidewire, and 2 sleeves to accommodate the 2 X OTW balloons 
. 
a) Graduated retraction of the silicone tube sleeve (Figure 77 below) would allow the 
proximal end of the graft to gradually expand releasing the graft in a controlled 
manner.  In this first iteration it would rely upon controlled manual pull-back of the 
sleeve.  In later iterations this sleeve retraction could be made more controlled 
with a graduated pull-back wind mechanism on the handle. 
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Figure 77 silicone tube sleeve 
 
 
 
An outer retractable silicone tube sleeve (OD 6mm, ID 5mm), manual pull back would allow gradual release of the ATAG 
b) Two push rods with integrated OTW balloons.  For the purposes of this PoC I 
utilised 2 x expired NinjaTM OTW balloons (3 mm x 15 mm, Cordis Bridgewater , 
NJ, USA).  The balloon shaft is made of a graduated hypo-tube as drawn in 
Figure 78 below: 
Figure 78 Laser cut profile of the hypo-tube and Ninja OTW balloon 
 
 
 
 
 
 
Graduated laser cut hypo tube forms the central core of the push rod, with a balloon section and marker bands added. 
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Figure 79 below shows the central core delivery catheter: 
Figure 79 The central core delivery catheter 
 
 
 
 
 
 
 
 
The central core of the delivery catheter is triple lumen in design.  A central lumen for the 0.038” LV wire, with left and right 
channels for the coronary “push rod / OTW balloon sleeves”.  These sleeves were made from braided polyamide, allowing 
smooth movement and transmission of push from the OTW balloons within. 
The 2 x OTW balloon push rods are inserted into their support sleeves as shown above.  
At the time of ATAG stowing, orientation of the ATAG stent graft to the correct coronary 
sleeve push rod / OTW balloon is vital.  
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During testing it became clear that the outer retractable sleeve would kink upon 
traversing the arch of the aorta (>180 degree bend).  This made controlled retraction of 
the sleeve and subsequent delivery of the ATAG impossible as the sleeve would kink 
and catch on the nitinol frame of the graft. 
I designed around this by inserting a layer of braided material, which upon traversing the 
arch would not kink and would allow smooth passage of the outer sleeve enabling 
controlled retraction and device deployment.  Figure 80 below shows the integration of 
braided kink resistant material into delivery system: 
Figure 80 shows the addition of the grey braided kink resistant material 
 
  
 
 
 
Integration into delivery system of grey braided material (arrowed), which prevents friction and kinking of the retractable 
silicone tube during passage around the aortic arch. 
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Figure 81 below shows the completed delivery system with the addition of the retractable 
silicone sleeve: 
Figure 81 shows the addition of the clear silicon 6mm retractable sleeve 
 
 
 
 
 
Outer silicone sleeve (clear tube) can be easily retracted over the central delivery catheter.  A Central 0.38” core lumen 
can be seen (blue), as well as the 2 * OTW balloons within the gold polyamide sleeves. 
3.3.2.1 ATAG endograft loading instructions 
Loading instructions of the PoC ATAG device are demonstrated in Figures 82 a) – d) 
below: 
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Figure 82 a) ATAG loading 1 
 
 
 
 
 
The graft is placed over the central shaft and the OTW balloon push rods are loaded through the coronary sleeves.  It must 
be ensured that the push rods and graft are in the correct orientation (L and R). 
Figure 82 b) ATAG loading 2 
 
 
 
 
 
The push rods are positioned so that the balloon collar is around 1mm distal to the sleeve.  ATAG coronary sleeve stents 
are crimped onto the deflated OTW balloon pushrods by hand. 
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Carefully load the graft by folding the frame inwards from the distal stent, compressing 
the wave form.  With care load each band taking care not to catch the frame on the 
sleeve or displacing the crimped stents on the side arms or the balloons.  Figure 82 c) 
below shows the ATAG graft frame being folded inwards into the silicone deployment 
sleeve: 
Figure 82 c) ATAG loading 3 
 
 
 
 
 
 
 
Load the final section of the graft in to the sleeve taking care not to stress the crimped stents on the side arms. 
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Figure 82 d) below shows the fully loaded ATAG graft taking up the “diving man” position 
with coronary sleeves facing forwards: 
Figure 82 d) ATAG loading 4 
 
 
 
 
 
 
Continue until fully loaded – the coronary sleeves take up the “diving man” position with arms pushed forwards.  Coronary 
0.014” guide wires (already fixed in RCA and LMCA) can now be fed through the coronary OTW balloons / push rods.  The 
0.038” superstiff guidewire can then be fed through the central lumen (0.38” wire already fixed in LV cavity).  The device is 
now ready for insertion. 
3.3.2.2 Steps of ATAG deployment  
Figures 83 a) – d) detail the steps of ATAG deployment from within the stowed delivery 
sheath, once the device has been advanced to the implantation zone within the aortic 
root: 
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Figure 83 a) ATAG deployment 
 
 
 
 
 
Retraction backwards of silicone delivery sheath 10 mm to allow the coronary sleeves to move towards the LMCA & RCA 
Figure 83 b) ATAG deployment 
 
 
 
 
 
Further retraction of the outer sleeve, the coronary push rods and balloons are pushed forwards engaging the stents within 
the LMCA and RCA.  The LMCA balloon is then inflated to fix the LMCA stent sleeve in position, before being repeated on 
the RCA.  
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Figure 83 c) ATAG deployment 
 
 
 
 
 
With the LMCA and RCA coronary sleeves and stents deployed, further retraction of the outer sleeve releases the ATAG 
Figure 83 d) ATAG deployment 
 
 
 
 
 
 
Deployment of ATAG and removal of the delivery sheath 
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3.3.2.3 Proof of concept ATAG device build conclusions 
The manufactured PoC ATAG graft fulfilled our design output specification, accepting 
that it has some deficiencies and simplifications, that will need to be optimised later in the 
device development process. 
Likewise the delivery system is simple, but would appear to have all of the necessary 
components to enable successful proof of concept within a bench test glass aorta. 
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3.4  PoC ATAG in vitro testing (glass model) 
Having detailed both device and design specification, and built a prototype device 
satisfying the output specification for the PoC ATAG endograft and delivery 
system, it was now time to test whether I could truly prove the concept by 
implanting percutaneously a branched aortic endograft with 2 coronary sleeves 
into a normal sized glass model aortic root from femoral access over the wire 
using a percutaneous delivery system firstly under direct vision and then under 
fluoroscopic guidance. 
3.4.1 Aim 
To prove the concept of whether delivery of the PoC ATAG “inverted t-shirt” graft (main 
aortic body with 2 coronary sleeves as described in 3.2) with delivery system is feasible 
in a glass aorta model under both direct vision and fluoroscopy.  
3.4.2 Methods 
The test rig comprised a “normal” sized adult male glass aortic model (Farlow Scientific, 
California, USA) from the LVOT to the femoral arteries.  The model was then fixed to 
hardboard.  The delivery was performed in air without fluid flow which would 
overcomplicate this first PoC.  Deployment would first be performed under direct vision, 
and once practiced, repeated under fluoroscopy in a similar manner. 
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3.4.3 Results 
3.4.3.1 Results in glass model under direct vision 
Standard 130 cm x 0.014” coronary guide wires were delivered via at Judkins left 4 (JL4) 
catheter to the LMCA, and via a Judkins right 4 (JR4) catheter to the RCA from access 
within the right femoral artery.  These guide wires were then “clamped” at the coronary 
arteries so that they would not retract on insertion of the ATAG device.  A 130 cm x 
0.038” Amplatzer Superstiff wire was then placed through the aortic valve and into the 
“left ventricle” where it was secured.  Figure 84 a) – g) show the stages of ATAG 
deployment in the glass model.   
Figure 84 a) ATAG PoC deployment 1 
      LMCA 
          LV wire 
 
 
         RCA                      
The left coronary wire at 12 o’clock in the picture hugs the “outer” curve of the aorta in the arch segment, while the RCA 
guide wire at 5 o’clock hugs the inner curve leading to a crossing point in the centre of the aorta about 2cm above the 
coronary arteries (arrowed).  This must be “uncrossed” if the ATAG is to be delivered without complication.  In addition the 
position of the LV wire has important implications for technique used to “unwrap” the LCA and the RCA wire. 
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Figure 84 b) ATAG PoC deployment 2  
 
  
 
 
 
With the wires in position (LMCA, RCA, and LV) all 3 wires are then fed into the stowed ATAG device outside of the patient 
/ glass model. 
It is vital at this point that the marked guide wires are inserted into the correct side and 
that there is no visible wrapping of the wires.  Once the device is loaded upon all three 
guide wires with both distal wire fixation (clamped) to avoid retraction and proximal wire 
fixation by operator assistant the ATAG within delivery catheter is advanced up the 
descending aorta, and around the aortic arch.  See Figure 84 c) below: 
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Figure 84 c) ATAG PoC deployment 3 
 
 
 
 
 
 
 
ATAG device on guide wires advanced around arch and towards landing zone (arrows denote proximal end of ATAG 
device) 
ATAG is then pushed into the ascending aorta just above the “landing zone”.  At this 
point because of wire wrap visually it was obvious that the device would advance no 
further and as such the central LV wire was withdrawn from the LV and back into the 
central lumen of the delivery catheter.  The delivery catheter was then rotated 180 
degrees clockwise to un-wrap the 2 coronary wires before the LV wire was then replaced 
back into the LV and fixed.  
Once the wires are “uncrossed” it is possible to re-advance the ATAG so that the 
proximal end is within the aortic sinuses, and the coronary sleeves are pointing towards 
the appropriate coronary ostia, as shown in Figure 84 d) below: 
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Figure 84 d) ATAG PoC deployment 4 
 
 
 
 
 
Following the “unwrapping wire manoeuvre”, the ATAG device is advanced forward so that the proximal flared end is within 
the aortic sinuses and the coronary sleeves are aligned towards the coronary ostia.  
Figure 84 e) ATAG PoC deployment 5 
 
 
 
 
 
 
The sheath of the delivery system is then partially retracted and the proximal nitinol flared graft self-expands.  
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It is important to retain position of the graft while the delivery catheter is retracted as 
there is a tendency otherwise for the graft to move upwards towards the RBCT.  The 
coronary stent sleeves are then advanced by pushing the pushrods into the coronary 
arteries, to anchor position, and protect coronary artery blood flow.  The LMCA is stented 
first followed by the RCA as shown in Figure 84 f) below:  
Figure 84 f) ATAG PoC deployment 6 
 
  
 
          LMCA             RCA 
 
 
 
 
The LMCA sleeve is inserted first, once in position the balloon is inflated to high pressure (18atm) to deploy the integrated 
coronary sleeve stent. This is repeated for the RCA. 
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Figure 84 g) ATAG PoC deployment 7 
 
 
 
 
 
 
 
Once the ATAG has been secured proximally with LMCA and RCA coronary sleeves, the delivery system is fully retracted 
allowing full expansion of the entire ATAG graft.  The ATAG delivery sheath is then withdrawn over the guide wires and 
removed from the glass circulation.  Finally the 2 coronary guide wires and the LV guide wires are removed to leave the 
device in situ.  The graft position did not change with removal of the delivery system and the 3 guide wires. 
3.4.3.2 ATAG delivery in glass model under fluoroscopic guidance 
After numerous “trial runs” to perfect the procedure technique under direct vision it was 
decided to reproduce the ATAG in vitro glass model delivery without flow, but under 
fluoroscopic guidance.  The methods and techniques utilised were identical to that of the 
deployment under direct vision, but the glass model was covered so that the operator 
(TK) had to rely upon fluoroscopic imaging in the AP position to guide deployment.  
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First the 2 coronary guidewires and the LV guidewire were inserted into position and 
fixed as in the direct vision experiment as shown in Figure 85 a) below: 
Figure 85 a) ATAG PoC fluoroscopic deployment 1 
 
 
 
 
 
 
 
Insertion of RCA and LMCA coronary guidewires (0.014”), and LV superstiff guidewire (0.38”).  When the wires are fixed in 
position the device is loaded on the 3 guidewires and inserted into the model and pushed up into the descending aorta 
(arrow shows position of ATAG tracking on the 3 guidewires within the descending aorta). 
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Figure 85 b) ATAG PoC fluoroscopic deployment 2 
 
 
 
 
 
ATAG passed up and over arch under fluoroscopy.  It can be seen here that the RCA balloon has moved forward from the 
crimped stent (arrow), this was rectified by pulling the balloon catheter back approximately 10mm until it was back within 
the stented portion of the RCA ATAG sleeve. 
Figure 85 c) ATAG PoC fluoroscopic deployment 3 
 
 
 
 
 
With the wire wrap removed (LV wire withdrawn into delivery catheter, followed by 180 degree clockwise delivery catheter 
rotation, and replacement of the LV wire) the delivery sheath was retracted allowing self expansion of the nitinol graft.   
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Figure 85 d) ATAG PoC fluoroscopic deployment 4 
 
 
 
 
    a)                                                       b)              
a) The LMCA sleeve balloon was then pushed into the LMCA and inflated, followed by  b) similar procedure with the 
RCA.  The silicone sleeve was then fully retracted allowing full deployment of the main ATAG body within the 
ascending aorta. 
Figure 85 e) ATAG PoC fluoroscopic deployment 5 
 
 
 
 
A still image of the final implantation position, with both coronary sleeves implanted into the appropriate coronary ostium, 
and the ATAG graft in its fully expanded form.  The delivery catheter has been retracted into the descending aorta, and the 
guide wires are still in situ. 
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For the purposes of this PoC all radiographic acquisitions were performed in the AP 
position, but it is anticipated that in vivo and future implantations multiple imaging 
angulations will be required to ensure optimal positioning.  
3.4.4 Proof of concept Conclusions 
I have shown that a self expanding nitinol graft can be manufactured, with a silicone / 
polyester graft covering and 2 covered coronary sleeves in an “inverted t-shirt” formation.  
This graft can then be crimped into a 6 mm (18 F) delivery catheter, with a central core 
guide wire (0.038”) and 2 x OTW balloon push rods.  When stowed the device and 
delivery system can be advanced over 3 fixed guide wires into a glass model vascular 
system via the femoral artery.  
The device and delivery system can be advanced up the aorta and around the aortic 
arch, to a position 2 cm above the coronary arteries.  This is the point at which the LMCA 
and the RCA guide wires “cross”.  Uncrossing requires retraction of the central LV guide 
wire and then a 180 degree clockwise rotation of the delivery catheter and graft.  The 
coronary sleeves of the ATAG then point towards their respective coronary ostium.  The 
central LV guide wire can then be replaced into the LV before advancing the device to 
the implantation site.  
ATAG implantation is achieved by retracting the outer deployment sleeve allowing 
expansion of the proximal end of the ATAG graft and the push rods can then be pushed 
into both LMCA and RCA, followed by further retraction of the sleeve.  Once achieved 
both the coronary push rods are advanced into the coronary ostia and then the balloons 
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inflated to secure the t-shirt sleeves into the coronary arteries.  This process was first 
practiced under direct vision and then successfully performed under fluoroscopic 
guidance. 
3.4.5 Discussion of PoC ATAG delivery in a glass aorta 
The PoC ATAG device has successfully proved that the concept of an “inverted t-shirt” 
graft with a triple lumen delivery system and coronary push rod sleeves is feasible under 
both direct vision and fluoroscopy in an air filled normal anatomy glass aorta from the 
femoral artery with fixed coronary and LV guide wires.  There are however a number of 
important limitations of this testing that must be discussed moving forward to both 
dynamic flow in vitro testing and subsequently in vivo testing: 
3.4.5.1 Limitations 
i) All 3 guide wires were actively fixed in their positions in the LV and 2 coronary 
arteries.  This will not be possible to replicate in vivo.  The exact forces placed 
on the guide wires by the delivery system and device must be thoroughly 
investigated on the benchtop so that guide wires can be designed with 
specific “holding” features, whether this is a “noodle” wire in the coronary 
artery, or a “screw in wire” into the LV cavity.  I believe that a specific guide 
wire for the purpose will need to be designed and tested and supplied with the 
ATAG device.  It may well also provide new intellectual property. 
ii) The glass aorta was filled with air and not fluid.  The graft and delivery system 
moved very smoothly around the air filled aorta and was lubricated with 
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silicone oil.  In the real in vivo situation there will be pulsatile blood flow at 
around 120 mmHg moving against the device, in a likely atheromatous, 
tortuous and heavily diseased and irregular aorta.  This will provide significant 
obstruction to the advancing of the delivery system.  At the point of 
implantation I have already eluded to the fact that cardiac output will be 
temporarily reduced by rapid RV pacing or other means so as to allow the 
most accurate and precise delivery possible. 
iii) The wire crossing is a real technical issue, and while under direct vision it is 
extremely straight forward to “uncross”, it is very difficult under fluoroscopy. 
One must also bear in mind that the fluoroscopic image was of superb quality 
as there was no soft tissue to absorb or scatter the x-rays.  I do not 
underestimate the challenge of uncrossing the wires and allowing straight 
passage of the ATAG device into the landing zone.  Work will have to focus 
on design of the marker aspects of the next generation ATAG and delivery 
systems to enable exact orientation in 3 dimensions in multiple fluoroscopic 
views, as once committed to sleeve retraction and coronary implantation one 
must be sure that all parts of the device are correctly aligned. 
iv) The delivery system must allow 1:1 reliable rotational movement of the device i.e. 
180 degrees clockwise rotation of the delivery system handle brings about an 
identical movement of the delivery system tip and ATAG graft, allowing exact 
and precise changes to orientation.  I think also rather like a “trans-septal 
needle” has an arrow pointing to the relative direction of the puncture needle 
the ATAG delivery system will also have an arrow informing us of the 
orientation of the delivery system and device.  
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v)    In an air filled model there was no pressure on the time taken to deploy the 
graft.  In the first in vivo cases time will be absolutely critical, as coronary 
ischaemia time, and rapid RV pacing time must be minimised otherwise 
cardiac arrest may well ensue and without prompt return of coronary 
circulation / cardiac output resuscitation may be impossible. 
vi) This particular glass model did not have an aortic valve, so it was impossible to 
determine whether any of the ATAG deployments would have impinged and 
interrupted the aortic valve integrity, which might lead to severe AR requiring 
TAVI implantation.  The next in vitro trials will be performed in a silicone 
model with intact aortic valve leaflets, so that these questions can be better 
addressed.  As has already been discussed a valved ATAG has also been 
intellectually protected. 
vii) Although macroscopically the ATAG graft looked as though it had been deployed 
in the “correct” position with the coronary sleeves in the coronary arteries I 
have no idea as to the potential degree of reduction in coronary blood flow 
due to the stents / material.  The PoC does not provide any indication as to 
the likelihood of endoleaks acutely which will have considerable bearing on 
the acute success of the implantation.  This work will all need to be covered in 
further in vitro and in vivo testing protocols.  
3.5 ATAG deployment videos 
Videos of both ATAG implantations in the glass model under direct vision, and under 
fluoroscopy are found in the accompanying CD attached to this thesis. 
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3.6 Project management, funding, academic collaborations and 
industrial partners – an update  
The ATAG project was commenced in September 2007.  At that time Professor Rothman 
(MTR) and I (TK) formed the clinical team.  We were supported financially by £50k proof 
of concept funding by NHS Innovations London (NHSIL) for the first 12 months.  NHSIL 
also helped us with Intellectual Property management (Dr Andrew McCulloch, AM) and 
general project management (Dr Torsten Struntz TS). 
Following successful proof of concept testing (TK / MTR), NHSIL awarded us a further 
£75k for further development work of the ATAG 2nd generation (2G) device with the aim 
of early in vitro work.  During this period I wrote as co-applicant with Professor Rothman, 
and was successful in winning an NIHR invention for innovation (I4I) grant for £743,000 
over 3 years to allow our development plan to be taken through further in vitro 
assessment, delivery system refinement, and finally in vivo animal trials.  (Further 
development plan attached as NIHR application form, within Appendix). 
There are 2 major academic collaborators: 
i) Professor Stephen Greenwald – QMUL professor of cardiovascular mechanics 
and an expert in flow rig set up, physiology and testing. 
ii) Professor Dan Brockman – Royal Veterinary College (RVC), Professor of small 
animal surgery, with a special interest in cardiac surgery.  I also collaborated 
with Dr David Connelly a small animal cardiologist with an interest in TOE, 
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and Mr Michael Boyd who has undertaken many in vivo trials at RVC Camden 
campus. 
Torsten Struntz (project manager NHSIL) was appointed ATAG project manager and 
searched for industrial partners with the expertise in stent design, laser cutting, graft 
covering materials and development of delivery systems.  After consulting and having a 
number of quotes from the UK, US, and other European companies we felt that 
Qualimed (www.Qualimed.de) a German company based near Hamburg offered us the 
best “one stop product development shop”.  All further ATAG device development work is 
directed and driven by TK / MTR in collaboration with Thomas Nissl and the engineers at 
Qualimed, funded by NHSIL and the I4I grant. 
It was always my intention that I would design and produce the 2G ATAG graft, but that 
all subsequent project work including 3G ATAG, delivery system iterations and in vitro 
and in vivo work would be performed by my successor. 
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Chapter 4 : 2G ATAG specification, build & testing 
4.0  2nd Generation (2G) ATAG design specification  
Chapter 4 will now build on the experience of the PoC testing and design and 
specify a second generation (2G) ATAG device.  I will then describe the 2G ATAG 
device build and mechanical testing all performed at Qualimed’s facility in 
Hamburg, Germany. 
With the lessons learned from the proof of concept model, financial backing from 
NHSIL and NIHR, and a commercial engineering collaboration with Qualimed I re-
specified the ATAG design brief for the 2G device.  Qualimed were contracted to 
perform the medical engineering work, producing devices to my design 
specification.  I will now describe in detail the deficiencies of the PoC ATAG and 
potential design iterations for the 2G device.  
4.1 Deficiencies of the PoC ATAG and potential 2G iterative 
improvements 
1) The PoC nitinol self expanding frame while adequate in function for the purpose 
of proving the concept would be unlikely to possess the radial strength necessary 
to provide adequate proximal and distal seal, and as such I was keen to design a 
more bespoke nitinol frame that could have radial testing formally performed and 
ensure that it was comparable to competitor aortic devices.  The PoC graft had no 
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longitudinal stent attachments and as such the graft could shorten or concertina 
under the compressive forces of delivery. 
The PoC graft very labour intensive to manufacture and if this could be 
mechanised it would make large scale manufacture later in the development 
cycle more straight forward. 
Design iteration for 2G device 
2G ATAG would be laser cut from nitinol tubing with a purpose built stent frame 
design theoretically capable of treating aortic dimensions from 25 mm to 65 mm.  It 
will be designed to have similar radial strength to its competitors (descending 
thoracic grafts and CoreValve frame), and will be formally tested against 
commercially available grafts.  The stent design will incorporate longitudinal struts 
to minimise graft shortening. 
2) The PoC endograft covering material was too thick for use in the next generation 
graft and with no vascular regulatory dossier use of this material would be 
extremely high risk from a regulatory perspective.  While both Dacron and ePTFE 
are utilised in competing grafts in the descending aorta, because of the coronary 
branch angulation variation, and small coronary vessel size I felt that we should 
consider a novel covering material that may confer some material advantage.  
Design iteration for 2G device 
The material investigated for use in this 2G device is electro-spun polyurethane 
(PU) made by a company in Israel (Nicast, Lod, Israel).  They are world leaders in 
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electro-spinning technology and have a commercially available and CE marked PU 
product in the vascular domain called AVFlowTM.  I collaborated with both 
Qualimed who would design and manufacture the nitinol frame, and Nicast who 
would coat the endograft with electro-spun PU.  I hoped that it might have 
beneficial effects upon graft stowing, flexibility of coronary angulation, and long 
term coronary sleeve patency - a concern with small vessel Dacron and ePTFE 
grafts. 
3) The design of the proximal (aortic end) of the PoC endograft is sub-optimal.  To 
allow proximal seal the endograft may benefit from a proximal tri-lobed “flare” 
engaging the proximal portion into the sinuses of Valsalva, attempting to mirror 
the native anatomy.  
Design iteration for 2G device 
The proximal portion of the ATAG will have 3 sinus “feelers” extending into the 3 
sinuses of the aortic root, mirroring the anatomy in an attempt to minimise aortic 
valve incompetence and also attempting to improve proximal sealing to decrease 
the risk of type I endoleak.  
4) The coronary artery branches need to be attached as low down as possible on 
the endograft so as to minimise aortic valve disruption. The attachment of the 
coronary sleeves on the PoC model was also inadequate being hand sewn with a 
join at the ostium of the coronary artery. 
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Design iteration for 2G device 
In an ideal world the coronary sleeves and integrated stents will be “attached” to 
the main aortic endograft by being electro-spun into a single one piece “t-shirt” 
configuration.  
 
4.2 General design brief for 2G ATAG 
This device specification is planned for implantation into a “normal” sized bespoke 
manufactured silicone aortic model with functioning aortic valve leaflets (Elastrat, 
Geneva, Switzerland).  Normative values were taken from the paper on aortic sizes 
published by Parish et al. in 2009 (87).  The silicone model I developed and Elastrat 
manufactured had the following diameters as shown in Table 20 below: 
Table 20 Bespoke made silicone model aortic diameter 
 
 
 
 
Normal aortic sizes taken from Parish et al. (87). 
Location Normal aortic diameter (mm) 
Annulus 26 
Sinus 34 
STJ 29  
Ascending aorta 30 
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4.2.1 Device description 
Key feature of the ATAG is the insertion of a covered aortic endograft near the aortic 
valve.  The graft will have covered coronary stents attached to the main graft body 
(inverted t-shirt configuration) that protect the coronaries and allow perfusion.  The 
important feature is that the main graft stent has a very short proximal section with 
attachment of coronary stents to minimize interfering with the aortic valve apparatus in 
the sinuses of Valsalva. 
4.2.2 Intended use 
The intended use is for a percutaneously delivered stent graft to treat diseases of the 
ascending aorta.  ATAG will need to proactively protect the coronary arteries and 
maintain the aortic valve competence.  The device is intended to treat primarily AAAD in 
a percutaneous fashion.  
4.3 Design requirements 
4.3.1 ATAG stent graft main body 
Table 21 below shows the ATAG stent graft frame design requirements: 
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Table 21 ATAG stent graft frame design requirements 
Item Requirements 
Description Self expandable nitinol main body Stent (electro polished) and laser cut 
Stent Design: QM653 – a Qualimed stent frame design 
Architecture: 
Open cell design, cylindrical with flaring at the proximal end to ensure pressure fit, 
longitudinal bars to maintain longitudinal position, but allow arch flexibility. 
Indicated for diameter 
To fit normal aorta bespoke silicone model (Elastrat, Geneva, CH). Data from 
Parish et al (87) Sinus of Valsalva = 34 mm, Ascending aorta 30 mm therefore with 
20% over-sizing main endograft 36 mm flaring to 42 mm at the proximal end 
within sinuses. 
Nominal Stent Lengths: Total stent length 60 mm: 50 mm cylinder, max 10 mm flaring end;  
Principle Drawing of 
Stent design: 
 
 
 
 
 
 
Crimping diameter Start with 24 F, goal 18 F (stowed graft) 
Radial Force: Radial force has to be at least as high as the force of competitor products 
Radio-opacity 
The Stent has to be radiopaque; the stent body needs x-ray markers on the 
proximal “feelers” which facilitate the correct positioning of the proximal portion 
into the sinuses, as well as distal stent end.  The attached coronary side branch 
stents should also be radio-opaque, and be mounted on balloons with markers 2 
rings for RCA and 1 ring for LMCA to allow orientation. 
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Table 21 ATAG stent frame 
cont. 
 
Further mechanical properties 
High flexibility: stent has to be able to turn over the arch of the aorta 180° without 
cracking 
Flexibility at least as high as competitor products (CoreValve
TM
) 
Further important feature 
A very short proximal section with attachment of coronary stents to minimize 
interfering with the aortic valve apparatus in the sinuses of Valsalva 
4.3.2  Coronary side branch stents  
Table 22 below describes the coronary side branch design requirements: 
Table 22 Coronary side branch stent design requirements 
Item Requirements 
Description Balloon expandable Stent (electro polished) stainless steel 
Stent design Qualimed current stent design 
Architecture: Tbc 
Indicated for diameter 
3.5 mm RCA, 4.5 mm LMCA Coronary sleeves will be attached at an angle of 150 degrees 
to one another 
Nominal Stent Lengths: 8 mm 
Foreshortening  
max. 5% (Current coronary Stents 3 mm on the market shortened during expansion by 0 – 
7.8% [Schmidt et al 2005 (Biomedizinische Tech)] 
Recoil (mean value): Recoil should be within the range of current coronary stents (max 5%) 
Radial Force: 
Higher than QualiMed in-house set target due to accomplished benchmark: ≥ 1500 mN for 
an 18 mm long Stent  
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4.3.3  Graft material  
4.3.3.1 Electro statically spun Polyurethane (PU) 
Unlike PET and ePTFE, PU’s are a complex and diverse group of related compounds.  
PU’s can be rigid or soft, depending on their composition.  Electro-spun PU is a fibre 
forming polymeric material.  Electro-spinning involves giving a polymer in solution an 
electrostatic charge and releasing this solution in a jet fired at a moving grounded 
structure (in this case the stent placed onto a mandrel).  The jet accelerates and is 
thinned by the electric field and results in small diameter filaments that collect as a non-
woven fabric on the grounded structure by evaporation of a solvent. 
Graft porosity depends upon the angle of winding, pitch angle, thickness of the filament 
and number of layers.  There are currently no endografts utilising PU as a covering 
material, and historically PU’s in vascular prostheses have failed because of 
biodegradation.  More recently in PU’s such as ChronoflexTM (Polymedica, Woburn MA), 
the polymer chain sites deemed at risk of cleavage are replaced for chemical groups 
resilient to degradation.  Given the potential disadvantages of both PET and ePTFE as 
already documented I felt from an early stage exploring a novel cardiovascular graft 
material that may have properties more suited to the ascending aorta and the aorto-
coronary junction might provide part of the answer to developing a successful branched 
stent graft in the ascending aortic position. 
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The theoretical advantages of PU for ATAG are as follows: 
PU can be spun very thin (<100 m), yet be extremely strong and robust.  PU can also 
be designed to be less rigid than both PET and ePTFE, and therefore conform more 
smoothly to the curvature of the aorta.  Being more conformable and elastic may provide 
advantages at the coronary ostia with regard to being able to treat more variability of 
coronary angulation.  Electro-spinning can create multi-porosity layers throughout the 
graft material, with differing pore sizes and different permeability on the luminal and 
aortic surface. 
I do not under-estimate the potential work involved within this experimental process, but 
Nicast (Lod, Israel) our PU industrial partners are a world renowned PU electro-spinning 
company who already have a commercially available PU vascular graft (AVFlo) - a 
haemodialysis implantable fistula membrane which means that much of the regulatory 
and manufacturing know how has already been overcome.  Table 23 below details the 
ATAG graft material design requirements: 
Table 23 ATAG graft material design requirement 
Item Requirements 
Description 
Electro spun medical grade polyurethane by Nicast (Lod, 
Israel)  
Raw material Medically biocompatible polycarbonate urethane 
Material thickness  Aim for <100 microns if possible.  
Joint method 
Coronary arms to be electro spun by Nicast and then 
attached by glue to the main graft body in the first instance. 
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4.3.4  2G ATAG delivery system 
Before formal in vitro flow rig or in vivo testing of the 2G ATAG device, a 2G delivery 
system must be developed.  While this development is beyond the scope of this thesis, I 
expect it to possess all of the basic components of the PoC delivery system, but have a 
lower profile, be more flexible, have 1:1 torque characteristics allowing delivery to be 
more precise, accurate, controllable and less traumatic to the native aorta. 
4.3.5 ATAG 2G Design specification conclusions 
The 2G ATAG has been designed to be delivered and tested in a normal sized bespoke 
made aortic silicone model with “functional aortic valve”.  As the device and the delivery 
system improve this silicone aorta can be integrated into an in vitro pulsatile flow rig. 
The 2G endograft has a number of design improvements compared to the PoC device.  
These include: 
i) Laser cut electro-polished nitinol frame with higher radial strength, built in 
longitudinal tie bars to prevent stent longitudinal shortening. 
ii) A novel thin electro-spun PU endograft covering. 
iii) A tri-lobed flared proximal portion to sit more naturally within the sinuses of 
Valsalva. 
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iv) Coronary sleeves to be electro-spun in a similar fashion to the endograft and 
these to be attached low down on the body frame to minimise disruption of the 
aortic valve. 
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4.4 2nd Generation ATAG build and stent body mechanical 
testing 
Qualimed have a very experienced team of medical device engineers that have 
previously developed similarly sized stents for non-cardiovascular applications 
namely the trachea and oesophagus.  They have also developed a number of bare 
metal, drug eluting and biodegradable coronary stents.  They are highly 
experienced in regulatory approval and their unit near Hamburg, Germany has all 
the necessary developmental, testing, manufacturing, and CE mark approvals 
facilities.  
This section describes the mechanical properties of nitinol, setting the scene for 
the 2G ATAG build and radial strength testing of the evolving 2G device.  I 
performed all of the testing documented at Qualimed’s facility in Germany.  
4.4.1 The properties of nitinol and radial strength testing 
Nitinol (Nickel-Titanium alloys) exhibit a combination of properties which make these 
alloys particularly suited to self-expanding stents.  Nitinol stents are manufactured to a 
size slightly larger than the target vessel and crimped down into a delivery system of 
relatively small diameter.  After deployment they position themselves against the vessel 
wall with a low chronic outward force.  They resist radial compression forces. 
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4.4.1.1 Super-elasticity and shape memory in Nitinol 
Super-elastic nitinol appears macroscopically to be very elastic.  However the 
mechanism of deformation is different from conventional elasticity.  When a stress is 
applied to nitinol, and after a modest elastic deformation the material yields to its applied 
stress by changing its crystal structure.  When the stress is removed the material 
recovers its original shape and crystal structure.  
Shape memory is a result of thermal phase transformation.  When super-elastic nitinol is 
cooled to below a critical temperature (the transformation temperature, which is 
dependent on alloy composition and processing) it also changes its crystal structure.  
The material can be plastically deformed in the low temperature phase, but the original 
shape can be restored by heating above the transformation temperature.  Self expanding 
nitinol stents are manufactured with their transformation temperature set to around 30 
degrees centigrade (oC).  They can easily be crimped at low temperature into a delivery 
system, and upon delivery to the vascular site (temperature 37 oC) the stent expands to 
its original dimensions and conforms to the vessel wall. 
4.4.1.2 Material considerations 
Nitinol is an alloy composed of 55% nickel and the remainder titanium.  The properties of 
solid state transformation which can be triggered thermally or mechanically is dependent 
on the composition and processing of the material and adds a further layer of complexity 
to material composition, specification and subsequent properties. 
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4.4.1.3 Biocompatibility and corrosion 
Nitinol requires controlled processing to achieve optimal shape memory and super-
elastic properties.  In 1999 the medical community and device industry were alerted to 
the issue of corroded nitinol graft scaffold (131).  To prevent nickel corrosion in vivo it is 
now generally accepted that nitinol is electro-polished.  
4.4.1.4 Material specific device characteristics 
The most unusual property of nitinol alloys is stress hysteresis, which results in a device 
feature termed “biased stiffness”.  This phenomenon is explained in the following stress / 
strain curve derived from a crimping / deploying cycle of a nitinol stent graft as described 
in Figure 86 below: 
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Figure 86 Hoop force curve for stowing and then expanding a nitinol endograft 
 
 
 
 
 
 
 
Note the x-axis is reversed i.e. increasing stent diameter from right to left.  A stent of a given size larger than the vessel 
(point a) is crimped into a delivery system (point b, having followed the dark blue curve).  After insertion into the target site 
the stent expands (along the red curve) until it opposes the vessel (point c).  At this point further expansion of the stent is 
prevented.  Since the stent did not expand to its pre-set shape it continues to exert a low outward force termed chronic 
outward force.  It will resist recoil pressure, or external compression forces with forces dictated by the loading curve from 
point c to d, termed radial resistive forces (132). 
The hoop force curves will be presented for the ATAG 2G graft and competitor 
endografts later in this section. 
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4.4.2 Radial strength testing 
Given the problems experienced with relative poor radial strength in the PoC, in 
association with our engineering partner Qualimed, it was decided to perform a first 2G 
ATAG manufacture run purely to test whether the graft body had the appropriate radial 
strength when compared to competitor devices. 
Following the original ATAG specification document Qualimed made the first prototype 
laser cut nitinol stent frame from 5 mm hollow nitinol tubing.  Only the graft body was cut 
(without proximal flare) and was 36 mm in diameter (30 mm + 20% over sizing), picture 
shown below in Figure 87. 
Figure 87 First Qualimed laser cut ATAG body frame  
 
 
 
 
 
The first 2G ATAG design consisted of 3 closed cell rings joined by 5 “tie bars” (arrowed) which give longitudinal strength 
but allow for flexibility of the graft during delivery around the aortic arch. 
272 
 
For the purposes of radial strength testing the middle ring was used although it was still 
attached to the outer rings by longitudinal tie bars. 
4.4.2.1Aim 
To test the radial strength of the ATAG nitinol cut stent frame body against competitor 
devices: 
i) a descending thoracic stent graft (Medtronic Talent graft) and  
ii) the CoreValve aortic re-valving system TM nitinol frame. 
4.4.2.2 Methods 
The constriction (hoop strength) method is a standardised method to determine the radial 
strength of stent grafts by applying a traction force to a flat collar around one segment of 
the stent.  The temperature for this procedure has to be physiological (37°C).  The force 
necessary to constrict the stent to 75% of the original diameter is called radial force.  It is 
measured in milli Newton (mN).  The hoop strength testing rig set up is shown below in 
Figure 88. 
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Figure 88 Radial hoop strength testing rig 
 
 
a) 
 
 
 
 
b) 
 
  
 
Radial strength testing performed in a water bath (a) at 37
o
C, using the constriction loop method (b).   The loop is wrapped 
around the stent, while one end is clamped in a jaw, the other attached to the bottom of the water tank.  The jaw is moved 
upwards with a velocity of 50mm / min until the stent diameter is 25% of its unloaded diameter (d initial ).  This characteristic 
point is reached, when the jaw has pulled the collar by an amo initial.   
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The computer records the data from the force measuring station.  A chart showing the 
radial force versus elongation of the collar is automatically generated.  Table 24 below 
shows the hoop strength rig set up: 
Table 24 Hoop strength set up 
 
 
 
 
 
 
Full macroscopic and microscopic photographic documentation of the first ATAG stent 
frame, the Medtronic Talent stent, and the CoreValve re-valving system TM frame can be 
found within the Appendix.  
 
 
Initial Stent diameter 36 mm 
Width of constriction hoop 20 mm 
Constriction 25% 
Change in length 27,5 mm (ΔL=0.25*п*dinitial) 
Jaw velocity 50 mm / min 
Load at start 0.1 mN 
Temperature 37°C (water tank) 
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4.4.2.3 Radial strength testing results 
For each of the grafts tested a hoop force curve is produced.  Measurements were 
repeated at least twice and an average hoop force measurement calculated. 
The average hoop force for each graft is important, but more information about the 
stiffness and graft characteristics can also be measured from the graphs.  For each graft 
test I have then measured from the graph the force required to deform the stent 10%, 
and 20% of the diameter, and then on the re-expansion curve (the lower of the 2 curves) 
the amount force that the graft is still exerting at 20% and 10% constriction – this gives 
an indication of the amount of chronic external force that the graft might impart upon the 
vessel wall if oversized by 20% and 10%, as is the current standard in aortic stenting. 
Hoop force curves, and the subsequent 10% and 20% analyses are shown in Figure 89 
a) and b) for the 2G ATAG, Figure 90 a) and b) for the Talent graft, and Figure 91 a) and 
b) for the CoreValve system below: 
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Figure 89 a) Radial Strength of centre ring portion of ATAG graft 
 
 
 
Force required to achieve 25% graft 
diameter reduction. 
Mean value  = 4965 mN 
The x axis here denotes the contraction in mm of the constriction loop.  The y axis is the force required to bring about this 
constriction and is measured in mN.  The axis labels for all other graphs are similar.  
 
Contraction of constriction loop (mm) 
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Figure 89 b) Radial Strength of centre ring portion of ATAG graft 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10% constriction = 11mm requires 2700 mN on constriction and exerts 540 mN on expansion 
20% constriction = 22mm requires 4770 mN on constriction – inaccurate measurement on expansion, but is at least 2500 mN. 
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Figure 90 a) Radial Strength of Medtronic Talent graft (with Dacron woven covering) 
Constriction of the 2nd distal segment 
 
 
 
Force required to achieve 25% graft diameter 
reduction. 
Mean value of 6 measurements = 2771mN 
 
 
Change in length of constriction loop 
(mm) 
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Figure 90 b) Radial Strength of Medtronic Talent graft with Dacron covering 
 
 
10% constriction = 5.4mm requires 1620 mN during constriction and 400mN during expansion 
20% constriction = 10.8mm requires 2430 mN during constriction and exerts 1020 during expansion 
 
Change in length of constriction loop (mm) 
(mm) 
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Figure 91 a) Radial Strength of Corevalve Re-valving TAVI system Nitinol frame 
Constriction at the smallest diameter 
 
 
 
Force required to achieve 25% graft 
diameter reduction. 
Mean value of 2 measurements = 5063 mN 
 
 
 
Change in length of constriction loop 
(mm) 
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Figure 91 b) Radial Strength of Corevalve Re-valving TAVI system Nitinol frame 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10% constriction = 7.28 mm requires 4610 mN during constriction and 1980mN during expansion 
20% constriction = 14.56mm requires 4900 mN during constriction and 4800mN during expansion 
Change in length of constriction loop 
(mm) 
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Constriction testing was only possible at the smallest diameter of the Corevalve frame 
(the area aligned to the coronary arteries – as the constriction loop would slip from all 
other positions)  
4.4.2.4 Conclusion 
When only the force needed to deform the stents by 25% of their diameter is taken into 
account the basic 2G ATAG (4965 mN) would seem to have a similar radial strength to 
the CoreValveTM nitinol frame (5063 mN), and nearly twice the radial strength of the 
Medtronic Talent graft (2771 mN).  In terms of adequacy of radial strength to oppose the 
arterial wall it would seem that the current ATAG stent design has sufficient hoop 
strength when compared to the most anatomically similar device on the market 
(CoreValveTM).  
These values alone however do not reveal the full picture.  The shapes of the curves are 
also important, and inside the real patient’s aorta it is the re-expansion profile (i.e. the 
lower curve) force that will be exerted chronically on the aortic vessel wall.  It is the 
relative stiffness that affects the shape of these curves with the CoreValveTM  being stiffer 
than both the ATAG and the Talent graft.  This relatively increased stiffness can be 
attributed to the frame design of the CoreValveTM. 
As can be seen in Figure 92 below the CoreValve has a completely closed cell structure, 
compared to the more open ring structure of the ATAG with longitudinal tie bars.  It is this 
closed structure that gives the CoreValve its radial strength, particularly at its mid-point 
which is not in contact with the aortic wall, but instead takes up a concave shape 
opposite the coronary arteries. 
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Figure 92 Medtronic CoreValve
TM
 frame 
 
 
 
 
 
The CoreValve frame is completely closed cell and the mid portion, which is not in contact with the aortic wall has the 
highest radial strength (arrowed) 
When we compare the CoreValve to the ATAG and the Medtronic Talent graft we see 
obvious differences.  The basic 2G ATAG has 3 rings which are joined by 5 tie bars, 
when testing radial strength on the middle ring therefore the tie bars enable the 2 
circumferential rings either side to impart additive radial strength.  In comparison the 
Talent graft which has a longitudinal bar running the entire graft length attached to the 
material and then to the circumferential rings.  As such any force measurement is 
provided predominantly by the ring around which the hoop is attached.  It is possible that 
the Dacron material attached to the Talent graft could provide some additional radial 
strength as like the tie bar it allows some transmission of the hoop forces onto the 
circumferential nitinol rings at either side of the one being tested.  Figure 93 below 
highlights the longitudinal design differences between the 2G ATAG and the Talent graft: 
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Figure 93 shows 2G ATAG and Talent graft 
 
 
 
 
ATAG basic graft (left) with 3 circumferential rings and 5 longitudonal tie bars (arrowed on left).  The Talent graft (right) is 
sewn onto a Dacron graft which also has a single longitudinal bar (arrowed on right) sewn along its length to give it 
longitudinal strength and prevent longitudinal  shortening / concertina effect. 
As mentioned above, the shape of the force / deformation curves is also important, 
particularly on the re-expansion profile as for instance the 20% re-expansion profile 
(measured from the graphs) essentially mimics the implantation of a 20% oversized 
endograft into a target vessel.  As can be seen from the relative data the stiffest device 
the CoreValve still exerts an outward force of 4800 mN when deformed by 20% on the 
re-expansion phase.  It is important to stress that this part of the CoreValve is not in 
contact with the aortic wall. 
At 20% re-expansion the ATAG exerts at least 2500 mN, and the Talent graft 1020 mN 
against the aortic wall.  At this early stage of the 2G device development I think it can be 
reasonably concluded that the 2G ATAG radial strength is sufficient to prevent vascular 
recoil, but the exact nature of forces involved is highly dependent on stent design, nitinol 
properties and chemical treatments.  It is important as we proceed with ATAG design 
285 
 
iterations to keep all of these mechanical characteristics in mind, ensuring that while the 
radial strength of the ATAG is adequate it does not expose the already diseased aortic 
wall to additional long term stress and strain. 
 
4.4.3  2G ATAG stent graft manufacture with 3 semi-lunar 
“feelers” 
The simple 3 ringed ATAG body stent with 5 interconnecting longitudinal bars has 
proven radial strength at 25% diameter reduction when compared to a CoreValve 
nitinol stent frame, and twice the radial strength compared to a Medtronic Talent 
endograft.  
With Qualimed I now moved towards making the full 2G graft stent with 3 proximal 
flared feelers in an attempt to mirror the aortic valve sinus anatomy and allow 
attachment of the coronary sleeves as close to the proximal end of the graft as 
possible.  
Moving forward it was also important to iterate the stent design.  Professor Rothman was 
concerned that if the 2G ATAG body had longitudinal bars at the same point on the 
circumference (as in Figure 93), then this could make the graft relatively inflexible as it 
passes around the aortic arch.  Qualimed therefore spaced out the longitudinal bars, off 
setting them and making the device more flexible within the arch of the aorta.  
Qualimed’s 2G ATAG with sinus feelers is shown in Figure 94 below: 
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Figure 94 Drawing of compressed nitinol 2G ATAG Frame  
 
 
 
 
 
 
 
 
 
2G ATAG with proximal “feelers” and off-set longitudinal tie bars  
Figure 95 below shows photographs of the first build 2G ATAG with sinus feelers:  
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Figure 95 Photographs of 2G expanded stent frame 
 
 
 
 
 
 
 
 
2G ATAG with sinus feelers expanded frame with measurements and arrows showing off-set longitudinal tie bars 
4.4.4 Radial strength of uncoated 2G ATAG with sinus “feelers” 
4.4.4.1Aim 
To test the radial strength of the 2G ATAG nitinol cut stent frame graft with 3 “feelers”, 
and staggered longitudinal tie bars. 
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4.4.4.2 Methods 
The constriction (hoop strength) method was used in an identical manner as already 
described in section 4.4.2.  Figure 96 below shows the 2G ATAG with sinus feelers within 
the constriction loop: 
Figure 96 2G ATAG with sinus feelers within the constriction loop 
 
 
 
 
 
4.4.4.3 Results 
The radial strength was tested over the middle ring as documented below in Figure 97 a) 
below, and the constriction / re-expansion profile at 10% and 20% measured in Figure 97 
b): 
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Figure 97 a) Radial strength of 2G ATAG with sinus feelers 
 
 
 
Mean value [mN] 
Force required to achieve 25% graft 
diameter reduction. 
4870 mN 
 
Change in length of constriction loop 
(mm) 
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Figure 97 b) Radial strength results of 2G ATAG 
 
 
 
 
 
 
 
 
 
 
 
 
10% constriction = 11 mm requires 1850 mN during constriction and 1050 mN during expansion 
20% constriction = 22mm requires 4300 mN during constriction and 2450 mN during expansion 
Change in length of constriction loop 
(mm) 
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4.4.4.4 Conclusion 
The tri-lobed 2G ATAG stent graft, with spaced longitudinal tie bars has essentially 
identical radial strength as compared to the simple 3 ring structure with 5 longitudinal 
bars at the same circumferential point. 
A 25% diameter reduction requires 4870 mN of force, and a 20% re-expansion profile of 
2450 mN is also similar to the original 2G ATAG of at least 2500 mN. 
 
4.4.5  2G ATAG with PU covering - further testing 
The 2G ATAG with sinus feelers was then sent to Nicast (Lod, Israel) a company with an 
expertise in electro-spinning devices with PU.  In order to electro-spin the PU onto the 
nitinol frame I designed and Qualimed made a spinning mandrel (design shown in Figure 
98 below). 
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Figure 98 Diagrams of the 2G ATAG mandrel for electro-spun PU coating 
 
     
 
 
 
 
 
The blue diagram represents a 2D model of the mandrel, onto which the 2G ATAG with sinus feelers will be placed.  There 
are projections for the coronary sleeves at an angle of 145 degrees to one another.  With the 2G ATAG nitinol frame 
placed over the mandrel, the PU will be electro-spun onto the moving mandrel ensuring a homogenous graft covering onto 
the nitinol stent frame. 
Nicast had already confirmed to us that at this time it was not technically feasible to 
electro- spin the ATAG “inverted t-shirt” in one piece and that the graft body would be 
coated and then the coronary sleeves would have to be attached by glue.  This was the 
accepted solution for the 2G device.  The reason for this is that currently the mandrel can 
only move in 2 dimensions to cover a standard stent in a homogenous PU covering.  To 
coat the coronary sleeves as well would necessitate the mandrel moving in 3 dimensions 
– this is not currently possible.  The aim was that the uniform electro-spun material would 
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have a thickness of <200 m in the first 2G prototype.  Ideally in further iterations and 
bench-testing we would like to get the PU coating thinner, <100 m for the purposes of 
stowing, but a trade-off would be made against material properties. 
4.4.5.1  2G ATAG with electro-spun PU graft covering 
Qualimed manufactured 2 x 2G ATAG stent graft devices and both were sent to Nicast 
for PU electro-spinning.  The first stent was covered with a 110 m PU material, the 
second graft with a 200m covering as shown in Figure 99 below, and documented in 
Table 25: 
Figure 99 2G ATAG with electro-spun PU coating.  
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Table 25  2G ATAG PU covered product description 
Sample Description 
Lot No. 
Nicast 
Lot No. 
QualiMed 
Polymer Type 
Coating 
Thickness 
Glue type 
1 
Coated Aorta 
Stent with glued 
coronary side 
branches 
ME09 1138 
A100954A 
ChronoFlex- 
medical grade 
polyurethane 
110 ± 10 µm Polymer 
solution made 
of ChronoFlex 
plus Titanium 
Dioxide 5% 2 ME09 1139 200 ± 10 µm 
4.4.5.2 Electro Spun layer configuration 
The PU has 3 discrete electro-spun layers with differing characteristics: 
1) Inner (lumen) layer characterized by porosity about 60%, pore size 0.5–3 µm , 
fibre diameter 0.5–1 µm, layer thickness about 45% of total thickness. 
2) Barrier layer is a non porous film, layer thickness is about 10% of total thickness. 
3) Outer layer = Inner layer. 
The stent itself is encapsulated inside of the barrier layer, in the middle of the coating. 
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4.4.6 Radial strength of the 200m PU covered 2G ATAG 
4.4.6.1 Aim 
To test the radial strength of the 2G ATAG nitinol cut stent frame body with PU covering. 
4.4.6.2 Methods 
The constriction (hoop strength) method was utilised as already described in 4.4.2. 
4.4.6.3 Results 
It must be stated that in fact the constriction method for measuring radial strength in an 
endograft where a material is tightly attached to a nitinol graft provides only a limited 
amount of useful data, as the PU material allows the constricting load to be spread over 
the nitinol rings either side of the ring being tested.  Therefore although this was 
performed, comparison of these results with those obtained from the bare metal stent are 
of limited value.  
As before the hoop force, deformation curves for the 200 m PU covered 2G ATAG are 
shown in Figure 100 a) and b) below: 
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Figure 100 a) Radial strength results of 2G covered ATAG 
 
 
 
Mean value [mN] 
Force required to achieve 25% graft 
diameter reduction. 
9141mN 
 
 
 
Change in length of constriction loop 
(mm) 
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Figure 100 b) Radial Strength result of 2G covered ATAG 
 
 
 
 
 
 
 
 
 
 
 
 
20% constriction = 22mm requires 7800 mN during constriction and exerts approximately 2500 mN during re-expansion 
Change in length of constriction loop 
(mm) 
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4.4.6.1. Conclusions 
The standardised hoop strength as measured by constriction method for the PU covered 
2G ATAG is 9141 mN, as compared to 4870 mN for the identical but uncovered 2G 
ATAG graft, 5063 mN for the CoreValve TAVI frame, and 2271 mN for the Medtronic 
Talent aortic Dacron covered stent frame.  The PU 200 m coated 2G ATAG graft has an 
apparent radial strength almost twice that of the uncoated graft, as the PU acts as a 
continuous longitudinal link giving the graft more combined radial strength, by spreading 
the load over a greater length of the device.  
The re-expansion profile at 20% is essentially the same as the uncovered graft i.e at 20% 
re-expansion, the force that remains exerted on the vessel wall at the graft / vessel 
interface is approximately 2500 mN (the same as the uncovered 2G ATAG). 
Also worthy of note in this testing protocol is that the covered 2G PU covered ATAG graft 
behaved in a robust manner and serial manipulations and constrictions at 37oC in water 
did not result in any damage to the frame or PU covering.  
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4.4.7  2G PU covered ATAG stowage testing 
4.4.7.1 Aim 
To assess the minimum stowed diameter of the 2G ATAG with and without the 200 m 
PU graft covering. 
4.4.7.2 Methods 
Using a commercially available circumferential stent crimper (similar to a disposable 
device which is used to crimp the Edwards TAVI), and Kalte 75 a spray which cools 
nitinol to -55oC the 2G grafts were crimped and then transferred into a suitably sized 
hollow piece of clear plastic tubing (to act as a stowage sleeve). 
4.4.7.3 Results 
The uncovered 2G ATAG frame could be crimped to 6 mm, which allowed stowing into a 
22 F (7.3 mm) delivery sheath (see Figure 101 below): 
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Figure 101 shows the uncovered 2G ATAG frame crimped to 6mm 
 
 
 
 
 
  
The 200 m PU covered 2G ATAG could be compressed to 7.5 mm and stowed into a  
28 F (9 mm) outer diameter delivery pod as shown in Figure 102 below: 
Figure 102 Stowage of the 200 m PU covered ATAG 
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4.4.7.4 Conclusions 
Stowage testing of the 2G PU covered ATAG reveals that the current minimum stowage 
diameter is 9 mm or 28 F, which is approximately 3 mm and 10 F larger than our 
specified design input.  It will be vital in further iterations that the device profile and 
stowing diameter is reduced to allow greater deliverability and minimise vascular 
complications.  
4.4.7.5 Stowage testing discussion 
It must be remembered that this is the first ATAG graft that we have manufactured to a 
high specification, and that this is a highly iterative process.  We accept that 28 F is 
significantly larger than our original design brief, but this at least now gives us a stent 
design, and electro spun covering that we can now optimise as we move forward. 
The first CoreValveTM percutaneous aortic valve graft implanted into humans was a 25 F 
device which took just 2 years and 2 generations before it was 18 F as is now 
commercially available.  Not only does the CoreValveTM easily crimp to 18 F but it also 
has a porcine pericardial tri-leaflet aortic valve attached within the lumen.  I expect similar 
advances over the next development cycle with the ATAG system.  
The proposed ATAG prototype and the CoreValveTM frame do have some generic 
similarities.  They are both nitinol frames with diamond shaped cells.  The ATAG has 
open cell structure with longitudinal tie bars making it more flexible versus the more rigid 
CoreValve architecture.  I have tested the prototype ATAG against the CoreValve nitinol 
frame and find the following as shown in Table 26 below: 
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Table 26  Average nitinol stent design characteristics  
Characteristic 2G ATAG prototype CoreValve 
Material thickness (µm) 489  420   
Strut width (µm) 204  310 
Connector width (µm) 246  420 
 
Moreover I believe that the special ATAG ‘honeycomb’ design is new and crucial points 
will lie in the detail.  For instance the application of the wave design allows for different 
segment widths matched to the flexural load with a single laser cut pattern.  
With regard to the PU graft covering 200 m is the starting thickness and it will be 
interesting to work with Nicast to see if adequate performance can be achieved with a 
thinner layer which again will lower the overall profile of the device.  
A vital part of the future 3G ATAG design and development will be devoted to minimising 
the stent graft and covering profile to minimise the stowing diameter, allowing easier 
vascular access and minimising vascular and embolic complications. 
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4.5 Potential 3G ATAG device iterations 
The formal design of a 3G ATAG device is beyond the scope of this thesis, but 
following on from all of the anatomical research and the testing of the 2G device I 
do have some recommendations for possible design iterations that might be 
considered within the 3G ATAG development process.  
4.5.1 Proximal aortic seal designs 
I think from the outset I have stressed the importance of the ATAG proximal stent design.  
The 2G sinus “feelers” are probably too long and too “pointed”.  I think the 3G ATAG may 
benefit from having the coronary sleeves attached to a more sinus shaped “feeler” 
protruding less into the sinus of Valsalva.  They may also have less outward flare force 
and be “softer”, reducing the risk of damaging the aortic valve apparatus.   
 
If softer less flared sinus feeler design is incorporated, proximal endograft seal may be 
worse increasing the risk of endoleak.  To mitigate against this, design iterations may be 
mandated just above the coronary arteries to ensure a seal at this point with a more 
flared portion or a self expanding cuff at or above the STJ to help seal so that proximal 
endoleak is less of a problem. 
 
The concept of a “valved ATAG” is desirable for a number of reasons, and during 3G 
ATAG development a “valved ATAG” development programme will run simultaneously.  
The reason why having an integrated aortic valve is so attractive is that in both the AAAD 
and the ATAA cohorts the annulus segment size is less variable, enabling annulus 
304 
 
proximal seal to be achieved, without the worry of interference with the aortic valve.  
Published data also suggests that the aortic valve will be incompetent and need repair or 
replacement in between 25-35% of all AAAD presentations, thus providing a suitable 
treatment modality for this mechanical complication (8). 
 
I do not underestimate the cost and development time required to integrate a functioning 
aortic valve into the ATAG, but conceptually I believe it may be mandated in the end user 
ATAG device, and for this reason is covered in our intellectual property. 
4.5.2 Coronary sleeve considerations 
Coronary entry and coronary sleeve stenting requires further bench test experimentation.  
Currently coronary artery flow is secured by stenting 2 coronary sleeves as branches off 
the main ATAG graft.  The ability of the coronary sleeves to adapt to coronary distance 
and angulation rests within the flexibility and elasticity of the PU material – bench testing 
with different coronary angulations and distances will help to inform as to whether this is 
sufficient.  Future coronary sleeve embodiments may consist of design features with the 
aim of increasing the range of coronary distances and angulations that are treatable.  
Potential design features might consist of a) conical coronary segments and b) stepped 
concertina segments as represented in Figure 103 below: 
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Figure 103 Possible coronary sleeve designs 
 
 
 
 
 a)       b) 
Possible coronary sleeve designs, with the aim of increasing the range of angulations and lengths that each device is 
capable of treating effectively. a) Conical coronary sleeves  b)  Stepped concertina effect of sleeve material. 
At this point in time it is still too early to suggest whether protection of the coronary flow 
in the manner I have outlined is technically feasible and / or physiologically tolerated in 
both animal models and human patients.  We must optimize the design and deployment 
characteristics, and have undergone significant in vitro delivery work before 
consideration of a first in vivo model.  As has already been outlined in the design 
specification if protecting both coronaries in a proactive way is not feasible we will retreat 
to a less ambitious design.  
Even if stenting of the LMCA and RCA using the “inverted t-shirt” ATAG is possible we 
will need to test the material durability and its risk of fatigue and thrombus formation / 
restenosis.  Further work will involve platelet and coagulation activation, as well as 
suggested strategies (heparin, aspirin and clopidogrel) to maintain long term patency.  
There is already interest in attaching molecules to the PU surface to increase 
306 
 
endothelialisation and improving long term patency rates (133;134), and one must 
consider whether a drug eluting layer could provide protection against re-stenosis.  
While currently the coronary sleeves require gluing to the main ATAG body frame I am 
hopeful that within the 3G ATAG a one piece electro-spun T shirt will be possible 
integrating both coronary sleeves.   
4.5.3 Iterations related to aortic curvature  
The first 2-3cm of the ascending aorta is relatively straight and can be managed using a 
straight graft (like the CoreValveTM).  After this proximal portion there is curvature in 2 
dimensions, a factor that has partially been taken into account with the 2G ATAG design, 
but relies upon the stent frames ability to flex to conform to the shape of the aorta in this 
region, with an open cell design connected by staggered longitudonal struts as already 
described in Figure 95. 
Optimisation of the longitudonal strut geometry is required to maximise endoluminal 
apposition and is reflected in our future work packages and will allow for optimal graft 
shape minimising the formation of “wrinkles”.  
The formation of “wrinkles” of the graft covering material may also be material specific.  
Four of the seven main descending thoracic aortic endografts use Dacron woven 
material as their covering (Medtronic Valiant, Bolton Medical Relay, Cook Zenith, and 
Jotec Evita).  They all have rudimentary Z shaped stents, Dacron material and the grafts 
have developed little since their inception.  The grafts themselves often have significant 
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infoldings of material even when placed in a straight tube (see Figure 104 below of 
Medtronic Talent graft) 
Figure 104 Medtronic Talent graft 
 
 
 
 
Medtronic Talent graft with Dacron covering showing material infolding (arrowed) 
When treating the ascending aorta, protection of the coronary arteries and aortic valve is 
likely to require a more sophisticated graft, capable of conforming to the curvature of the 
aorta, lined with a covering that is novel, thin, flexible, strong, biocompatible, thrombus 
resistant and impermeable.  
The 3G ATAG may well have a shorter inner aortic curve, or at least tie bars which can 
compress on the inner curve compared to expanding on the outer curve, in an attempt to 
allow better apposition of the ATAG graft and covering material to the aortic wall, which is 
likely to improve the distal seal and minimise distal endoleak. 
Further information on the aortic angulation in 3 dimensions will be required, and will be 
obtained most readily from CT or MRI angiography. 
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4.5.4  3G ATAG profile 
Much design consideration with 3G ATAG will focus on reducing the overall stowing 
profile from the current 28 F towards our original aim of 18 F.  The 3G stent frame needs 
to be stowable with reduced profile, while maintaining radial strength.  The graft material 
must be as thin as possible while maintaining its barrier function, and being robust.  
 
4.5.5  Radio-opacity and optimizing visualization 
As 3G ATAG moves towards more sophisticated testing, stent radio-opacity and 
visualisation under fluoroscopy must be prioritised.  As has already been shown 
visualisation and orientation in 3 dimensions is vital for successful deployment and as 
such we must focus on these factors.  Current designs have radio-opaque markers on 
ends of the graft, coronary balloons and stents (with L and R orientation).  Only through 
further testing and simulation will it become clear whether this is adequate or whether 
more sophisticated markings are required. 
 
4.5.6  Guide wire specification 
One of the major limitations of the PoC deployment in vitro model was that once the 
guidewires were in both coronary arteries and LV cavity, they were fixed in position, a 
manoeuvre that cannot be replicated in vivo.  Attention must be focused on bench testing 
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and determining the amount of force ATAG imposes on the guide wires within the 
coronary arteries and LV cavity when the device is advanced up the aorta and around 
the arch into the landing zone.  With this information it will be possible to design coronary 
and LV guidewires with specific properties to keep them in position and allow ATAG 
advancement.  Possible guidewire designs include balloon securing wires, noodle wires, 
and possibly a screw in LV wire. 
4.5.7 Sizing protocol 
Over-sizing is likely to be device specific and we will need to work hard during bench 
tests to evaluate radial strength and propose an evidence based over-sizing protocol for 
the ATAG instructions for use. 
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Chapter Five  
Development of a simple in vitro flow loop, and 
investigating the most suitable in vivo animal 
model for future work 
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Chapter 5 : Development of in vitro and in vivo models 
5.1 Development of a simple in vitro flow loop  
In vitro assessment of a new vascular endoprosthesis is a vital part of testing for 
both regulatory and device and delivery system design / iteration.  The next phase 
of the ATAG iteration and testing (documented within the successful NIHR grant 
and beyond the scope of this thesis) would involve flow rig analysis of 
implantation and device behaviour resulting in further iterations of both the ATAG 
device and the delivery system.  
There are commercially available flow rigs (http://www.blockwise.com/robopulse) 
capable of replicating human physiological conditions including arterial wave 
form, blood pressure, temperature  etc, but at $100,000 are beyond the reasonable 
budget of this project.  
To develop my own simple flow rig I collaborated with Professor Steve Greenwald 
who is Professor of Cardiovascular Mechanics at QMUL with the aim of building 
from scratch a basic prototype flow rig which could then be improved and 
optimised by my successor for ATAG testing with the Elastrat silicone aorta.  
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5.1.1 Flow rig experiment  1 
5.1.1.1 Aim 
To set up a simple in vitro flow rig with semi-physiological conditions. 
5.1.1 2 Simple In vitro flow rig specification 
 To be able to implant ATAG into cylindrical aortic portion with coronary artery 
branches 
 Flow rig to utilise water in first iteration (less viscous than blood) 
 Water to be a physiological human body temperature of 37oC 
 Have a flow rate of 5 litres / minute (L/min) up to a supra-physiological 14 L/min to 
potentially test possible migration / stent stability and fixation characteristics  
 To be capable of delivering a constant mean pressure of 80 mmHg (phasic 
pressure / flow beyond the realms of this simple flow rig) 
 Pumped return system 
5.1.1.3 Materials and methods 
5.1.1.3.1 Materials  
Table 27 below details the materials used in the simple flow rig: 
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Table 27 Materials for flow rig 
32 mm Internal Diameter (ID) rigid Perspex tubing 
3.5 mm ID rigid Perspex tubing (RCA) 
4.5 mm ID rigid Perspex tubing ( LMCA) 
Perspex bonding cement 
20 mm ID clear silicone tubing 
13 mm ID clear silicone tubing 
22 mm white plastic plumbing pipe 
Flow regulator / 22 mm Tap 
37
o
C thermostatically controlled water bath 
Electric DC water pump capable of > 5 L/min 
10 litre storage tank 
5.1.1.3.2 Methods 
A 32 mm internal diameter (ID) Perspex tube 15 cm long was chosen for the implantation 
zone (IZ) to simulate the ascending aorta.  To this 2 coronary artery portions were 
attached – a 4.5 mm Perspex tube for the LMCA and a 3.5 mm Perspex tube for the 
RCA.  The coronary arteries were attached at an angle of 155 degrees to one another, 
representing essentially “normal” ascending aortic and coronary size and geometry.  It 
was accepted that Perspex tubing could not take into account the natural curvature of the 
ascending aorta, the shape of the sinuses, take off angle of the coronary arteries, or the 
elastance / physical properties of the native aorta.  Figure 105 shows the Perspex IZ: 
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Figure 105 Shows the Perspex IZ  
 
 
 
 
 
Photographs showing Perspex aorta with LMCA and RCA branches attached by bonding cement at 155 degrees to one 
another. 
This Perspex area will form the ATAG IZ.  It will be supplied by an aortic inflow where 
physiological warm water (37oC) will flow through the graft at a rate of 5 L/min.  Using 
only gravity this device can really only test the device in one of two ways: 
i) High flow, low resistance / pressure – the tubing would allow approximately 14 
L/min, but at a very low pressure. 
Or 
ii) High pressure between 80-94 mmHg but with low / no flow i.e. the hydrostatic 
pressure created from water being 2-2.5 m above the implantation zone with 
resistance after the IZ increasing pressure. 
The majority of the tubing making up the circuit is a 20 mm ID silicone tube.  There are 
joining portions of 22 mm plastic tubing – allowing the integration of flow regulator taps. 
1550 
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A thermostatically controlled water bath was used as a reservoir for the 37oC water which 
was then pumped into a 10 L storage tank suspended 2 metres above the graft giving 
gravitational pressure and flows through the graft implantation zone.  Figure 106 and 107 
below show the experimental set up: 
Figure 106 First flow rig experimental set up 
 
 
           Inflow regulator tap 
 
 
 
 
A 10L reservoir for storing the water is placed at 2-2.5 metres above the IZ.  This leads into a inflow regulator to control 
flow.  Water passes into the IZ and can flow either straight through the IZ, or through the attached coronary Perspex 
branches.  Water is collected from all routes and the volume over time measured.  The 37 degree water bath also acts as 
a reservoir connected to an electrical water pump recycling water up to the elevated reservoir. 
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Figure 107 Photograph of experimental set up 
10 L water reservoir 
Water pump 
          
          Inflowtap 
370C waterbath        
 
 
Flow per minute was measured by collecting the water that had run through the system 
during a 15 second period, weighing it (1 litre weighs 1 Kg) and multiplying by 4 to get 
L/min. 
5.1.1.3.3 Result 
5.1.1.3.3.1 Temperature 
Over the testing period, with continuous circulation the water bath remained at a constant 
temperature of 37 +/- 1 oC.  
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5.1.1.3.3.2 Flow measurement 
Flow could easily be adjusted (adjusting flow regulator tap) to allow a reliable “circulating 
volume” / min.  Table 28 below shows the flow of water through the IZ in L/min when the 
angle of the inflow regulator tap is adjusted: 
Table 28 shows angle of inflow tap against total flow through IZ 
 Angle of inflow regulator tap   (
o
) Flow in L/min 
1. 45 1.45 
2. 60 4.56 
3. 70 6.42 
4. 68 5.61 
A volume of 5.6 +/- 0.14 L/min  (measured by the total weight of water (Kg) from outflow 
over a minute period), could be reproduced with the flow regulator tap at 68 degrees 
angulation as shown in Table 29 below: 
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Table 29 Reproducibility of flow measurements 
 
Run  Flow in L/min 
1 5.76 
2 5.49 
3 5.58 
Mean 5.61 
Standard deviation 0.14 
 
5.1.1.3.3.3 Pressure assessment 
Pressure wire assessment of the pressure within IZ revealed essentially a hydrostatic 
pressure of 80 mmHg when the storage vessel was placed at 2 m height, and the outflow 
from the IZ and coronaries was clamped (i.e. static pressure).  The maximal constant 
pressure that could be created by this flow loop within this lab was 94 mmHg with the 
storage reservoir at 2.5 m above the IZ, and the outflow of the graft clamped (i.e. high 
pressure, no flow). The pressure at the IZ during flow of 5.6 L/min was approximately 20 
mmHg. 
5.1.1.4 Conclusions 
During this first simple flow rig experiment I had set up a circuit capable of reliably 
pumping 5.6 L/min of water at 37oC through a mock aortic root, with 2 coronary arteries 
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at a pressure of 20 mmHg.  The greatest hydrostatic pressure that could be created was 
94 mmHg (with no flow and outflow clamped).  Flows of around 14 L/min could be 
achieved with the inflow tap completely open, and no distal resistance.  
5.1.2 Flow rig experiment  2 
5.1.2.1 Aim 
To implant the ATAG into the specially made Perspex “ascending aorta IZ”, as 
documented in 5.1.1). 
5.1.2.2 Methods 
The 2G ATAG did not contain coronary stents, but instead cylindrical sleeves of Nicast 
PU material with a material thickness of 152 m. 
Figure 108 below shows a photograph of the 2G ATAG with PU covering:  
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Figure 108 Photograph of the proximal end of the 2G ATAG with coronary sleeves  
 
 
 
 
 
 
The 2G ATAG device was manually inserted into the Perspex IZ, with each coronary 
sleeve positioned into the respective coronary artery. 
5.1.2.3 Results 
The 2G ATAG with PU coronary sleeves (but no coronary stents) was successfully 
implanted manually into the Perspex ascending aorta as shown in Figure 109 below: 
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Figure 109 Shows 2G ATAG implanted into the Perspex ascending aorta 
 
 
 
 
 
 
 
It was noted however that the coronary artery sleeves collapsed down precipitating major 
flow of fluid around the graft and not through it, as shown in Figure 110 below: 
Figure 110 Involution and collapse of the PU materials within the coronary ostia 
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I decided to stent the branches in place as detailed in the design specification.  This was 
achieved using a 4.5 mm stent in the LMCA and a 3.5 mm stent in the RCA.  Both stents 
were from my expired stock and were cut to around 8 mm in length, as shown in Figure 
111 below: 
Figure 111 Coronary stents inserted to LMCA and RCA PU coronary sleeves  
 
 
 
 
 
 
Implantation of coronary stents into the Nicast PU sleeves resulted in a seal between the ATAG graft and coronary arteries 
so that the predominant flow came through the stent graft and sleeves.   
Using water as the fluid at 370C it was impossible to rule out that some may “bypass” the 
sleeve and come around, but this is likely to be minimal. 
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5.1.2.4 Conclusion 
It was possible to implant the 2G ATAG graft into the IZ of the Perspex model, but the 
unsupported coronary sleeves involuted allowing predominant flow around the graft 
rather than through it. 
It was rectified by stenting the coronary sleeves into the LMCA and RCA resulting in 
macroscopically the majority of the flow through the coronary arms. 
 
5.1.3 Flow rig experiment 3  
In the human, the coronary circulation receives approximately 5% of the cardiac output at 
rest (135).  With resistance only placed on the inflow or outflow of the main ATAG graft 
the relative coronary flows were supra-physiological (between 20% and 57%), coronary 
flow being the path of least resistance.  
5.1.3.1 Aim 
Using flow regulators (resistance valves) on the main outflow and the coronary outflows 
create the most physiologically correct simple flow rig possible (proportional flow through 
the aortic stent and coronaries). i.e. create a mock circulation with a total cardiac output 
of around 5 L/min, with 95% going through the main stent graft body and 5% through the 
coronary arteries.  
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5.1.3.2 Methods 
With ATAG already implanted in the IZ, and coronary sleeves stented, by serially testing 
the flow rig with water, adjusting the flow resistance of outflow, and both coronary 
arteries to achieve a physiological cardiac output as documented above. 
Figure 112 below shows the ATAG with stented coronary portions implanted within the 
Perspex IZ: 
Figure 112 covered ATAG inserted into IZ of Perspex aorta 
 
 
 
 
 
ATAG implanted into the IZ, and the coronary sleeves stented in position. With silicone tube attachments to the coronary 
Perspex sleeves coronary flow could be easily collected and measured: 
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5.1.3.3 Results 
Table 30 below shows flow of water through the main aortic stent and through the 
coronary arteries: 
 
Table 30 physiological coronary flow achieved with the simple flow rig 
Flow 
through 
end of 
Stent in 
15 sec 
(ml) 
LMCA 
flow in 15 
sec (ml) 
RCA flow 
in 15 sec 
(ml) 
Total Flow 
Through Stent 
(ml/min) 
Percentage 
total flow 
through Left 
Coronary (%) 
Percentage 
total flow 
through 
Right 
Coronary (%) 
Percentage of 
Total Flow 
through Both 
Coronaries (%) 
1208 53.2 44 5220.8 4.07 3.37 7.44 
 
Using water within the flow loop the most physiological set-up managed was a total 
cardiac output of 5.2 L/min, with 7.4% of the cardiac output going down the coronary 
arteries – this is clearly supra-physiological as normally 5% of cardiac output fills the 
epicardial coronary arteries at rest, but was the best we could reliably achieve with this 
simple flow rig set up.  
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5.1.3.4 Conclusion 
With water as the loop fluid and resistance taps on the aortic outflow and both coronary 
artery outflows it was possible to create a flow loop with physiological proportions of fluid 
flow through the main stent body and through the coronary arteries. 
 
5.1.4 Experiment 4 ATAG flow rig testing with contrast under 
fluoroscopy 
5.1.4.1 Aim 
To visualise the flow of contrast through the ATAG graft and coronary sleeves under 
fluoroscopy within a flow loop. 
5.1.4.2 Methods 
The flow rig from experiment 3 was set up in the cardiac catheter laboratory of the 
London Chest Hospital, with a flow of 5.5 L/min, with similar coronary and outflow 
resistances.  Just proximal to the ATAG graft a 6 F pigtail catheter was inserted through 
a 6 F sheath to inject iodinated contrast (by a automatic contrast injector at 20 ml / 
second for 2 seconds) through the graft to be captured on fluoroscopy.  Experimental set 
up is shown in Figure 113 and 114 below: 
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Figure 113 shows flow rig set up in cath lab 
 
 
 
 
 
Left picture reveals the introducer needle in the silicone tubing proximal to the implantation zone (ascending aorta), using 
the Seldinger technique a wire is passed through the needle and into the silicone “aorta”.  Over the wire a 6 F arterial 
sheath is inserted into the silicone artery. 
Figure 114 Pre-contrast fluoroscopy image of the ATAG 
 
          ATAG graft 
 
RCA stent         LMCA stent 
 
 
6F Pigtail 
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5.1.4.3 Results 
CD ROM attached to this thesis documents the video captured fluoroscopy, a still image 
is shown in Figure 115 below: 
Figure 115 Still fluoroscopic image from the contrast injection into ATAG 
 
 
 
 
 
 
 
 
 
 
It appears contrast travels through the coronary arteries and stent graft body.  The ability to detect and quantify endoleak is 
impossible by this means, and would be better achieved under direct vision with the use of a dye tracer, which would be 
seen to track outside of the graft material. 
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5.1.5 Conclusion and discussion 
The set up of an extremely simple flow loop with variable coronary and outflow 
resistances enabled me to get a first “understanding” of flow loop dynamics, and really 
acted as an introduction to further more complex pulsatile flow rigs with resistance and 
capacitance. 
I was able to set up a flow rig with a maximal flow of 14 L/min and low pressure, as well 
as a maximal pressure of 94 mmHg with no flow (outflow tap closed = hydrostatic 
pressure from 2.5 metres).  In both of these scenarios there appeared to be no migration 
of the ATAG graft macroscopically, although we must accept that the lack of migration 
may have had much to do with the materials used in the loop (i.e. Perspex and PU). 
I was also able to set up a flow rig with physiological cardiac output and correctly 
proportioned flow through the main graft and into both coronary arteries. 
The flow assessment under fluoroscopy added little to our understanding of the graft, 
apart from its radio-opacity.  Endoleak cannot be formally assessed, although contrast 
could clearly be seen to track behind the 3 proximal “feelers”, implying that proximal seal 
would not have been sufficient in this case.  It must however be pointed out that because 
of constant size of the Perspex model and no sinus dilatation the specifically designed 
feelers were unable to take up their anatomical position and potential proximal seal.  This 
will be better assessed within future work in vitro testing utilising a silicone anatomically 
correct model (Elastrat, Geneva , CH), with integrated aortic valve.  
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5.2   Animal model selection for ATAG in vivo studies 
The successful NIHR grant for further ATAG testing and development will take the 
3G ATAG once built into in-vivo trials (beyond the scope of this thesis).  During 
numerous meetings with Professor Brockman and Dr Connelly it became clear that 
the selection of an appropriate animal model for ascending aortic ATAG work is 
not straight forward.  
While most TAVI valve and coronary stent testing had been performed in porcine 
models there are a number of issues that make the porcine ascending aorta less 
favourable as a model for testing ATAG.  There is also a lack of robust published 
anatomical data about the ascending aorta in all animal models.  I first decided to 
do a literature review on published aortic dimensions of potential animal models. 
5.2.1 Possible animal models 
The 3 animal species models most frequently utilised to test new cardiovascular devices 
are – ovine, porcine, and bovine.  A literature review of aorta size in these 3 animals 
species revealed the following, summarised in Table 31 below: 
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Table 31 An overview of animal model aortic sizes 
Animal model Aortic size (mm) 
2-5 year old ovine (55-95 Kg)  32.9 (range 28.3 – 39.7)(136) 
1 year old porcine (30 Kg) 19 (range 19 – 25)(137;138) 
4 month old bovine (120 Kg) 37.2 (SD +/- 9) (139) 
Adult bovine (300 Kg) 60 (SD +/- 4)(139) 
 
At first glance the ovine aorta may look promising for ATAG testing in that the ascending 
aortic size is similar in an adult sheep to that of an adult human.  The porcine model 
would seem to have a relatively small aorta, and the juvenile bovine model has a good 
sized aortic diameter (37.2 mm), but if implanted at this size the ATAG would not be 
capable of expanding and keeping pace with the natural growth of the aorta resulting in 
the animal outgrowing the aortic graft. 
There are also follow-up implications.  Most regulatory in-vivo studies have at least 6 
month follow up.  The gold standard in aortic follow up like in human beings is either MRI 
or CT aortography.  It is not possible to CT or MRI scan any adult animal > 120 Kg and 
as such for the reason of growth and sheer size the bovine model is impractical for 
regulatory ATAG testing. 
A single echocardiographic ascending aorta diameter does not tell the whole story with 
regard to optimal in-vivo model for the implantation of ATAG.  In the absence of 
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published data on animal model aortic size / length, coronary and aortic valve anatomy I 
decided to obtain cadaveric samples of all three species and perform my own 
examination and measurements. 
5.2.2 Cadaveric measurement of ovine, porcine, and bovine 
aortic and coronary dimensions 
5.2.2.1 Introduction 
As can be seen from the literature review above there is a paucity of accurate and 
reliable aortic, great vessel and coronary anatomical data to allow us to pick the best in 
vivo ATAG animal model for further prototype development.  As a result I decided to 
obtain cadaveric samples of sheep heart and aorta (termed “pluck”), as well as pig and 
cow from Smithfield livestock market, City of London.  
5.2.2.2 Aim 
In cadaveric sheep, pigs and cows to dissect and accurately measure aortic diameters 
and distances of great vessels, comparing them to the known human reference vessels. 
5.2.2.3 Methods 
Cadaveric animal heart and aorta were obtained.  The aortas were dissected using 
scalpel and fine scissors, and then diameter and length measurements were made by a 
single operator (TK or SP assisted by Professor Brockman) using callipers capable of 
measuring to the nearest 0.1 mm. 
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5.2.2.3.1 Aorta and coronary measurements 
The following measurements were made in all 3 animal cohorts, as shown in Table 32 
below: 
Table 32 Aortic and coronary measurements taken in each animal model 
Ascending aorta diameter (mm) 
LMCA ostium diameter (mm) 
RCA ostium diameter (mm) 
Distance from RCA to first great head and neck vessel (mm) 
Distance from LMCA to first great head and neck vessel (mm) 
Diameter of the first great head and neck vessel (mm) 
Diameter of the mid aortic arch (mm) 
5.2.2.4 Experiment 1 - ovine measurements 
5.2.2.4.1 Study population 
Measurements were performed on 4 adult 60-70 Kg sheep plucks consisting of the heart, 
ascending aorta and aortic arch. Plucks had been frozen and then thawed prior to 
measurement.  
 
 
334 
 
5.2.2.4.2 Results 
The ovine ascending aorta is short, giving rise to a single great head and neck vessel - 
the brachiocephalic trunk.  This then divides into the left and right subclavian arteries, 
and a branch that then gives rise to both the right and left common carotid arteries (see 
Figure 116 below): 
Figure 116 Ovine heart and ascending aorta  
 
 
 
 
 
 
 
The ovine ascending aorta is short, giving rise to a single great head and neck vessel - the bracheo-cephalic trunk.  This 
then divides into the left and right subclavian arteries, and a branch that then gives rise to both the right and left common 
carotid arteries 
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Table 33 Ovine aorta and coronary measurements 
Sample Ascending 
Aortic diameter 
(mm) 
LMCA 
diameter 
(mm) 
RCA diameter 
(mm) 
Distance from 
RCA to 1
st
 
branch (mm) 
Distance from 
LMCA to point 
opposite 1
st
  
branch (mm) 
Diameter  mid 
aortic arch (mm) 
Diameter of 
the  1
st
 aortic 
branch  (mm) 
1 20.8 6.9 2.8 23.8 14.1 14.2 11.2 
2 22.2 7.7 2.3 20 11.4 16.5 12.2 
3 19 7.8 2.7 14.8 12 16.1 9.5 
4 17.4 5.9 1.9 16.2 12.5 12.6 9.8 
Mean 19.9 7.1 2.4 18.7 12.5 14.9 10.7 
SD 2.09 0.88 0.41 4.05 1.16 1.80 1.26 
 
5.2.2.4.3 Conclusion 
The measurements of the vasculature of adult sheep plucks from 60–70 Kg animals 
suggested many anatomical differences to that seen in the human population. 
The measurements showed the average ascending aortic diameter was smaller at 19.9 
+/- 2 mm, whereas an average normal human ascending aortic diameter is 32.7 ± 4 mm 
(11).  
The anatomical features of the sheep were also different; the average LMCA diameter 
was 3 times that of the RCA, 7.1 mm and 2.4 mm respectively.  Sheep also have one 
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large common branch off the aortic arch compared to three in humans.  This vessel also 
branches off earlier leaving an average ascending aortic length of only 18.7 mm 
compared to 92.6 mm in humans (11). 
5.2.2.5  Experiment 2  - porcine measurements 
5.2.2.5.1 Study population 
Measurements were performed on 3 adult 60-70 Kg porcine plucks consisting of the 
heart, ascending aorta and aortic arch.  Plucks had been frozen and then thawed prior to 
measurement.  
5.2.2.5.2 Results 
The porcine aorta also has a different great vessel anatomy when compared to both the 
human and the ovine model.  The porcine ascending aorta gives rise to 2 arch vessels, a 
brachiocephalic trunk and a LSCA as shown in Figure 117 below: 
Figure 117 2 aortic arch vessels in the Porcine animal model 
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Table 34 Porcine aorta and coronary measurements 
 
*The 1
st
 heart was cut in half so not all the measurements were available (N/A) 
5.2.2.5.3 Conclusions 
There are differences between the porcine model and the normal human aorta. The 
ascending aorta is smaller with a mean diameter of 20.1 mm.  The LMCA is larger at 7.8 
mm, and nearly double the size of the RCA ostium (4.0 mm).  The distance from the 
coronary arteries to the first great head and neck vessel is shorter (35 mm and 37.7 mm).  
The aortic arch consists of 2 branches: 
Sample Asc. Aortic 
diameter 
(mm) 
LMCA 
diameter 
(mm) 
RCA diameter 
(mm) 
Distance from 
RCA to 1
st
 
branch 
Distance from 
LMCA to point 
opposite first 
branch (mm) 
Diameter 
aortic arch 
(mm) 
Diameter of 
the  1
st
 aortic 
branch  (mm) 
1 19.7 8.3  N/A* N/A*  38 N/A*  N/A*  
2 21 8.6 4.0 38 40 17.5 10.2 
3 19.7 6.4 4.0 32 35 16.6 9.2 
Mean 20.1 7.8 4.0 35 37.7 17.1 9.7 
SD 0.75 1.19 0 4.24 2.52 0.64 0.71 
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1) The first, a brachiocephalic trunk, which then splits into the right subclavian artery 
and a cephalic trunk that then further splits into the right and left common carotid 
arteries. 
2) The left subclavian artery. 
The anatomical finding of the 2 branch aortic arch is shown in Figure 118 below: 
Figure 118 Diagrammatic representation of porcine aorta and branches 
 
 
 
 
 
 
 
 
The porcine aortic arch gives rise to a brachiocephalic trunk, which then splits into the right subclavian artery and a 
cephalic trunk that then further splits into the right and left common carotid arteries.  The second arotic arch branch is the 
left subclavian artery. 
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5.2.2.6 Experiment 3 Bovine aorta (Juvenile calves 140-150 Kg, 26-28 weeks old) 
5.2.2.6.1 Study population 
Measurements were performed on 3 juvenile 140-150 Kg calf plucks consisting of the 
heart, ascending aorta and aortic arch.  Plucks had been frozen and then thawed prior to 
measurement.  
5.2.2.6.2 Results 
The bovine aorta is relatively similar to the ovine aorta in that it has a relatively short 
ascending aortic portion before giving rise to a single arch vessel the brachiocephalic 
trunk, as shown in Figure 119 and 120 below: 
Figure 119 Bovine aorta with single bracheocephalic trunk 
 
 
 
 
 
The bovine aorti has a single brachiocephalic trunk, which then further subdivides into the right subclavian artery, a bi-
carotid trunk and the LSCA. 
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Figure 120 Photographs of bovine ascending aorta, single great head and neck 
vessel and proximal arch  
 
 
 
 
 
 
Table 35 Bovine aorta and coronary measurements  
Sample Asc. Aortic 
diameter 
(mm) 
LMCA diameter 
(mm) 
RCA diameter 
(mm) 
Distance from 
RCA to 1
st
 
branch (mm) 
Distance from LMCA 
to point opposite 
first branch (mm) 
Diameter 
aortic arch 
(mm) 
Diameter of 
the  1
st
 aortic 
branch  (mm) 
1 32.5 8.4 3.7 29.0 27.7 23.8 20.7 
2 32.6 8.3 5.3 31.5 29.1 21.5 16.7 
3 32.0 7.8 3.4 30.6 27.0 23.2 19.6 
Mean 32.4 8.2 4.1 30.4 27.9 22.8 19.0 
Standard 
Deviation 
0.3 0.3 1.0 1.3 1.1 1.2 2.1 
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5.2.2.6.3 Conclusions 
The juvenile calf shares a similar aortic size to the human, but has just one common 
head and neck branch, which divides into three main vessels.  
The coronary arteries are LMCA 8.2 mm and RCA 4.1 mm in size, but again the distance 
from the coronary arteries to the first great head and neck vessel is short at only around 
30 mm. 
5.2.3 Discussion of potential animal model results 
Table 36 below summarises the mean measurements from each animal model: 
Table 36  Comparing the mean measurements of each animals vessel sizes 
Sample Asc. Aortic 
diameter 
(mm) 
LMCA 
diameter 
(mm) 
RCA 
diameter 
(mm) 
Distance from 
RCA to 1
st
 
branch 
Distance from LMCA 
to point opposite 
first branch (mm) 
Diameter 
aortic arch 
(mm) 
Diameter of the  
1
st
 aortic 
branch  (mm) 
Sheep 19.9 7.1 2.4 18.7 12.5 14.9 10.7 
Pig 20.1 7.8 4 35 37.7 17.1 9.7 
Calf 32.4 8.2 4.1 30.4 27.9 22.8 19 
The first thing to say is that both the ovine and porcine animal cohorts were of adult size, 
whereas the calves were Juveniles and as compared to the literature search the juvenile 
aortic diameter is about half of the full grown aortic diameter.  The size of the animal at 
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the time of implantation and the animal’s ability for growth are important features for 2 
reasons: 
I) If we implant a 4 cm diameter ATAG graft into a juvenile calf 3.4 cm aorta, then by 
the time the animal is fully grown the graft will be massively undersized to the 
full grown aortic diameter and this will make it a very unreliable in vivo model 
with many confounding factors in long term follow up. 
II) The best endovascular graft follow up is achieved by CT or MRI scanning, but this 
is not technically feasible for full size cows as they are too large and too 
heavy for the CT scanner at the RVC.    
All three animal models have a different aortic arch configuration compared to the human 
(traditionally with 3 arch vessels).  This is itself not a problem, but it is the relative short 
distance between coronary arteries and first great head and neck vessel that will require 
a bespoke “shortened ATAG” for in vivo testing.  We must also factor into the in vivo 
ATAG the fact that the coronary arteries are relatively large compared to the human, and 
their angle of take off relative to one another may be very different to the human angle of 
154 degrees (not possible to accurately measure in these cadaveric samples). 
Because of the relative large size, and growth considerations with follow up I think it is 
unlikely that the bovine model will be a robust survival model. 
We are therefore left with both the ovine and porcine model.  The aortic diameter  is very 
similar in both (approximately 20 mm), considerably smaller than humans, but the ovine 
model has an even shorter distance from coronary artery to first great vessel (<20 mm) 
which I think makes the ovine model impractical.  As a result I think the model that is 
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likely to best approximate that of the human is the porcine. The Pig has a mean aortic 
diameter of 20.1 mm, and an ascending aortic portion of 37.7 mm.  My only concern 
about the porcine model are the personal communication comments from the Chuter 
group during their ascending aorta stent graft testing in pigs where they felt the model did 
not tolerate the procedure very well (presumably coronary ischaemia), but this data is 
unpublished. 
The adult porcine and ovine models are both of sufficient size for device implantation - 
although as has been discussed both will require ATAG devices specifically designed for 
their aortic anatomy with smaller aortic diameter, larger coronary sleeves, and a shorter 
main body portion.  Utilising the adult porcine model will also enable CT follow up as they 
can easily be accommodated within the CT scanner at RVC.  
5.2.3.1 Study limitations 
The flaccid nature of the vessels meant it was difficult to determine the exact diameter, 
also the vessels had to be held to make them circular for the measurements to be taken.  
This investigation was also limited by the difficulty faced, even with the help of a 
veterinary surgeon in identifying some of the structures. 
5.2.3.2 Recommendation ATAG In Vivo testing model 
From the information gained from the anatomical study any animal model implantation is 
going to require a bespoke graft for that species, taking into account the aortic diameter, 
coronary diameter and distance to first head and neck vessel.  The bovine model, while 
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of good aortic calibre may be useful for a first acute non survival model, but its relative 
size and growth potential make survival model follow up in the form of CT impossible. 
The ovine model while it has a smaller aortic diameter of 20 mm, and will fit easily within 
a CT scanner for robust survival follow up, it has a very short ascending aorta from 
coronary arteries to first head and neck vessel (<20 mm).  As a result I would propose 
that for the reasons outlined above the porcine model in the first instance is the best 
animal model for future 3G ATAG in vivo studies although the models ability to tolerate 
myocardial ischaemia will need to be critically appraised.  If the procedural tolerability is 
an issue a shortened ATAG may be utilised potentially in an ovine model.  Further testing 
is required before these decisions can be taken. 
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Chapter Six : Health Economics 
6.0 Health economic and cost considerations 
A medical device in its early stage of development is difficult to accurately assess the 
proposed final device cost.  The final proposed market price for ATAG will be affected by 
many factors including the effectiveness of the device, the health care cost of the 
‘conventional’ treatment, the price and performance of potential competitor devices.  
I will give some insight into potential ATAG costings by commenting on the current costs 
associated with 2 related clinical areas: 
i) The endovascular treatment of abdominal aortic aneurysm (AAA) 
ii) Trans-catheter aortic valve (TAVI) therapies  
Endovascular treatment of abdominal aortic aneurysm (AAA) has high success rates and 
has reduced hospital stay from a mean of 13 days to 6 days (140).  There are a number 
of competing devices on the market and currently in the UK they sell for around £5k, and 
in the US $12k.  This is set against a fully loaded build cost of around £800 for one 
device manufactured in the UK (verbal communication with Professor Rothman who is a 
main board director of this company). 
Treatment of aortic stenosis in Octogenarians and other high risk groups turned down for 
conventional aortic valve replacement surgery has been revolutionised in the last 4 years 
with the development of TAVI with very encouraging mortality, morbidity and quality of 
life improvements.  In the UK and Europe there are 2 commercially available devices; the 
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Edwards SapienTM aortic valve, and the Medtronic CoreValveTM.  Both devices currently 
sell in the UK for approximately £12,500.  
In the UK the Department of Health categorises each surgical procedure performed with 
an HRG reimbursement code specific to the procedure.  There is currently no specific 
code for “surgical treatment of ascending aortic dissection”, or “surgical treatment of 
ascending aortic aneurysm”, but instead : 
 Coronary artery bypass 
 Cardiac valve procedures   
 Other cardio-thoracic procedures with cardio-pulmonary support 
Depending on the exact nature of the aortic dissection and aneurysm surgery required 
different tariffs will be attracted depending on the anatomy and concomitant coronary and 
valve disease (the tariffs vary between £4.5k – £7.5k).  However this tariff does not 
reflect additional ITU stay, or the cost of renal dialysis where extra costs are incurred and 
are not reimbursed.  Other factors affecting length of stay are co-morbidities and age.  
Neri et al report that operation for AAAD in Octogenarians (a high risk group n=24) had 
an 83% in-hospital mortality rate.  Mean hospital stay was 37 days and mean intensive 
care stay was 19 days.  None of the patients were able to function normally and survival 
at 6 months was 0% (141). 
In our institution (London Chest Hospital, E2) an intensive care bed day costs £2k, HDU 
bed £800, and CCU bed £300.  One can therefore extrapolate from this high risk elderly 
cohort described that the mean cost would be: 
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Procedural tariff   = £4.5 – £7.5k 
19 ITU bed days * £2k    = £38k 
5 HDU bed days * £800  = £4k 
13 bed days * £300   = £3.5k 
This therefore corresponds to a mean cost in this high risk group of £51.5k with 
horrendous levels of associated morbidity and mortality.  
Depending on the final ATAG clinical performance we believe that a cost similar to that of 
the percutaneous aortic valve plus potentially an “unmet clinical need premium” would be 
appropriate.  We would hope that in a similar way to endovascular treatment of both the 
abdominal aorta and aortic valve, ATAG would reduce hospital stay and morbidity and 
mortality which may result in cost effectiveness – this will be fully analysed as the project 
progresses. 
Thus in summary we expect the health care cost of an admission to be of the order of 
£50k, against which the ATAG end-user price (if the only solution in the market) would be 
set at around £20k, with a fully loaded manufacturing cost (when production is stabilised) 
of around £1000. 
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Chapter Seven : ATAG Conclusion 
7.0  ATAG thesis discussion and Conclusions 
There is a huge unmet clinical need for a new, safe and effective minimally invasive 
treatment for Acute Ascending Aortic Dissection.  In 2012 AAAD has a mortality rate of 1-
2% per hour within the first 24 hours, and even with contemporary surgical techniques, 
advanced intensive and post operative care, the mortality from AAAD following surgery in 
most series remains in the unacceptable range of 10-30% at 30 days (2;3).  28% of 
patients presenting with AAAD are denied life saving surgery often because of age or co-
morbidity - medical therapy alone associated with an in hospital mortality rate in excess 
of 50% (2;4-6). 
The last decade has seen a rapid expansion in percutaneous therapies for 
cardiovascular disease.  The emergence of TAVI is now offering elderly and high risk 
patients with severe aortic stenosis an alternative to conventional aortic valve surgery, 
with proven outcome and symptom improvement at 1 year (28;113).  Endovascular repair 
of infra-renal abdominal aortic aneurysm (EVAR) is now a standard of care, and TEVAR 
has an emerging role in the treatment of complicated Type B aortic dissection and 
descending thoracic aortic aneurysm (5;6;94). 
There are however stark differences in uptake and development of technologies between 
TAVI and endovascular aortic stenting, and I think this partly explains the lack of 
development of a suitable ascending aortic graft.  Despite Cribier’s FIM TAVI (2002) 
being performed 11 years after Parodi’s first endovascular aneurysm repair (EVAR 
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1991), the TAVI devices have evolved much more rapidly, and have accumulated much 
more randomised clinical data (112;113;142). 
In TAVI, both CE marked devices gained early clinical use with a profile >25 F, and within 
2 generations and inside 5 years are now 18 F in diameter, with the Edwards Sapien XT 
being implanted through an expandable 16 F eSheathTM, as compared to the standard 
range of TEVAR devices (Medtronic Valiant Captiva) whose delivery sheath diameter 
remains between 22-25 F.  TAVI devices have elegant delivery systems capable of 
traversing the aortic arch, minimising vascular complication, CVA and maximising 
accurate deployment, while TAA and AAA endografts continue to be deployed with bulky, 
inflexible and large diameter delivery systems.  Many of the stent frame, stowing and 
delivery sheath technologies developed with TAVI devices are potentially transferable to 
a ascending aortic graft, and I think will be necessary if a endovascular solution for AAAD 
is to be realised. 
TAVI has also taught us of the importance of working in multi-disciplinary teams, and of a 
“heart team” to make collegiate decisions for the patient and perform the interventions 
together with varied skill sets.  In the future with the development of ATAG devices I 
envisage the heart team growing into a cardiovascular team, with the addition of a 
radiologist, and endovascular surgeon. 
This thesis describes in detail the anatomical, and device design barriers that I believe 
have prevented the development of a dedicated percutaneous solution for ascending 
aortic syndromes.  These include proximity and involvement of AAAD with aortic valve 
function, and coronary artery location, and the ability of an endovascular graft to obtain 
proximal seal so close to these vital structures.  The curvature of the ascending aorta, 
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the pulsatile flow and variability in diastolic and systolic diameters, coupled with the 
landing zone close to the RBCT adds further layers of complexity (15). 
The current thoracic endografts are bulky and inflexible, and covered in rigid materials 
which are prone to infolding.  PET and ePTFE as well as conforming poorly to the arterial 
wall create an overt inflammatory reaction with a cellular migration and infiltration 
promoting cell adhesion, thrombosis and poor long term patency in small calibre vessels.  
The anti-migration mechanisms are often crude with 5 mm barbs to anchor the graft into 
position, a strategy that is liable to complication so close to the aortic valve and coronary 
arteries.  Not only are the current TAA endografts rudimentary they are deployed using 
large diameter inflexible delivery systems.  It is easy to understand why endovascular 
stent grafting of the ascending aorta is confined to a handful of case reports using short 
grafts inserted via various access routes (114). 
In my opinion successful treatment of AAAD with a dedicated graft will only occur with 
significant investment from device companies in state of the art nitinol frame design, 
novel graft material and developing deployment systems similar to those already 
available for TAVI.   
To bring this thesis to a conclusion I am going to discuss in detail what features an ATAG 
device, or a family of ATAG devices must have to successfully treat AAAD and 
potentially ATAA.  I do not underestimate the complexity and the amount of work 
involved in bringing my suggested device specifications to reality. 
This thesis has informed me that there are likely to be a family of probably 3 ATAG 
devices, all sharing core technologies, but having different design specifications to deal 
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with the specific anatomical challenges that are posed.  Core features in all grafts will be 
a low profile nitinol frame with appropriate radial strength, coupled with a thin non-porous 
polyurethane covering, housed in a flexible delivery sheath with precise and accurate 
deployment mechanisms.  There are likely to be a number of implantation routes 
including, femoral, subclavian, direct aortic and possibly carotid.  The optimal route for 
each patient will depend upon pre-procedure CT scanning.  Implantation is likely to occur 
in a hybrid theatre with a cardiovascular multi-disciplinary team. 
In the simplest terms the 3 embodiments of ATAG that I envisage are: 
1) The “supra-coronary tubular ATAG”, for treating AAAD with an intimal tear in the 
ascending aorta, no coronary or aortic valve involvement and adequate landing 
zones above the coronary arteries and before the RBCT. 
2) The “inverted t-shirt ATAG” to pro-actively protect coronary artery flow and 
achieve proximal seal within the sinuses in patients with an intimal tear in close 
association or involving the coronary arteries. 
3) The “valved ATAG” to treat patients who have significant AR, to achieve a 
proximal seal at the annulus when anatomy suggests it would be difficult to 
achieve with embodiment 1) or 2), and in those patients who have hugely dilated 
aortic root, so that the ATAG can seal proximally at a relatively normal annulus 
size to a distal seal at normal ascending aorta proximal to the RBCT. 
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Embodiment 1) ATAG Tubular Graft 
The IRAD reported in 2007 that of the 682 patients who had surgical repair of AAAD, 
58.5% had an isolated supra-coronary aortic replacement (9).  Sobocinski in 2011 goes 
on to suggest that at least one third of all AAAD patients based on CT scans could 
technically be treated by deploying a “simple” supra-coronary tubular endograft, between 
coronary arteries and RBCT, excluding the intimal tear, and avoiding interference with 
the coronary arteries or aortic valve (8). 
Successful uncomplicated ATAG tubular graft deployment will require considerable 
technological advances with regard to grafts and delivery systems when compared to 
current TEVAR endografts. 
The graft must be stowable to a lower profile than currently available with 18 F being 
desirable.  The stent frame must be flexible to allow passage around the aortic arch, yet 
still retain adequate radial strength.  The graft is likely to benefit from the advanced laser-
cut nitinol frame, which may have longitudinal tie bars on the inner and outer curve 
capable of relative expansion on the outer aortic wall and compressing on the inner wall 
enabling better apposition of graft to aortic wall.  A novel PU graft material which is thin, 
non-porous, and biologically inert might oppose the aortic wall and be capable of 
withstanding the mechanical stress of aortic pulsatility and the 17% variability in aortic 
size between systole and diastole (15).  The delivery catheter must resemble that of a 
TAVI device with accurate and precise deployment mechanism, probably with the aid of 
rapid ventricular pacing. 
355 
 
ATAG graft sizing is an important consideration.  Currently the largest commercially 
available TEVAR graft is 46 mm in diameter.  This means with a 20% over-sizing 
protocol the largest true lumen size that can be treated is 38 mm (which corresponds to a 
total aortic size of 46 mm).  The Parish AAAD dimension data suggests that to be able to 
treat 85% of aortic diameters an endovascular graft will need to be capable of treating 
total aortic diameters between 40 – 65 mm (87).  The problem with treating larger aortic 
diameters, is that the stent graft has to be of a greater size which in turn has both stent 
design and stowing implications.  Only with further stent bench testing will it become 
clear as to the maximal aortic diameter that can be manufactured and stowed to our 18 F 
goal.  
All embodiments of ATAG will need to be stocked in the cardiac centre in a number of 
diameters and lengths, immediately available given the urgent nature of AAAD 
intervention. If during the procedure the aortic valve becomes compromised, 
commercially available TAVI implantation can be considered so long as the annulus size 
is acceptable. 
Embodiment 2 “inverted t- shirt” ATAG 
In patients with AAAD who have coronary artery involvement, or whose intimal tear is 
within 2 cm of a coronary artery, to enable proximal endograft seal and to pro-actively 
secure coronary artery flow the “inverted t-shirt ATAG” should be developed.  Compared 
to embodiment 1) this is a more complex device. 
The proximal “sinus feelers” must oppose the sinus wall, creating a proximal seal, 
delivering the coronary sleeves to both LMCA and RCA at the same time not interfering 
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with aortic valve competence.  While I have proven that in a normal glass aorta this 
technique is feasible there are many in vivo complexities which will make successful 
deployment of this device very challenging. 
There is the need for 3 wires – one in each coronary and one within the left ventricle.  
One of the major limitations in the proof of concept testing was the fact that these 
guidewires were fixed in position - a manoeuvre that cannot be replicated in vivo.  In the 
future as the 3G ATAG device and delivery system is iterated and developed 
simultaneous bench top testing must occur to determine the guidewire forces required to 
keep position and design wires with appropriate holding specifications.  Another 
complicating factor that may be difficult to resolve in vivo is the fact that the coronary 
wires tend to cross 2 cm above the implantation zone.  In vitro and under fluoroscopy this 
is resolved by retracting the LV wire from the LV, turning the delivery catheter through 
180 degrees clockwise and then re-advancing the LV wire.  This manoeuvre allows the 
coronary sleeves to re-align towards their respective ostia, and may be more difficult to 
reproduce in vivo. 
As we move into the future 3G ATAG in vitro testing it will be vital to critically appraise 
the adequacy of ATAG graft, coronary sleeves and delivery system fluoroscopic markers, 
and this will be something that must be optimised before moving into the in vivo setting.  
It is also possible that while animal model implantations will be performed using C-arm 
fluoroscopy, ATAG implantation in humans may be aided in the hybrid catheter lab by 3D 
realtime CT to help guide graft and coronary sleeve orientation. 
At this stage an important unknown is the human’s ability to tolerate prolonged global 
and particularly coronary hypo-perfusion during the rapid ventricular pacing and proximal 
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ATAG deployment.  There is still a question mark over whether bilateral protection of 
coronary flow with sleeves is technically feasible and physiologically tolerated.  In the 
future, 3G ATAG will be tested most likely in the porcine model and this data will help tell 
us more as to whether the procedure can be performed.  As has already been elucidated 
if “inverted t-shirt” ATAG is too technically and physiologically challenging we may need 
to retreat to a position where only one coronary is protected and the other is opposed by 
a fenestration.  The answers to these questions should be addressed in the I4I future 
work packages which are found in section 8.0 and within the Appendix. 
I designed the proximal end of the ATAG “inverted t-shirt” embodiment to mirror the 
natural sinuses of Valsalva so that the sinus “feelers” enter into the sinuses, with an 
external flare to gain adequate proximal seal to prevent endoleak, but do not interfere or 
disrupt the aortic valve integrity.  This theory is as yet unproven, and it will be interesting 
during testing of the 3G ATAG whether these assumptions are substantiated.  It is highly 
likely that further iterations will be required following in vitro testing to optimise proximal 
graft seal and understand the extent of aortic valve interference.  In keeping with 
embodiment 1), if the aortic valve competence is compromised so long as the annulus is 
of an appropriate size the implantation of a commercially available TAVI can be 
considered. 
Important novel anatomical information was gained from the CT analysis of patients 
presenting with AAAD, which informed the device specification of this embodiment.  My 
AAAD CT data suggests that the annulus is normal sized, leading into a mildly dilated 
sinus of 29.1 mm, a dilated STJ of 41.6 mm, an ascending aorta of 43.5 mm.  The RCA 
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would seem to be displaced cranially by about 10 mm (23 mm above annulus), with the 
LMCA only mildly displaced 3.8 mm compared to normal) (11). 
The angle between both coronary arteries in the AP plane is a mean of 162.5 degrees 
(range 131.6 – 201.8), and has important implications for the design specification of the 
coronary sleeves for both embodiment 2) and 3).  It will decide what angle the sleeves 
are attached to the graft body, and the material considerations enabling the sleeves to 
treat a range of coronary angles.  During bench testing we must critically appraise the 
coronary angulations that PU coronary sleeves are able to treat, and whether further 
sleeve designs are required.  Bench testing will also focus on the durability of sleeve / 
body join (currently glued), and whether with time the “inverted t-shirt” can be electro-
spun in a single piece.  Given the cell infiltration and poor long term patency rates of 
small diameter PET and ePTFE grafts I do believe that investigating a novel material for 
this embodiment is mandated. 
Embodiment 3 “The Valved ATAG” 
The “valved ATAG” is an endograft that would have its proximal seal at the aortic 
annulus, leading to a functional aortic valve, then into a coronary portion with two 
coronary artery sleeves to protect coronary flow, and finally a tubular portion with distal 
seal before the RBCT.  I envisage this being a potential percutaneous solution for the 25-
35% of AAAD patients who require aortic valve repair or replacement conventionally 
during AAAD surgery (9).  It might also be a possible endovascular solution for treating 
ATAA if it can be performed with similarly low complication rates when compared to 
contemporary surgery. 
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It will I believe also be the percutaneous solution for patients with significantly dilated 
sinus segments of aorta with AAAD, in which achieving an adequate proximal seal with 
either embodiment 1) or 2) will probably be unsuccessful.   
It is possible that a valved ATAG might be deployable without coronary sleeves 
(depending on the dissection anatomy), with a valved portion deployed into the aortic 
annulus giving aortic valve function, followed by a uncovered region opposing the 
coronary arteries allowing for unrestricted coronary flow, necessitating a robust and 
adequate seal at the sino-tubular junction to prevent type 1 endoleak.  
Like all other embodiments of ATAG I do not underestimate the design and mechanical 
engineering challenges that must be overcome to realise this device.  
Conclusion 
I have demonstrated within this thesis a thorough understanding of the disease 
processes of AAAD and ATAA, and the current contemporary surgery management.  I 
have identified that the largest current unmet clinical need is AAAD.  The current 
endovascular stent grafts designed for use in the thoracic and abdominal aorta are not 
capable of being deployed reliably in the ascending aorta. 
Within this thesis novel CT and MRI anatomical data in association with a literature 
search has led to the formulation of a design specification for 3 ATAG embodiments, one 
of which the “inverted t-shirt” ATAG has been successfully built and delivered within a 
normal sized glass model.  A second generation (2G) ATAG has been manufactured 
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using a laser-cut nitinol frame and covered in 200 m PU, being stowed to 28 F.  The 
graft has a similar radial strength to competitor devices.   
As co-applicant with Professor Rothman I have written a full 3 year future ATAG 
development plan that will build and test a 3G ATAG with delivery system both in vitro 
and in vivo, with survival animals.  At the end of this period of investigation the aim will be 
to licence out the technology for commercialisation, or spin out a company and seek a 
large commercial partner to help move us a step closer to providing a percutaneous 
solution for treating patients with AAAD. 
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Chapter Eight : Future directions  
8.0  ATAG future directions 
I have divided the future directions of the ATAG project into 5 discrete work packages 
which mirror the project plan from the NIHR funded I4I grant. 
These work packages are described briefly below for directional purposes and more 
detail can be found within the attached NIHR proposal found in Appendix. 
8.1  Work package 1 
Development of a 3G ATAG prototype, with in-vitro flow testing. 
Flow models allow detailed investigation of the graft behaviour under anatomical and 
physiologically realistic situations allowing graft and delivery system optimisation.   
8.1.1 Aim 
To characterise the behaviour of a 3G ATAG in different anatomical flow models. 
3G ATAG stent graft prototypes will be specified and built in close collaboration with our 
contracted medical engineering partner (Qualimed, Hamburg, Germany).  A basic 
delivery system will be designed and built.  The stent graft samples will be mechanically 
characterised (stowing, radial forces, forces to deliver).  
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Elastrat (www.elastrat.com) will manufacture 4 silicone ascending aortic models from CT 
images (normal, proximal AATA, distal AATA, and dilated aorta like that seen in AAAD).  
A flow rig to simulate physiological conditions (pulsatile pressure and flow at body 
temperature and blood viscosity) will be assembled and characterised.  
The ATAG will be repeatedly implanted under direct vision into the 4 silicone flow models 
with differing aortic anatomy to see how the graft behaves, documenting the following 
objective end points: 
a) Pressure and flow measurements within the coronary arteries, the excluded 
aneurysm portion (sac), across the aortic valve and ascending aorta. 
b) Interference with aortic valve function 
c) Flow pattern analysis using a dye tracer 
d) Expansion of the graft body assessed using an endoscope  
e) Presence of endoleak  
f) Proximal and distal seal assessment 
g) Extent of ATAG migration 
The results will be fed back and used to design an advanced prototype 4G stent graft for 
WP2.  
8.2 Work package 2  
In-vitro graft delivery and deployment study 
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8.2.1 Aim 
Design specification and development of fully functional 2nd generation delivery system 
for ATAG. 
Stent graft prototypes and delivery systems will be manufactured and characterised in 
bench top set up (tracking forces, forces to deploy and traction on guide wires).  A series 
of samples will be used to study the deployment in detail in the flow-rigs under direct 
vision. 
The study will then be repeated for delivery and deployment of ATAG in the 4 flow 
models under both direct vision and fluoroscopic guidance.  
Focus will be upon measuring the following: 
a) Positioning precision  
b) Force required to push device and delivery system around aortic arch from 
femoral artery into implantation position 
c) The torque forces of the delivery system 
d) Force needed to deploy coronary stents on push rods 
There will also be considerable end user feedback with the investigator critically 
appraising the ability of the device to track around the aortic arch, provide adequate 
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“pushability” of the coronary arms, and torque to allow the delivery system to transfer 
subtle movement of the hands to the front of the device in positioning.   
WP2 is again likely to lead to further design iterations of both graft and delivery system. 
At this time point the new ATAG stent graft samples will also be subject to cyclic load 
testing to ensure durability of up to 6 months to satisfy the 6 month survival and safety 
study. Full regulatory cyclic load testing and durability is beyond the scope of this project. 
8.3 Work package 3  
Acute In-vivo study 
A 60-90 Kg pig may well provide the best in-vivo model for testing graft design and 
deliverability.  The pig has an aortic diameter smaller than that of a human, but it has the 
longest “ascending aorta” before the first great head and neck vessel compared to both 
ovine and bovine models.  Tolerability of the procedure may be an issue, but this 
experience will only be gained by an acute in vivo study. 
All in-vivo studies will be carried out at the Royal Veterinary College with supervision by 
Professor Dan Brockman, and TOE guidance provided by RVC cardiologist Dr David 
Connelly.  Dr Chris Lamb will provide CT follow up for survival animals and Prof Cheryl 
Scudamore will provide histopathology analysis post mortem.  
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8.3.1 Aim 
To evaluate acute ATAG deployment in a porcine (non-survival) model 
8.3.2 Methods 
In 5 adult pigs under GA the ATAG device will be delivered to the aortic root under x-ray 
guidance and simultaneous TOE. 
8.3.3 End Points 
 Ability to implant ATAG in correct position without complication 
 Stenting and patency of coronary arteries 
 Integrity of aortic valve function (measured by TOE) 
 Incidence of early migration 
 Ability to create proximal and distal seal 
 Incidence of early endoleak 
 Incidence of heart rhythm disturbance 
 Incidence of death as a result of implantation and its likely mechanism 
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 Histopathology of explanted samples 
 
8.4 Work package 4 
In-vivo survival and safety study 
It is envisaged that there will be a further device update following on from WP3.  
8.4.1 Aim 
To evaluate the survival and safety of the ATAG device implanted in a porcine model 
(under x-ray and TOE guidance). 
8.4.2 Methods 
In 15 adult pigs under GA deliver the ATAG device and characterise the safety and 1, 3, 
& 6 month survival. (Identical implant team to WP3) 
The first 5 will have a CT scan at 1 month before device is explanted and examined. 
The second cohort of 5 will have a CT at 1 and 3 months before explantation and histo-
pathological analysis. 
The last 5 will have CT scan at 1, 3, and 6 months before explantation and analysis. 
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8.4.3 End points 
 The ability to implant ATAG in correct position without complication 
 Stenting and patency of coronary arteries 0, 1, 3 and 6 months (on CT) 
 Integrity of aortic valve function (measured by echocardiography at 0, 1, 3 & 6 
months) 
 Incidence of early migration acutely, 1, 3, & 6 months 
 Ability to create proximal and distal seal 
 Incidence of endoleak 
 Incidence of heart rhythm disturbance 
 Implantation leading to death and mechanism 
 Histopathology of explanted samples 
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8.5 Work package 5 
Development of IP and business plan  
In order to take the device to CE mark (regulatory processes), significant investment will 
be required.  A business plan will be drafted to reflect this financial input and also to 
highlight potential exit points for investors.   
Patentable IP will be collated and decisions will be made on patent filing at monthly 
meetings with patent team.  Non-patentable IP including know how will be protected 
through a strict non-disclosure policy throughout the project.  
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GRANTS WON / EQUIPMENT SPONSORSHIP  
Grant won October 2006  
Grant body NHS Innovations London – PoC funding 
Grant holder Prof Martin T Rothman 
Grant amount £ 50,000 
Grant won October 2007  
Grant body NHS Innovations London -  2G development 
Grant holder Prof Martin T Rothman 
Grant amount £ 75,000 
Grant won December 2009  
Grant body NIHR i4i stream 2 funding body 
Grant holder  Dr Thomas Keeble, Prof Stephen Greenwald, Prof Dan 
Brockman, Prof Martin T Rothman,    
Grant amount £ 743,000 
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Grant won December 2010  
Company  GE healthcare and diagnostic imaging 
Grant holder Dr Thomas Keeble 
Equipment Delivery, installation and application training of the GE 
9800 C-arm and cardiovascular table 
Cost Not disclosed, covered by GE healthcare and diagnostic 
imaging. 
Grant won December 2010  
Company  GE healthcare and diagnostic imaging 
Grant holder Dr Thomas Keeble 
Equipment Delivery, and use of 2 TOE probes for in vivo ATAG 
testing 
Cost Not disclosed, covered by GE healthcare and diagnostic 
imaging. 
 
 
 
373 
 
PRELIMINARY DELIVERY SYSTEM TESTING  
Purpose of test 
I) To define length of system components 
II) To define proposed procedure sequence 
III) To demonstrate the positioning of balloon and coronary stent using a twin 
delivery system. 
Methods 
Silicone tubing was used to simulate the aorta and artery path. Silicone tube 11mm OD 
x 7mm ID was taped to a bench top to form a 2D profile which represents entry through 
the femoral artery, abdominal aorta and descending aorta, into ascending aorta. The 
total cut length of the tube was 1000mm.  
Two 7mm OD x 4mm ID Silicone side tubes represent the left and right coronary artery. 
All tubes were lubricated with silicone oil. A tape measure was secured alongside the 
model to add scaling. 
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Figure A-1 showing photograph of the first mock aorta and coronary sleeves (before delivery of realistic glass model) 
During the measurement of the device lengths, consideration was given to the 2D 
layout and we accept this is a simplification as we are not taking into account the 
“depth” of tissues and tortuosity of the arteries in the third dimension. At this time of 
testing we had not taken receipt of the life size aortic glass model and as such this was 
the most realistic testing available to us. 
Delivery Sequence  
Over a standard J tipped 0.038” floppy guide wire 130cm usable length a 6F JR4 
standard guide catheter was advanced into the “left ventricular cavity”. The floppy wire 
was then retracted and replaced with a 260cm usable length Superstiff wire into the LV 
followed by removal of the 6F catheter. 
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Figure A-2 showing 0.038” Superstiff guide wire in “LV” of the mock silicone aorta 
Location of Left Coronary Guide Wire 
A 6F JL4 Guide Catheter was located in to the left tube (LMCA) with ease over a 
standard 0.038 J wire. 
 
 
 
 
Figure A-3 shows JL4 guide catheter (arrow) in LMCA 
A 260cm “floppy tip 0.014” guide wire was inserted in to the left branch, and the JL4 
guide catheter removed. The process was then repeated for the RCA, with a 6F JR4 
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 guide catheter advanced to the RCA ostium and a 260cm “floppy tip 0.014” guide 
inserted into the right coronary branch. Both guide catheters were then removed to 
leave the 3 guide wires in situ. 
 
 
 
 
Figure A-4 show that the RCA guide wire has a tendency to hug the inner curve of the ascending aorta, and the LMCA 
coronary wire has a tendency to curve towards the outer wall of the aorta, leaving a crossing point marked by the arrow.  
Success of ATAG delivery will require techniques to allow these wires to straighten and 
“uncross”. 
Insertion of Delivery Catheter 
A basic model of the delivery catheter was fabricated using two 7Fr guide catheters. 
These were inserted in to a 4.5mm polyamide sleeve. This allowed adequate space for 
the both of the 7Fr catheters and the 0.038” guide wire, whilst remaining within the 
design limits. 
 
377 
 
 
 
 
 
 
Figure A-5 Delivery catheter was advanced to the guide wire crossing location 
During the advancement it was noted that the guide wires find their natural path and no 
pull back of the wires within the coronary branches was seen. Twisting did not occur. 
Insertion of Coronary Stents 
Two expired monorail LibertéTM 3.0mm x 20mm coronary stent systems (Boston 
Scientific, USA) were loaded in to the 7Fr guide catheters over the 0.014” guide wires. 
They were positioned within the Delivery catheter in the “as loaded” location.  The 
balloon catheters did not affect the tracking of the delivery device. 
The balloon catheters have a 26cm flex monorail section and 120cm steel inflation 
shaft. The balloon catheters tracked through the delivery and into the side arms without 
any problems. 
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Figure A-6 Tracking of Right Coronary Stent from Delivery Catheter 
 
 
 
 
 
Figure A-7 Advancement of Right Coronary Stent 
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The process was repeated using the Left Coronary Stent. This process would be used 
to deploy the side arms of the graft. 
 
 
 
 
Figure A-8 Left and Right Coronary Stents in position close to “ostium” of LMCA and RCA 
 
 
 
 
 
Figure A-9 Left and Right stent and balloon catheters (rapid exchange) loaded in Delivery Device 7F Lumens 
At this stage the balloons would be inflated delivering the stents and thereby releasing 
the side arms of graft. 
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Removal of the Delivery Device 
Once the stents are located, it is possible to remove the delivery catheter leaving the 
wires in place, thereby completing the test.  
Conclusions 
We have shown in the most simplistic way that a delivery catheter with 3 separate 
lumens can be advanced over 3 guide wires (2 * 0.014” * 260cm guide wires and 1 * 
0.038” * 260cm Superstiff LV wire) around the arch and into the landing zone. Standard 
over the wire balloons can then tracked and delivered to the implantation zone. The 
stents can be delivered and the delivery system can be retracted without removal of the 
guide wires. It also enabled us to calculate all of the usable lengths for each component 
part.  
Study Limitations  
This hugely simplified model with component parts was extremely useful for planning 
the 1st generation proof of concept delivery system. We must however acknowledge 
that it had a number of limitations: 
i) The ID of the silicone tubing was only 7mm as compared to the glass model 
which will be between 19 and 25mm. This unrealistic internal diameter (ID) 
was chosen as it was the only silicone tubing that we had available to us. 
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ii) The simplified model was made of silicone tubing with lubricated silicone oil as 
compared to a glass model aorta. 
iii) There was no tortuosity of either the aortic arch of the peripheral vessels which 
in the aortic glass model and in real life will add another layer of complexity. 
iv) The ATAG device and inverted “T-Shirt” coronary sleeves were not fully 
functional / loaded in this device testing. 
v) Because the guide catheters could move within the 4.5mm delivery sheath the 
wire crossing was never going to be a significant issue as they were capable 
of just untangling and the coronary stents then navigating around any bends. 
This will not be the case with the “real device”, which will require a technique 
to “uncross” the wires and allow smooth implantation of the coronary sleeves 
into the respective coronary arteries. 
vi) This preliminary test gave us no idea as to the push forces needed to deploy the 
coronary arms / stents. Further work is required to elucidate the push 
needed, and whether either rapid exchange type balloons or OTW are 
capable of delivering the coronary sleeves in vitro.  
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A DETAILED ASSESSMENT OF 2G ATAG, COREVALVE NITINOL FRAME AND 
THE MEDTRONIC TALENT STENT GRAFT 
ATAG 2ND Generation stent frame body only 
 
  
 
 
A10 Photographs of 3 ringed ATAG with longitudinal tie bars 
Dimension before electro polishing (incoming inspection)  
Average material thickness 489 µm 
Average strut width 184 µm and 204 µm (at different measuring point) 
Average connector width 246 µm 
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Medtronic talent stent graft 
 
 
 
 
 
Expanded Stent Graft proximal part    Expanded Stent Graft distal part 
Figure A-11 macroscopic photographs of graft 
Microscope 50x wide angle 
 
 
 
 
 
 
Figure A-12 Microscopic *50 magnification photographs of the Medtronic graft 
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Figure A-13 Microscopic *50 magnification photographs of the Medtronic graft 
Wire frame measurement 
 
 
 
 
 
Bracing wire diameter approx 195µm               Wire diameter approx 500µm 
Figure A-14 microscopic measurement assessment of wire frame of the Medtronic graft 
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Corevalve re-valving system nitinol frame 
 
 
 
 
Figure A-15 macroscopic photograph of CoreValve frame 
Microscope 50x wide angle 
 
 
 
 
Figure A-16 microscopic frame measurements assessment (*50) 
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IN VITRO ASSESSMENT OF PLATELET ACTIVATION OF THE NICAST ELECTRO 
SPUN COVERING VERSUS DACRON AND ePTFE 
This platelet activation work was devised and supervised by TK, but performed by 
Stephanie Parnell within the laboratory of Prof Tim Warner. 
Aim 
To assess the platelet activation of the 2G ATAG Nicast polyurethane coating, and 
compare it to Dacron and ePTFE from currently available thoracic aortic stent grafts. 
Background 
Nicast have produced a polyurethane covering for the 2G ATAG graft in 2 thickness 
coatings – 
device which has CE mark and is in clinical trial (AVflo fistula material). 
 
 
 
 
Figure A-17 Nicast AVFlow
TM
 A-V fistula graft  
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Literature suggests that when prosthetic grafts are placed in arterial vessels a pseudo-
intima forms upon the surface of the Dacron and ePTFE, made of fibrin and platelets. 
Vascular injury caused by insertion of the graft can also result in the exposure of highly 
thrombogenic substances present in the vessel wall.(143)  
In the aorta the relative large diameter means complete occlusion is unlikely unless the 
material implanted is highly thrombogenic. However, if a platelet clump forms 
(particularly if close to the sleeves of the coronary ostia) it has a potential risk of 
embolisation due to the high shear stress caused by the blood flow in the ascending 
aorta, releasing small platelet rich fragments into the circulation which could occlude 
coronary vessels leading to myocardial infarction, or intracranial arteries causing a 
stroke.  
Although Dacron and ePTFE have 5 year patency rates in aortic bifurcation grafts of 
93% and 91-95% respectively they are not suitable for small diameter grafts (<4mm) 
with 5 year patency rates for femoro-popliteal bypass grafts reported as 43% and 45% 
respectively.(144) 
My main aim was to assess the Nicast materials ability to activate platelets and ensure 
that it was non-inferior to that of both currently utilised materials Dacron and ePTFE, as 
if it were significantly higher it may be a covering which is unlikely to useful in the critical 
position of the ostium of the LMCA and RCA. I hoped that this would de-risk the use of 
this novel material as the ATAG system moved into 3rd generation development.  
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Methods 
Platelet adhesion of the 3 graft materials (Dacron, ePTFE, and Nicast PU) was 
assessed using 96 well plate aggregometry method followed by assessment of platelet 
adherence. Platelet rich plasma (PRP) and platelet poor plasma (PPP) were obtained 
from the citrated blood of healthy volunteers. 
Material preparation 
Materials were prepared and tested in a standardised manner. To achieve this goal a 
hole punch was utilised to make 5mm round pieces of respective graft material. The 
thickness of the material was also measured using a micrometer screw gauge, so that 
surface area could be calculated for each sample as the Nicast material was thicker 
and as such the result must be standardised for the relative surface area. 
The ePTFE (taken from commercially obtained LeMaitre TEVAR graft) and Dacron 
(taken from commercially available Jotec TEVAR graft) had material thickness 
measured at 157µm and 79µm respectively compared to the Nicast sample used which 
had a thickness of 727µm (we were sent this material from Nicast, rather than destroy 
one of our 2 manufactured grafts).  
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Figure A18 a) ePTFE LeMaitre graft   b) Jotec Dacron graft 
Platelet adhesion methodology 
The PRP was added to the wells of a 96 well plate as shown in the diagram below. PRP 
was pipetted into 2 half rows of each of the graft materials (standardised 5mm hole 
punches of each material) and 2 half rows with no material as a control; one row for 
each of the agonists, collagen and ADP at 6 different concentrations – allowing 
comparison of the graft materials with different concentrations of the agonists collagen 
and ADP. The material itself is unlikely to promote platelet activation and as such the 
agonists ADP and Collagen are required to facilitate the platelet activation / adherence 
process in a standardised way. 
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Figure A19 Schematic diagram of plate organisation for Platelet Aggregometry 
There was also a control row for each graft material, and 1 with no material, where no 
agonist was added. These rows contained 4 wells of phosphate buffered saline (PBS), 
4 wells of PRP and 4 wells of PPP. The plates were then placed in a plate reader 
(Sunrise, Tecan Group, Mannedorf, Germany), and the results given by the plate reader 
were not used as the wells contained pieces of graft material. The plate reader was 
391 
 
used to give reproducible shaking of the wells and heat them to 37oC to encourage 
platelet activation.   
The graft specimens were then removed from the plates and washed twice with 0.9% 
phosphate-buffered saline, as were the plates themselves to remove the platelets that 
had not adhered properly to either the plates or the material.  The specimens were then 
returned to clean wells in the other half of the plates and assay buffer was put into all 
the wells except the wells previously containing PBS where a 100% control was added. 
This allowed platelet adhesion to the wells and the graft materials to be measured 
separately, so that any platelets found in the wells when measuring platelet adhesion to 
the grafts had adhered to the graft material itself and not the plates. The plates were 
incubated at 37 °C for 30 minutes. The assay buffer contained p-nitrophenyl phosphate 
at pH4 with detergent.  This buffer breaks down the platelets adhered to the material or 
plate and the acid phosphatase within converts the p-nitrophenyl phosphate to p-
nitrophenyl. 2M NaOH was then added to each well which turns the p-nitrophenyl 
yellow. So that where there is a high concentration of platelets there is strong yellow 
colour. All specimens were then removed and the plates put in the plate reader again. 
The concentration of platelets in each well (and therefore the degree of platelet 
adhesion) was thus assessed colorimetrically by measuring the optical absorption at a 
wavelength of 405 nm for each well using the wells containing 100% platelets as 
controls.  The results were analysed using GraphPad Prism 5 software. 
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Figure A20 Schematic diagram of organisation of Graft Material for Colourimetric Analysis 
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Results 
Results of experiments comparing the platelet adhesion to 3 graft materials. 
Graft 1:  Lemaitre, ePTFE material 
Graft 2:  Jotec, Dacron material 
Graft 3:  Nicast, Polyurethane 
Graft Material Thickness 
 Lemaitre Material 
(ePTFE) (µm) 
Jotec Material 
(Dacron) (µm) 
Nicast Sample from 
AVFlo stent 
(polyurethane) (µm) 
1 152 76.2 737 
2 152 88.9 737 
3 152 76.2 711 
4 165 76.2 711 
5 165 76.2 737 
Mean 157.2 78.74 726.6 
Surface Area of 5mm Diameter 
Hole Punch Piece of Each 
Material (mm
2
) 
41.7 40.5 50.7 
Material thickness measurements using a micrometer screw gauge 
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Therefore there was 25% and 22% more Nicast material in each experiment than 
Dacron (Jotec) and ePTFE (Lemaitre) respectively.  
Each graph shows the mean results for each graft material +/- the standard error. 
 
 
 
 
 
 
Figure A21 Percentage platelet adhesion to materials with ADP                 
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Figure A-22 Percentage platelet adhesion to materials with collagen 
 
 
 
 
 
 
Figure A-23 Percentage adhesion to graft with ADP as agonist / corrected for surface area  
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Figure A-24 Percentage adhesion to graft with Collagen as agonist / corrected for surface area 
Statistical results  
Even before correction for material surface area there is no statistically significant 
difference between the platelet activation of Nicast PU when compared to both the 
ePTFE and Dacron with both agonists (ADP and Collagen). Similar non significant 
differences are also seen when the samples are corrected for surface area.  (TTest 
P>0.05).  
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Conclusion 
The Nicast polyurethane material when tested against both ePTFE and Dacron would 
appear to have statistically similar platelet activation characteristics when corrected for 
surface area.  
Using Collagen as an agonist Nicast PU is clearly the least activating although it does 
not reach statistical significance. The raw values for ADP agonist platelet activation 
would appear to suggest a trend towards more activation for the Nicast PU material as 
compared to the ePTFE and Dacron, but this does not reach statistical significance, and 
the trend disappears when proper correction for surface area is factored in. 
Platelet adhesion to the wells which contained the specimens of graft material was 
similar for all the grafts with both the agonists. Therefore, differences in platelet 
adhesion to the graft specimens were only due to the graft specimens themselves. 
Discussion 
Dacron and ePTFE in small diameter grafts (<4mm) have poor 5 year patency 
rates.(144) Our simple first analysis of platelet activation and adherence to graft 
materials suggests that the Nicast PU material is likely to activate platelets to a similar 
degree as currently commercially available stent graft materials. With the Nicast PU 
material there is a trend towards decreased activation when using collagen as an 
agonist, but a similar degree when ADP is utilised.   
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ADP binds to receptors on platelets causing platelet activation. P2Y12 is one of these 
receptors which are targeted for antiplatelet therapy. P2Y12 ADP receptor antagonists 
include Clopidogrel and Prasugrel. Clopidogrel with aspirin is given as standard-of-care 
therapy for all patients undergoing percutaneous coronary intervention (PCI) to reduce 
the risk of ischaemic events. Prasugrel, which is licensed in the US and Europe for use 
in Primary PCI and is a more potent platelet inhibitor with a 19% relative risk reduction 
for ischaemic events compared to clopidogrel and aspirin.(145) 
Patients with aortic dissection, for whom this stent is designed are highly likely to have 
other cardiovascular co morbidities and may already be on antiplatelet therapy. With 
P2Y12 ADP receptor antagonist treatment, ADP induced platelet aggregation can be 
inhibited and this may allow the use of this material in ascending aortic and coronary 
sleeves. To further test this theory the experiments should be repeated using commonly 
used anti-platelet therapies to evaluate their potential effects. 
Future animal experiments may also help in establishing the thrombogenic properties of 
the graft material under in-vivo conditions, although we must accept that animal models 
of platelet activation and clotting cascade do have differences when compared to the 
human. 
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ATAG hazard analysis  
Below is a tabulated list of potential ATAG failure modes.  It is broken down into 3 
specific parts: 
 Arterial access / ATAG delivery failure modes 
 ATAG deployment failure modes 
 Longer term follow up failure modes 
Arterial access / percutaneous delivery failure modes 
Arterial access / ATAG delivery failure modes 
Unable to crimp ATAG onto delivery system / poor coronary alignment 
Sheath gains access into the false lumen which extends into the femoral artery 
Peripheral artery too small / tortuous / calcified to accept ATAG device/ sheath 
Unable to pass device onto the 3 guide wires 
Device will not advance smoothly on guide wires 
Inadequate guidewire support to allow ATAG to advance 
Device will not advance in the descending aorta because of calcification or tortuosity 
Clot / aortic debris on proximal end of device / embolises 
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Sheath or device causes dissection or rupture of the arterial wall 
Wrapped wires mean that device cannot advance 
Impossible to ascertain exact position of device in 3D therefore unsure as to correct orientation 
Unable to elucidate exact position of 3 wires and therefore unable to “unwrap” 
Device will not traverse the aortic arch 
During arch manipulation causes embolic phenomenon to brain / arms / gut / kidneys / legs 
Clot formation on guide wires (What is the optimal desired ACT) 
Deployment failure modes 
Table ATAG deployment failure modes 
Unable to engage coronary ostia with guide catheter and position the guide wires 
Coronary guide wires do not possess sufficient “hold” in coronary arteries and pullout upon ATAG device 
advancement. 
Unable to engage correct position of front end of ATAG device 
Coronary arms do not align correctly 
Coronary arms kink and occlude 
Coronary ostia angles / distances are beyond scope of the device 
Balloon dilatation in the coronaries causes LMS / RCA dissection / slow flow / occlusion 
AV becomes disrupted with torrential AR 
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Unable to achieve a proximal seal resulting in endoleak and subsequent coronary collapse 
Proximal seal causes a proximal dissection with significant false lumen filling compromising true lumen 
Distal dissection causes spiral false lumen and occlusive arterial complication (CVA / renals etc – dependent on 
anatomy) 
Device is poorly positioned and is too long and occludes right bracheo-cephalic trunk and / or arch vessels 
Over sizing causes constant outward radial force resulting in aneurysm formation / dissection 
Undersized device resulting in distal embolisation / migration and risk of coronary occlusion and arterial occlusion 
depending on site of coverage. Migration by hydrodynamic forces (either shear or inertia) 
Thrombus formation in coronary arms (material considerations) 
Cover material fracture / degrading promoting endoleak 
Stent strut fracture – depending on site could be detrimental to coronary arms, potential to pierce arterial wall 
Distal segment of stent does not adhere to wall adequately (because of poor sizing or curvature of the aortic wall) 
resulting in endoleak 
Device expansion could trap a calcified AV leaflet behind graft causing occlusion of the LMS / RCA and severe AR 
95% of patients will have LMS and RCA in recognized angulation approx 1% will have anomalous anatomy and 
potentially device could occlude an anomalous artery 
Removal of device delivery system – possible pullback of the device from its optimal position 
Aortic or peripheral vessel damage secondary to delivery system removal 
Vascular complication related to sheath and hole closure (percutaneous suture based closure device) 
Coronary blood flow reduction – slow deployment of coronary branches (LMS and RCA cannot be done 
simultaneously)  
Failure of coronary deployment / incomplete expansion 
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Kinking of coronary arms 
Cardiac arrest during coronary sleeve implantation  
Coronary arms of insufficient length for the aortic anatomy 
Coronary side branches – pull out under pressure 
Kinking of body of stent graft 
Coronary stent thrombosis due to lack of endothelialisation (? Optimal duration of anti-platelet agents) 
Aortic thrombosis  
Longer term follow up events 
Table Longer term failure modes 
Instent re-stenosis (ISR) of coronary sleeves– how to treat – use of drug eluting coronary stents (DES) / drug eluting 
balloons (DEB) how will material fare with this. Does the LMS / RCA need to elute drugs in the first instance? Is this 
possible? 
Endoleak (I,II, III or IV) 
Aneurysm formation 
If too low in the LVOT ? Potential for conduction problems and need for PPM 
Constant outward radial force ? Dilatation of the sinus and possible resultant AR 
Material degradation (Fatigue under cyclic load) 
Stent frame fracture and fatigue 
Aortic flow reduction 
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